 EXHIBIT 2.1     

Exhibit 2.1

  

EXECUTION VERSION

  


 

  


 

  


 

  


 

  


 

  


 

  


 

  


 

  


 

      
 

  


 

  


 

  

 

AGREEMENT AND PLAN OF MERGER

  

  

dated as of MAY 17, 2011

 

  


 

  

by and among

  


 

  

 

SHIRE PHARMACEUTICALS INC.

  

  

("Parent"),

 

  


 

  

ABH MERGER SUB INC.

  


 

  

("Merger Sub"),

  


 

  

 

ADVANCED BIOHEALING, INC.

  

  

(the "Company"),

 

  


 

  

 

solely for the purposes of Section 2.7 and Articles III, IX and X, CANAAN VII
L.P.

 

  


 

  

(the "Equityholders' Representative")

  


 

  

and,

  


 

  

 

solely for the purposes of Section 10.17,

  

  

SHIRE PLC

 

  


 

  

("Buyer Parent")

  


 

  


 

  


    

  

 

 

 

  

 

  

 

  

 

 

 

  


 

  

  

 

 

   TABLE OF CONTENTS  
--- 
   |  |  | Page  
 ARTICLE I. DEFINITIONS  | 1  
   |  |  |   
   |  

SECTION 1.1

  |  

Certain Definitions

  |  

1

   
   |  

SECTION 1.2

  |  

Certain Additional Definitions

  |  

12

   
   |  

SECTION 1.3

  |  

Determination of Pro Rata Amounts Hereunder

  |  

14

   
   |  |  |   
 ARTICLE II. THE MERGER  | 15  
   |  |  |   
   |  

SECTION 2.1

  |  

The Merger

  |  

15

   
   |  

SECTION 2.2

  |  

Effects of the Merger

  |  

15

   
   |  

SECTION 2.3

  |  

Closing

  |  

15

   
   |  

SECTION 2.4

  |  

Effective Time

  |  

15

   
   |  

SECTION 2.5

  |  

Certificate of Incorporation and Bylaws; Directors and Officers

  |  

15

   
   |  

SECTION 2.6

  |  

Conversion of Securities; Treatment of Company Options and Warrants

  |  

16

   
   |  

SECTION 2.7

  |  

Total Cash Equity Price Adjustments

  |  

18

   
   |  

SECTION 2.8

  |  

Payment of Company Transaction Expenses; Pro-Rata Bonuses

  |  

21

   
   |  

SECTION 2.9

  |  

Calculations and Iterative Process

  |  

21

   
   |  |  |   
 ARTICLE III. EXCHANGE OF COMPANY CERTIFICATES  | 22   
   |  |  |   
   |  

SECTION 3.1

  |  

Exchange of Company Certificates

  |  

22

   
   |  

SECTION 3.2

  |  

Appraisal Rights

  |  

24

   
   |  

SECTION 3.3

  |  

Escrow

  |  

24

   
   |  

SECTION 3.4

  |  

No Further Ownership Rights in Shares of Company Capital Stock; Closing of
Company Transfer Books

  |  

24

   
   |  |  |   
  ARTICLE IV. REPRESENTATIONS AND WARRANTIES OF THE COMPANY | 25   
   |  |  |   
   |  

SECTION 4.1

  |  

Authority

  |  

25

   
   |  

SECTION 4.2

  |  

Organization; Subsidiaries

  |  

26

   
   |  

SECTION 4.3

  |  

Capitalization

  |  

26

   
   |  

SECTION 4.4

  |  

Conflicts

  |  

27

   
   |  

SECTION 4.5

  |  

Consents, Approvals, Etc

  |  

27

   
   |  

SECTION 4.6

  |  

Financial Statements; SEC Filings

  |  

28

   
   |  

SECTION 4.7

  |  

Undisclosed Liabilities

  |  

28

   
   |  

SECTION 4.8

  |  

Certain Changes or Events

  |  

28

   
   |  

SECTION 4.9

  |  

Tax Matters

  |  

28

   
   |  

SECTION 4.10

  |  

Litigation and Governmental Orders

  |  

30

   
   |  

SECTION 4.11

  |  

Compliance with Laws

  |  

30

   
   |  

SECTION 4.12

  |  

Permits

  |  

30

   
   |  

SECTION 4.13

  |  

Regulatory Matters

  |  

30

   
   |  

SECTION 4.14

  |  

Tangible Property

  |  

33

   
   |  

SECTION 4.15

  |  

Intellectual Property

  |  

33

   
   |  

SECTION 4.16

  |  

Certain Contracts

  |  

36

   
   |  

SECTION 4.17

  |  

Employee Benefit Matters

  |  

37

   
   |  

SECTION 4.18

  |  

Labor Matters

  |  

38

   
   |  

SECTION 4.19

  |  

Environmental Matters

  |  

39

   
   |  

SECTION 4.20

  |  

Foreign Corrupt Payments

  |  

40

   
   |  

SECTION 4.21

  |  

Insurance Coverage

  |  

40

   
 

  

  

 

 

 

  

 

i  

  

 

 

  

 

  

 

     |  

SECTION 4.22

  |  

Brokers

  |  

40

   
---|---|---|--- 
   |  

SECTION 4.23

  |  

Affiliate Transactions

  |  

40

   
   |  

SECTION 4.24

  |  

Information Statement

  |  

40

   
   |  

SECTION 4.25

  |  

Takeover Laws

  |  

40

   
   |  

SECTION 4.26

  |  

No Other Representations or Warranties

  |  

40

   
   |  |  |   
 ARTICLE V. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB  | 41   
   |  |  |   
   |  

SECTION 5.1

  |  

Authority

  |  

41

   
   |  

SECTION 5.2

  |  

Organization

  |  

41

   
   |  

SECTION 5.3

  |  

Conflicts

  |  

42

   
   |  

SECTION 5.4

  |  

Consents, Approvals, Etc

  |  

42

   
   |  

SECTION 5.5

  |  

Litigation and Governmental Orders

  |  

42

   
   |  

SECTION 5.6

  |  

Due Diligence Investigation

  |  

42

   
   |  

SECTION 5.7

  |  

Brokers

  |  

43

   
   |  

SECTION 5.8

  |  

No Prior Activities

  |  

43

   
   |  

SECTION 5.9

  |  

Sufficient Funds

  |  

43

   
   |  

SECTION 5.10

  |  

No Other Representations or Warranties

  |  

43

   
   |  |  |   
 ARTICLE VI. ADDITIONAL AGREEMENTS | 43  
   |  |  |   
   |  

SECTION 6.1

  |  

Conduct of the Company Prior to the Effective Time

  |  

43

   
   |  

SECTION 6.2

  |  

Access to Information

  |  

45

   
   |  

SECTION 6.3

  |  

Confidentiality

  |  

45

   
   |  

SECTION 6.4

  |  

Efforts to Consummate; Notification

  |  

45

   
   |  

SECTION 6.5

  |  

Indemnification; Directors' and Officers' Insurance

  |  

47

   
   |  

SECTION 6.6

  |  

Employee Benefit Matters

  |  

48

   
   |  

SECTION 6.7

  |  

Tax Matters

  |  

49

   
   |  

SECTION 6.8

  |  

No Solicitation

  |  

50

   
   |  

SECTION 6.9

  |  

FIRPTA Certificate

  |  

50

   
   |  

SECTION 6.10

  |  

Section 280G Waiver Agreement and Shareholder Approval

  |  

50

   
   |  

SECTION 6.11

  |  

Information Statement

  |  

51

   
   |  

SECTION 6.12

  |  

Notices and Consents

  |  

51

   
   |  |  |   
 ARTICLE VII. CONDITIONS TO CLOSING | 51   
   |  |  |   
   |  

SECTION 7.1

  |  

Conditions to Obligations of the Company

  |  

51

   
   |  

SECTION 7.2

  |  

Conditions to Obligations of Parent and Merger Sub

  |  

52

   
   |  |  |   
 ARTICLE VIII. TERMINATION, AMENDMENT AND WAIVER  | 53   
   |  |  |   
   |  

SECTION 8.1

  |  

Termination

  |  

53

   
   |  

SECTION 8.2

  |  

Effect of Termination

  |  

54

   
   |  |  |   
 ARTICLE IX. SURVIVAL; INDEMNIFICATION  | 54   
   |  |  |   
   |  

SECTION 9.1

  |  

Survival

  |  

54

   
   |  

SECTION 9.2

  |  

Indemnification

  |  

54

   
   |  

SECTION 9.3

  |  

Limitations

  |  

55

   
   |  

SECTION 9.4

  |  

Limitation on Set-off

  |  

56

   
   |  

SECTION 9.5

  |  

Mitigation

  |  

56

   
   |  

SECTION 9.6

  |  

Third Party Claim Procedures

  |  

56

   
   |  

SECTION 9.7

  |  

Direct Claim Procedures

  |  

58

   
   |  

SECTION 9.8

  |  

Treatment of Indemnification Payments

  |  

58

   
   |  

SECTION 9.9

  |  

Exclusive Remedy

  |  

58

   
 

  

  

 

 

 

  

 

ii  

  

 

 

 

  

  

  

   ARTICLE X. GENERAL PROVISIONS  | 58   
---|--- 
   |  |  |   
   |  

SECTION 10.1

  |  

Equityholders' Representative

  |  

58

   
   |  

SECTION 10.2

  |  

Expenses

  |  

60

   
   |  

SECTION 10.3

  |  

Notices

  |  

60

   
   |  

SECTION 10.4

  |  

Public Announcements

  |  

62

   
   |  

SECTION 10.5

  |  

Interpretation

  |  

62

   
   |  

SECTION 10.6

  |  

Severability

  |  

62

   
   |  

SECTION 10.7

  |  

Entire Agreement

  |  

63

   
   |  

SECTION 10.8

  |  

Assignment

  |  

63

   
   |  

SECTION 10.9

  |  

No Third-Party Beneficiaries

  |  

63

   
   |  

SECTION 10.10

  |  

Waivers and Amendments

  |  

63

   
   |  

SECTION 10.11

  |  

Governing Law; Consent to Jurisdiction

  |  

63

   
   |  

SECTION 10.12

  |  

Waiver of Jury Trial

  |  

64

   
   |  

SECTION 10.13

  |  

Equitable Remedies

  | 64  
   |  

SECTION 10.14

  |  

Counterparts

  |  

65

   
   |  

SECTION 10.15

  |  

Time is of the Essence

  |  

65

   
   |  

SECTION 10.16

  |  

Legal Representation

  |  

65

   
   |  

SECTION 10.17

  |  

Buyer Parent Guarantee

  |  

65

   
 

 

 

   
 

  

EXHIBITS

  


 

  

 

    

Exhibit A

  |  

-

  |  

Consent Agreement

   
---|---|--- 
  

Exhibit B

  |  

-

  |  

Escrow Agreement

   
  

Exhibit C

  |  

-

  |  

Letter of Transmittal

   
  

Exhibit D

  |  

-

  |  

Option Holder Letter

   
 

   
 

  

 

 

 

  

 

iii  

  

 

 

 

  


 

  


 

  

AGREEMENT AND PLAN OF MERGER

  


 

  

THIS AGREEMENT AND PLAN OF MERGER (this "Agreement ") is made and entered into
as of May 17, 2011 by and among Shire Pharmaceuticals Inc., a Delaware
corporation ("Parent"), ABH Merger Sub Inc., a Delaware corporation and a
wholly-owned subsidiary of Parent ("Merger Sub"), Advanced BioHealing, Inc., a
Delaware corporation (the "Company"), solely for the purposes of Section 2.7
and Articles III, IX and X, Canaan VII L.P., a Delaware limited partnership,
as the Equityholders' Representative, and solely for the purposes of Section
10.17, Shire plc, a public limited company incorporated under the laws of
Jersey, Channel Islands ("Buyer Parent"). Parent, Merger Sub, the Company,
solely for the purposes of Section 2.7 and Articles III, IX and X, the
Equityholders' Representative, and solely for the purposes of Section 10.17,
Buyer Parent are referred to collectively herein as the "Parties."

  


 

  

WHEREAS, the respective boards of directors of Parent, Merger Sub and the
Company have each determined that the merger of Merger Sub with and into the
Company (the "Merger") is advisable and in the best interests of their
respective stockholders, and such boards of directors have approved the
Merger, upon the terms and subject to the conditions set forth in this
Agreement;

  


 

  

WHEREAS, as an inducement to Parent and Merger Sub to enter into this
Agreement, certain of the Company's stockholders (the "Principal
Stockholders") are entering into a Consent Agreement, dated as of the date
hereof, in the form attached hereto as Exhibit A (the "Consent Agreement"),
pursuant to which, among other things, immediately following the execution and
delivery of this Agreement, the Principal Stockholders acting by written
consent will approve and adopt this Agreement and the Merger,

  


 

  

WHEREAS, concurrently with the execution of this Agreement, Parent, the sole
stockholder of Merger Sub, has approved and adopted this Agreement and the
Merger; and

  


 

  

WHEREAS, the Parties to this Agreement desire to make certain representations,
warranties, covenants and agreements in connection with the transactions
contemplated by this Agreement and also prescribe various conditions to the
transactions contemplated by this Agreement.

  


 

  

AGREEMENT

  


 

  

NOW, THEREFORE, in consideration of the foregoing premises, the mutual
covenants, promises and agreements hereinafter set forth, the mutual benefits
to be gained by the performance thereof, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged
and accepted, the Parties to this Agreement, intending to be legally bound,
hereby agree as follows:

  


 

  

ARTICLE I. 
 

  

DEFINITIONS

  


 

  

SECTION 1.1 Certain Definitions. As used in this Agreement, the following
terms shall have the following respective meanings:

  


 

  

"Action" means any claim, audit, action, suit or proceeding, arbitral action,
or criminal prosecution.

  


 

  

"Adjustment Amount" means the sum of the amounts (whether a positive or
negative number) of the Closing Date Cash Adjustment, the Closing Date
Indebtedness Adjustment and the Closing Date Working Capital Adjustment.

  


 

  

 

 

 

  

 

1  

  

 

 

 

  

  

"Adverse Experience" means, with respect to any biologic, device, drug or
product, any untoward medical occurrence in a patient or clinical
investigation subject administered such biologic, device, drug or product, and
which does not necessarily have a causal relationship with the treatment for
which such biologic, device, drug or product is used, including any
unfavorable and unintended sign (including an abnormal laboratory finding),
symptom, or disease temporally associated with the use of the biologic,
device, drug or product or the worsening in severity of a pre-existing
condition after administration of the biologic, device, drug or product, in
each case whether or not related to the biologic, device, drug or product.

  


 

  

"Affiliate" means, when used with respect to a specified Person, another
Person that either directly or indirectly, through one or more intermediaries,
controls, is controlled by or is under common control with, the specified
Person.

  


 

  

"Annual Bonus Program" means the annual bonus program as described on Section
2.8 of the Company Disclosure Schedule.

  


 

  

"Antitrust Laws" means the HSR Act, the Sherman Antitrust Act of 1890, as
amended, and the rules and regulations promulgated thereunder, the Clayton Act
of 1914, as amended, and the rules and regulations promulgated thereunder, and
any other Laws that are designed to prohibit, restrict or regulate actions
having the purpose or effect of monopolization or restraint of trade.

  


 

  

"Business" means the business and operations of the Company, as conducted as
of the date of this Agreement.

  


 

  

"Business Day" means any day that is not a Saturday, Sunday or other day on
which banks are required or authorized by Law to be closed in New York, New
York.

  


 

  

"Cash Equivalents" means the sum of cash, cash equivalents and liquid
investments, plus all deposited but uncleared bank deposits and cash held by
counterparties, and less all outstanding checks and cash posted by
counterparties, in each case of the Company, whether restricted or
unrestricted.

  


 

  

"Closing Date Cash Adjustment" means (whether a positive or negative number)
the amount of the Closing Date Cash as shown on the Closing Statement minus
the Estimated Closing Date Cash.

  


 

  

"Closing Date Indebtedness Adjustment" means (whether a positive or negative
number) the amount of the Estimated Closing Date Indebtedness minus the
Closing Date Indebtedness as shown on the Closing Statement.

  


 

  

"Closing Date Working Capital Adjustment" means (whether a positive or
negative number) the amount of the Working Capital Adjustment as derived from
the Closing Statement minus the Estimated Working Capital Adjustment.

  


 

  

"Code" means the Internal Revenue Code of 1986, as amended.

  


 

  

"Common Merger Consideration" means (a)(i) initially, the Total Cash Equity
Price assuming it is equal to the Estimated Total Cash Equity Price and,
thereafter, as adjusted from time to time by any Excess Payment or any release
of funds from the General Escrow Account or the Equityholders' Representative
Escrow Account to the Equityholders, plus (ii) the aggregate exercise price of
all Company Options outstanding immediately prior to the Effective Time having
an exercise price of less than the Option In-the-Money Amount, plus (iii) the
aggregate exercise price of all Common Warrants outstanding immediately prior
to the Effective Time having an exercise price of less than the Common

  


 

  

 

 

 

  

 

2  

  

 

 

 

  

  

  

Warrant In-the-Money Amount, plus (iv) the aggregate exercise price of all
Series B Warrants outstanding immediately prior to the Effective Time having
an exercise price of less than the Series B Warrant In-the-Money Amount, plus
(v) the aggregate exercise price of all Series C Warrants outstanding
immediately prior to the Effective Time having an exercise price of less than
the Series C Warrant In-the-Money Amount, plus (vi) the aggregate exercise
price of all Series C-1 Warrants outstanding immediately prior to the
Effective Time having an exercise price of less than the Series C-1 Warrant
In-the-Money Amount, less (b)(i) the Total Series A Preferred Merger
Preference, less (ii) the Total Series B Preferred Merger Preference, less
(iii) the Total Series C Preferred Merger Preference, less (iv) the Total
Series C-1 Preferred Merger Preference.

  


 

  

"Common Per-Share Merger Consideration" means the Common Merger Consideration
divided by the number of shares of Fully-Diluted Common Stock.

  


 

  

"Common Warrant In-the- Money Amount" means the amount, rounded to the nearest
cent, determined by the Iterative Process, equal to the Common Per-Share
Merger Consideration assuming that the Total Cash Equity Price is equal to the
Estimated Total Cash Equity Price.

  


 

  

"Company Certificate of Incorporation" means the Company's Third Amended and
Restated Certificate of Incorporation, dated as of February 23, 2007, as
amended by that certain Certificate of Amendment, dated as of September 6,
2007, and further amended by that certain Certificate of Amendment, dated as
of December 22, 2008, and by that certain Certificate of Amendment, dated as
of May 3, 2011.

  


 

  

"Company Employee" means any employee of the Company.

  


 

  

"Company Option Plan" means the Company's 2004 Stock Option Plan.

  


 

  

"Company Options" means all outstanding options to purchase shares of Common
Stock, whether vested or unvested, granted pursuant to the Company Option
Plan.

  


 

  

"Company Transaction Expenses" means (i) any fee or commission to any
investment bank, broker or finder in connection with the execution and
delivery of this Agreement or the consummation of the transactions
contemplated hereby, including the fees and disbursements payable by the
Company to Bank of America Merrill Lynch referenced in Section 4.22; (ii) the
fees and disbursements payable to legal counsel and accountants of the Company
that are payable by the Company in connection with the transactions
contemplated by this Agreement; and (iii) all other expenses or costs, in each
case, incurred by the Company in connection with the transactions contemplated
by this Agreement.

  


 

  

"Confidentiality Agreement" means the Confidentiality Agreement between the
Company and Parent, dated as of May 3, 2011.

  


 

  

"Contract" means any legally binding contract, agreement, indenture, note,
bond, loan, instrument, lease, conditional sales contract, mortgage or other
arrangement, whether written or oral.

  


 

  

"Controlled Group" means any trade or business (whether or not incorporated)
(a) under common control within the meaning of Section 4001(b)(1) of ERISA
with the Company or (b) which together with the Company is treated as a single
employer under Section 414 of the Code.

  


 

  

"Copyrights" means all copyright rights, whether registered or not, and
registrations or applications for registration of copyrights filed with any
Governmental Authority throughout the world, and any renewals or extensions
thereof.

  


 

  

 

 

 

  

 

3  

  

 

 

 

  

  

"Damages" means any Liabilities, losses, damages, penalties, fines, costs or
expenses (including reasonable expenses of investigation and reasonable
attorneys' fees and expenses in connection with any Action whether involving a
Third Party Claim or a claim solely between the Parties hereto).

  


 

  

"DGCL" means the General Corporation Law of the State of Delaware.

  


 

  

"Dissenting Stockholders" means holders of Company Capital Stock exercising
appraisal rights pursuant to Section 262 of the DGCL.

  


 

  

"Encumbrance" means any security interest, pledge, mortgage, deed of trust,
lien, charge, hypothecation, adverse claim, restriction on transfer (such as a
right of first refusal or other similar rights), defect of title or other
encumbrance of any nature whatsoever.

  


 

  

"Environmental Law" means any Law pertaining to land use, air, soil, surface
water, groundwater (including the protection, cleanup, removal, remediation or
damage thereof), the environment, health and safety (insofar as it relates to
the exposure to hazardous substances), pollutants, contaminants, wastes,
chemicals or any other environmental matter.

  


 

  

"Equityholder" means any holder of Company Capital Stock, Company Options or
Warrants that is entitled to receive the applicable Merger Consideration,
Option Payment or Warrant Payment under Section 2.6 and that has not perfected
its appraisal rights pursuant to Section 3.2.

  


 

  

"Equityholders' Representative Escrow Amount" means one million dollars
($1,000,000).

  


 

  

"ERISA" means the Employee Retirement Income Security Act of 1974, as amended,
any successor statute thereto, and the rules and regulations promulgated
thereunder.

  


 

  

"Escrow Agent" means JPMorgan Chase Bank, National Association, or such other
escrow agent as reasonably agreed by Parent and the Company.

  


 

  

"Escrow Agreement" means the Escrow Agreement, dated as of the Closing Date,
among the Equityholders' Representative, the Escrow Agent named therein and
Parent, substantially in the form of Exhibit B and with any changes reasonably
required by the Escrow Agent.

  


 

  

"Escrow Amount" means the sum of the General Escrow Amount and the
Equityholders' Representative Escrow Amount.

  


 

  

"Estimated Balance Sheet" means the estimated balance sheet of the Company, as
of the close of business on the day prior to the Closing Date prior to any
purchase accounting adjustments and prepared in accordance with GAAP using the
same applicable accounting methods, accounting practices, assumptions,
policies and methodologies as were used in preparing the Company Financial
Statements.

  


 

  

"Estimated Total Cash Equity Price" means an amount equal to (a) the Total
Cash Equity Price that would be payable if (i) the Estimated Closing Date
Indebtedness was deemed to be the Closing Date Indebtedness, (ii) the
Estimated Closing Date Cash was deemed to be the Closing Date Cash and (iii)
the Estimated Working Capital Adjustment was deemed to be the Working Capital
Adjustment (and as a result, there was no Shortfall Reduction or Excess
Payment) less (b) the Escrow Amount.

  


 

  

"Estimated Working Capital Adjustment" means the Company's estimate of the
Working Capital Adjustment as derived from the Estimated Closing Statement and
the calculation of Estimated Working Capital thereon

  


 

  

 

 

 

  

 

4  

  

 

 

 

  

  

"FDA" means the United States Food and Drug Administration.

  


 

  

"Federal Healthcare Program" means Medicare (Title XVIII of the Social
Security Act), Medicaid (Title XIX of the Social Security Act) or any other
state or federal health care program.

  


 

  

"Final Closing Statement" means the Closing Statement described in Section
2.7(b), as prepared by Parent (or, if Parent does not deliver the Closing
Statement in accordance with Section 2.7(b), the Estimated Closing Statement)
and, if applicable following a Notice of Disagreement submitted in accordance
with Section 2.7(c), as subsequently adjusted to reflect any written agreement
between the Equityholders' Representative and Parent with respect thereto, or
if submitted to the Arbitrator, the Closing Statement as amended or issued by
the Arbitrator.

  


 

  

"Fully-Diluted Common Stock" means (a) the number of shares of Common Stock
outstanding immediately prior to the Effective Time, plus (b) the number of
shares of Common Stock issuable upon exercise of all Company Options
outstanding immediately prior to the Effective Time having an exercise price
of less than the Option In-the-Money Amount, plus (c) the number of shares of
Common Stock (which may be fractional) issuable upon exercise of all Common
Warrants outstanding immediately prior to the Effective Time having an
exercise price of less than the Common Warrant In-the-Money Amount, plus (d)
the number of shares of Common Stock (which may be fractional) into which the
shares of Series A Preferred Stock outstanding immediately prior to the
Effective Time are convertible pursuant to the terms of the Company
Certificate of Incorporation, plus (e) the number of shares of Common Stock
(which may be fractional) into which the shares of Series B Preferred Stock
outstanding immediately prior to the Effective Time are convertible pursuant
to the terms of the Company Certificate of Incorporation, plus (f) the number
of shares of Common Stock (which may be fractional) into which the shares of
Series B Preferred Stock (which may be fractional) issuable upon exercise of
all Series B Warrants outstanding immediately prior to the Effective Time
having an exercise price of less than the Series B Warrant In-the-Money Amount
are convertible pursuant to the terms of the Company Certificate of
Incorporation, plus (g) the number of shares of Common Stock (which may be
fractional) into which the shares of Series C Preferred Stock outstanding
immediately prior to the Effective Time are convertible pursuant to the terms
of the Company Certificate of Incorporation, plus (h) the number of shares of
Common Stock (which may be fractional) into which the shares of Series C
Preferred Stock (which may be fractional) issuable upon exercise of all Series
C Warrants outstanding immediately prior to the Effective Time having an
exercise price of less than the Series C Warrant In-the-Money Amount are
convertible pursuant to the terms of the Company Certificate of Incorporation,
plus (i) the number of shares of Common Stock (which may be fractional) into
which the shares of Series C-1 Preferred Stock outstanding immediately prior
to the Effective Time are convertible pursuant to the terms of the Company
Certificate of Incorporation, plus (j) the number of shares of Common Stock
(which may be fractional) into which the shares of Series C-1 Preferred Stock
(which may be fractional) issuable upon exercise of all Series C-1 Warrants
outstanding immediately prior to the Effective Time having an exercise price
of less than the Series C-1 Warrant In-the-Money Amount are convertible
pursuant to the terms of the Company Certificate of Incorporation.

  


 

  

"Fundamental Representations" means the representations and warranties of the
Company set forth in Sections 4.1, 4.2, 4.3 and 4.22.

  


 

  

"GAAP" means generally accepted accounting principles in the United States.

  


 

  

"General Escrow Account" has the meaning set forth in the Escrow Agreement.

  


 

  

 

 

 

  

 

5  

  

 

 

 

  

  

"General Escrow Amount" means thirty-seven million and five hundred thousand
dollars ($37,500,000).

  


 

  

"Governmental Authority" means any government, any governmental entity,
commission, board, agency or instrumentality, and any court, tribunal or
judicial body, whether federal, state, county, local or foreign.

  


 

  

"Governmental Order" means any order, judgment, injunction or decree issued,
promulgated or entered by any Governmental Authority of competent
jurisdiction.

  


 

  

"Hazardous Material" means any material or substance that is prohibited or
regulated by any Environmental Law including, without limitation, asbestos-
containing materials, biomedical waste and petroleum, its derivatives and by-
products.

  


 

  

"Hazardous Materials Activity" means the handling, transportation, transfer,
recycling, storage, use, treatment, investigation, removal, remediation,
release, discharge, disposal, spill, leak, emission, or distribution of any
Hazardous Material.

  


 

  

"HSR Act" means the Hart-Scott- Rodino Antitrust Improvements Act of 1976, as
amended, any successor statute thereto, and the rules and regulations
promulgated thereunder.

  


 

  

"Indebtedness" of any Person means: (a) any liability of such Person (i) for
borrowed money (including the current portion thereof) and related accrued
interest payable on such borrowings, (ii) under any reimbursement obligation
relating to a letter of credit, bankers' acceptance or note purchase facility,
(iii) evidenced by a bond, note, debenture or similar instrument (including a
purchase money obligation), or (iv) for the payment of money relating to
leases that are required to be classified as capitalized lease obligations in
accordance with GAAP for all or any part of the deferred purchase price of
property or services (other than trade payables), and (b) any liability of
others described in the preceding clause (a) that such Person has guaranteed,
that is recourse to such Person or any of its assets or that is otherwise its
legal liability or that is secured in whole or in part by the assets of such
Person.

  


 

  

"Intellectual Property" means all (i) Patents, (ii) Trademarks, (iii)
Copyrights, (iv) trade secrets , (v) Know-How, (vi) domain names and domain
name registrations, (vii) moral rights, database rights, design rights,
industrial property rights, publicity rights and privacy rights and (viii) any
similar intellectual property or proprietary rights.

  


 

  

"IRS" means the United States Internal Revenue Service, and any successor
agency thereto.

  


 

  

"IT Assets" means computers, computer software, firmware, middleware, servers,
workstations, routers, hubs, switches, data communications lines, and all
other information technology equipment, and all associated documentation owned
by the Company or licensed or leased by the Company pursuant to written
agreement (excluding any public networks).

  


 

  

"Know-How" means information, specifications, processes, methods, knowledge,
experience, formulae, skills, techniques, schematics, drawings, blue prints,
utility models, designs, technology, software, inventions, discoveries, ideas
and improvements, including manufacturing information and processes,
engineering and other manuals and drawings, standard operating procedures,
flow diagrams, chemical, pharmacological, toxicological, pharmaceutical,
physical and analytical, safety, quality assurance, quality control and
clinical data, technical information, data, research records and similar data
and information.

  


 

  

 

 

 

  

 

6  

  

 

 

 

  

  

"Knowledge of the Company" and any other phrases of similar import means, with
respect to any matter in question relating to the Company, the actual
knowledge of Kevin Rakin, Kevin O'Boyle, Dean Tozer, Keith O'Briant, Kathy
McGee, Luke Albrecht and Andrea Loewen-Rodriguez.

  


 

  

"La Jolla Manufacturing Facility" means the manufacturing facility for
Dermagraft, together with all related space leased or subleased by the
Company, located at 10933 and 10931 North Torrey Pines, La Jolla, California.

  


 

  

"Law" means any statute, law (statutory, common or otherwise), ordinance,
regulation, rule, code, treaty, judgment, order, permit, injunction or other
requirement of any Governmental Authority of competent jurisdiction.

  


 

  

"Liability" means any and all debts, liabilities and obligations of any kind
or nature, whether accrued or fixed, absolute or contingent, matured or
unmatured, or determined or determinable.

  


 

  

" Licensed Intellectual Property" means all Intellectual Property owned by a
third party and licensed, sublicensed or otherwise granted to the Company or
for which the Company has obtained a covenant not to be sued.

  


 

  

"Material Adverse Effect" means (a) any change or effect that is, or would
reasonably be expected to be, materially adverse to the business, assets,
Liabilities, operations, financial condition or results of operations of the
Company; provided, however, that none of the following shall be deemed, either
alone or in combination, to constitute, and no change or effect resulting from
any of the following shall be taken into account in determining whether there
has been a Material Adverse Effect: (i) the negotiation, execution, delivery,
public announcement or pendency of this Agreement or any of the transactions
contemplated herein or any actions taken in compliance herewith; (ii)
conditions affecting the pharmaceutical or medical device industries or the
biologic, device or regenerative medicine segments thereof, except to the
extent any such condition has a substantially disproportionate effect on the
Company relative to other Persons principally engaged in such industry or
segments, but taking into account for purposes of determining whether a
Material Adverse Effect has occurred only the substantially disproportionate
effect on the Company; (iii) any changes or developments in financial, banking
or securities markets (including any increased interest rates or other costs
for, or reduction in the availability of, financing or suspension of trading
in, or limitation on prices for, securities on the New York Stock Exchange,
American Stock Exchange, or Nasdaq Stock Market) or the United States economy
in general; (iv) compliance with the terms of, or the taking of any action
required by, this Agreement, or otherwise taken with the consent of Parent;
(v) any breach by Parent or Merger Sub of this Agreement or the
Confidentiality Agreement; (vi) any change in GAAP or applicable Laws (or
interpretation thereof); (vii) any acts of God, calamities, acts of war or
terrorism, or changes in national or international political or social
conditions; (viii) any action required to be taken under applicable Laws; or
(ix) any failure in and of itself (as distinguished from any change or effect
giving rise to or contributing to such failure) by the Company to meet any
projections or forecasts for any period; provided further, that (1) any
Liability or Damage relating to any change or effect that is cured prior to
the Closing Date shall not be considered a Material Adverse Effect and (2) any
failure to achieve the clinical trial results necessary to gain or seek FDA
approval for a venous leg ulcer indication for Dermagraft ("VLU Indication")
or otherwise failing to obtain FDA approval for the VLU Indication for any
other reason shall not be considered a Material Adverse Effect; or (b) a
material adverse effect on the ability of the Company to perform its
obligations under this Agreement or consummate the transactions contemplated
by this Agreement.

  


 

  

 

 

 

  

 

7  

  

 

 

 

  

  

 

  "MDR Reportable Event" means (a) an event that user facilities become
aware of that reasonably suggests that a device has or may have caused or
contributed to a death or Serious Injury, or (b) an event that manufacturers
or importers become aware of that reasonably suggests that one of their
marketed devices: (i) may have caused or contributed to a death or Serious
Injury, or (ii) has malfunctioned and that the device or a similar device
marketed by the manufacturer or importer would be likely to cause or
contribute to a death or Serious Injury if the malfunction were to recur.

  


 

  

"Merger Consideration " means the sum of (a) the Total Common Merger
Consideration, plus (b) the Total Series A Preferred Merger Consideration,
plus (c) the Total Series B Preferred Merger Consideration, plus (d) the Total
Series C Preferred Merger Consideration, plus (e) the Total Series C-1
Preferred Merger Consideration.

  


 

  

"Option In-the-Money Amount" means the amount, rounded to the nearest cent,
determined by the Iterative Process, equal to the Common Per Share Merger
Consideration, as adjusted from time to time.

  


 

  

"Owned Intellectual Property" means all Intellectual Property owned or
purported to be owned by the Company.

  


 

  

"Patents" means all national and multinational statutory invention
registrations, patents and patent applications issued by or filed with any
Governmental Authority, or under any international treaty or convention,
anywhere in the world, including, without limitation, all provisionals,
nonprovisionals, divisions, continuations, continuations- in-part, revisions,
extensions, reissues, reexaminations and supplementary protection certificates
and the equivalents of any of the foregoing in any jurisdiction.

  


 

  

"Permit" means any license, franchise, permit, certificate, approval or other
similar authorization from any Governmental Authority required by applicable
Law for the operation of the Business.

  


 

  

"Permitted Encumbrances" means (i) liens for (A) current Taxes or assessments
not yet due and payable or (B) Taxes being contested in good faith by
appropriate proceedings (and for which in the case of clause (B) adequate
accruals or reserves have been established on the Company Financial
Statements); (ii) all landlords', workmen's, repairmen's, warehousemen's and
carriers' liens and other similar liens imposed by Law, in each case incurred
in the ordinary course of business; (iii) Encumbrances that will be released
and discharged at or prior to the Closing; (iv) Encumbrances identified on
title policies or preliminary title reports provided to Parent prior to the
date hereof; and (v) Encumbrances which would not reasonably be expected to,
individually or in the aggregate, materially detract from the value or
materially interfere with the present or intended use of the applicable asset
or property.

  


 

  

"Person" means any individual, general or limited partnership, firm,
corporation, limited liability company, association, trust, unincorporated
organization or other entity.

  


 

  

"Management Retention Bonuses" shall mean the bonuses to be paid to certain
employees of the Company in accordance with the Management Retention Bonus
Plan in an aggregate amount of eight million dollars ($8,000,000).

  


 

  

"Management Retention Bonus Plan" shall mean the Company Management Incentive
Plan, dated as of the date hereof.

  


 

  

"Series A Preferred Per-Share Merger Consideration" means (a) the Series A
Preferred Per-Share Merger Preference plus (b) (i) the Common Per-Share Merger
Consideration multiplied by (ii) the number

  


 

  

 

 

 

  

 

8  

  

 

 

 

  

  

of shares of Common Stock (which may be fractional) into which one share of
Series A Preferred Stock is convertible pursuant to the terms of the Company
Certificate of Incorporation immediately prior to the Effective Time.

  


 

  

"Series A Preferred Per-Share Merger Preference" means, with respect to any
share of Series A Preferred Stock, the "Series A Preference Amount" as defined
in and calculated in accordance with the Company Certificate of Incorporation.

  


 

  

"Series B Preferred Per-Share Merger Consideration" means (a) the Series B
Preferred Per-Share Merger Preference plus (b) (i) the Common Per-Share Merger
Consideration multiplied by (ii) the number of shares of Common Stock (which
may be fractional) into which one share of Series B Preferred Stock is
convertible pursuant to the terms of the Company Certificate of Incorporation
immediately prior to the Effective Time.

  


 

  

"Series B Preferred Per-Share Merger Preference" means, with respect to any
share of Series B Preferred Stock, the "Series B Preference Amount" as defined
in and calculated in accordance with the Company Certificate of Incorporation.

  


 

  

"Series B Warrant In-the-Money Amount" means the amount, rounded to the
nearest cent, determined by the Iterative Process, equal to the Series B
Preferred Per-Share Merger Consideration assuming that the Total Cash Equity
Price is equal to the Estimated Total Cash Equity Price.

  


 

  

"Series C Preferred Per-Share Merger Consideration" means (a) the Series C
Preferred Per-Share Merger Preference plus (b) (i) the Common Per-Share Merger
Consideration multiplied by (ii) the number of shares of Common Stock (which
may be fractional) into which one share of Series C Preferred Stock is
convertible pursuant to the terms of the Company Certificate of Incorporation
immediately prior to the Effective Time.

  


 

  

"Series C Preferred Per-Share Merger Preference" means, with respect to any
share of Series C Preferred Stock, the "Series C Preference Amount" as defined
in and calculated in accordance with the Company Certificate of Incorporation.

  


 

  

"Series C Warrant In-the-Money Amount" means the amount, rounded to the
nearest cent, determined by the Iterative Process, equal to the Series C
Preferred Per-Share Merger Consideration assuming that the Total Cash Equity
Price is equal to the Estimated Total Cash Equity Price.

  


 

  

"Series C-1 Preferred Per -Share Merger Consideration" means (a) the Series
C-1 Preferred Per-Share Merger Preference plus (b) (i) the Common Per-Share
Merger Consideration multiplied by (ii) the number of shares of Common Stock
(which may be fractional) into which one share of Series C-1 Preferred Stock
is convertible pursuant to the terms of the Company Certificate of
Incorporation immediately prior to the Effective Time.

  


 

  

"Series C-1 Preferred Per-Share Merger Preference" means, with respect to any
share of Series C-1 Preferred Stock, the "Series C-1 Preference Amount" as
defined in and calculated in accordance with the Company Certificate of
Incorporation.

  


 

  

"Series C-1 Warrant In-the- Money Amount" means the amount, rounded to the
nearest cent, determined by the Iterative Process, equal to the Series C-1
Preferred Per-Share Merger Consideration assuming that the Total Cash Equity
Price is equal to the Estimated Total Cash Equity Price.

  


 

  

 

 

 

  

 

9  

  

 

 

 

  

  

"Serious Adverse Event" means, with respect to any biologic, device, drug or
product, any Adverse Experience that results in any of the following outcomes:
death, a life-threatening Adverse Experience, inpatient hospitalization or
prolongation of existing hospitalization, a persistent or significant
disability/incapacity, a congenital anomaly/birth defect or any other effect
that may otherwise jeopardize the patient or may require intervention to
prevent one of the aforementioned outcomes.

  


 

  

"Serious Injury" means, with respect to a medical device, an injury or illness
that (a) is life-threatening, (b) results in permanent impairment of a body
function or permanent damage to a body structure, or (c) necessitates medical
or surgical intervention to preclude permanent impairment of a body function
or permanent damage to a body structure.

  


 

  

"Shared Company Transaction Expenses" means an amount equal to the lesser of
(i) fifty percent (50%) of the Company Transaction Expenses and (ii) ten
million dollars ($10,000,000).

  


 

  

"Subsidiary" means, when used with respect to any Person, any other Person of
which (a) in the case of a corporation, at least (i) a majority of the equity
and (ii) a majority of the voting interests are owned or controlled, directly
or indirectly, by such first Person, by any one or more of its Subsidiaries,
or by such first Person and one or more of its Subsidiaries or (b) in the case
of any Person other than a corporation, such first Person, one or more of its
Subsidiaries, or such first Person and one or more of its Subsidiaries (i)
owns a majority of the equity interests thereof and (ii) has the power to
elect or direct the election of a majority of the members of the governing
body thereof.

  


 

  

"Tax" or "Taxes" means any and all taxes, assessments, levies, tariffs, duties
or other charges or impositions in the nature of a tax (together with any and
all interest, penalties, additions to tax and additional amounts imposed with
respect thereto) imposed by any Governmental Authority, including income,
estimated income, gross receipts, profits, business, license, occupation,
franchise, capital stock, real or personal property, sales, use, transfer,
value added, employment or unemployment, social security, disability,
alternative or add-on minimum, customs, excise, stamp, environmental,
commercial rent or withholding taxes.

  


 

  

"Tax Return" means any return (including any information return), report,
statement, schedule, notice, form, election, estimated Tax filing, claim for
refund or other document (including any attachments thereto and amendments
thereof) filed or required to be filed with any Governmental Authority with
respect to any Tax.

  


 

  

"Total Cash Equity Price" means an amount equal to the sum of (a) seven
hundred and fifty million dollars ($750,000,000), minus (b) Closing Date
Indebtedness, plus (c) Closing Date Cash, plus or minus (as applicable) (d)
the Working Capital Adjustment, plus (e) the Shared Company Transaction
Expenses.

  


 

  

"Total Common Merger Consideration" means (a) the Common Per-Share Merger
Consideration multiplied by (b) the number of shares of Common Stock
outstanding immediately prior to the Effective Time.

  


 

  

"Total Series A Preferred Merger Consideration" means (a) the Series A
Preferred Per-Share Merger Consideration multiplied by (b) the number of
shares of Series A Preferred Stock outstanding (and not converted to Common
Stock) immediately prior to the Effective Time.

  


 

  

 

 

 

  

 

10  

  

 

 

 

  

  

"Total Series A Preferred Merger Preference" means (a) the Series A Preferred
Per-Share Merger Preference multiplied by (b) the number of shares of Series A
Preferred Stock outstanding (and not converted to Common Stock) immediately
prior to the Effective Time.

  


 

  

"Total Series B Preferred Merger Consideration" means (a) the Series B
Preferred Per-Share Merger Consideration multiplied by (b) the number of
shares of Series B Preferred Stock outstanding (and not converted to Common
Stock) immediately prior to the Effective Time.

  


 

  

"Total Series B Preferred Merger Preference" means (a) the Series B Preferred
Per-Share Merger Preference multiplied by (b) the sum of (i) the number of
shares of Series B Preferred Stock outstanding (and not converted to Common
Stock) immediately prior to the Effective Time and (ii) the number of shares
of Series B Preferred Stock (which may be fractional) issuable upon exercise
of all Series B Warrants outstanding immediately prior to the Effective Time
having an exercise price of less than the Series B Warrant In-the-Money
Amount.

  


 

  

"Total Series C Preferred Merger Consideration" means (a) the Series C
Preferred Per-Share Merger Consideration multiplied by (b) the number of
shares of Series C Preferred Stock outstanding (and not converted to Common
Stock) immediately prior to the Effective Time.

  


 

  

"Total Series C Preferred Merger Preference" means (a) the Series C Preferred
Per-Share Merger Preference multiplied by (b) the sum of (i) the number of
shares of Series C Preferred Stock outstanding (and not converted to Common
Stock) immediately prior to the Effective Time and (ii) the number of shares
of Series C Preferred Stock (which may be fractional) issuable upon exercise
of all Series C Warrants outstanding immediately prior to the Effective Time
having an exercise price of less than the Series C Warrant In-the-Money
Amount.

  


 

  

"Total Series C-1 Preferred Merger Consideration" means (a) the Series C-1
Preferred Per-Share Merger Consideration multiplied by (b) the number of
shares of Series C-1 Preferred Stock outstanding (and not converted to Common
Stock) immediately prior to the Effective Time.

  


 

  

"Total Series C-1 Preferred Merger Preference" means (a) the Series C-1
Preferred Per-Share Merger Preference multiplied by (b) the sum of (i) the
number of shares of Series C-1 Preferred Stock outstanding (and not converted
to Common Stock) immediately prior to the Effective Time and (ii) the number
of shares of Series C-1 Preferred Stock (which may be fractional) issuable
upon exercise of all Series C-1 Warrants outstanding immediately prior to the
Effective Time having an exercise price of less than the Series C-1 Warrant
In-the-Money Amount.

  


 

  

"Trademarks" means all trademarks, service marks, trade dress, logos, trade
names, brand names, certification marks, corporate names and other indications
of origin, whether registered or not, in any jurisdiction, all goodwill
associated with the foregoing, and all registrations and applications for
registration of the foregoing registered or filed with any Governmental
Authority throughout the world.

  


 

  

"Working Capital" means the amount (positive or negative) equal to (a) the
Company's accounts receivable, pre-paid expenses and inventory as of the
Closing (each as determined in accordance with GAAP and on a basis consistent
with the preparation of the Company Financial Statements) minus (b) the
Company's accounts payable and accrued expenses as of the Closing (each as
determined in accordance with GAAP and on a basis consistent with the
preparation of the Company Financial Statements) minus (c) to the extent not
included in clause (b), an amount equal to the aggregate Pro-Rata Bonuses
(which are to be paid by the Surviving Corporation after the Closing in
accordance with Section 2.8); provided, that the amount of Working Capital
shall exclude (i) all Indebtedness, (ii) all Company Transaction Expenses

  


 

  

 

 

 

  

 

11  

  

 

 

 

  

  

and Management Retention Bonuses and (iii) all current and deferred tax assets
or liabilities in respect of federal or state income taxes.

  


 

  

"Working Capital Adjustment" means the number (positive or negative)
calculated on the basis of the Working Capital as follows:

  


 

  

(a) If the Working Capital exceeds twenty-seven million eight hundred and
twenty thousand dollars ($27,820,000), then the Working Capital Adjustment
shall be a positive number equal to such excess.

  


 

  

(b) If the Working Capital is equal to twenty-seven million eight hundred and
twenty thousand dollars ($27,820,000), then the Working Capital Adjustment
shall be equal to zero.

  


 

  

(c) If the Working Capital is less than twenty-seven million eight hundred and
twenty thousand dollars ($27,820,000), then the Working Capital Adjustment
shall be equal to a negative number equal to such deficit.

  


 

  

SECTION 1.2 Certain Additional Definitions. As used in this Agreement, the
following terms shall have the respective meanings ascribed thereto in the
respective sections of this Agreement set forth opposite each such term below:

  

  

 

    

Term

  |  

Section

   
---|--- 
  

Agreement

  |  

Preamble

   
  

Alternative Proposal

  |  

6.8(b)

   
  

Arbitrator

  |  

2.7(d)

   
  

Audited Company Financial Statements

  |  

4.6(a)

   
  

Balance Sheet Date

  |  

4.6(a)

   
  

Benefits Continuation Period

  |  

6.6(c)

   
  

Buyer Guaranteed Obligations

  |  

10.17

   
  

Buyer Parent

  |  

Preamble

   
  

Certificates

  |  

3.1(b)

   
  

Certificate of Merger

  |  

2.4

   
  

Closing

  |  

2.3

   
  

Closing Balance Sheet

  |  

2.7(b)

   
  

Closing Date

  |  

2.3

   
  

Closing Date Cash

  |  

2.7(a)

   
  

Closing Date Indebtedness

  |  

2.7(a)

   
  

Closing Option Payments

  |  

2.6(d)

   
  

Closing Statement

  |  

2.7(b)

   
  

Collaborative Partners

  |  

4.13(c)

   
  

Common Stock

  |  

2.6(a)(i)

   
  

Common Warrant

  |  

2.6(e)(i)

   
  

Common Warrant Payment

  |  

2.6(e)(i)

   
  

Company

  |  

Preamble

   
  

Company Benefit Plans

  |  

4.17(a)

   
  

Company Bylaws

  |  

4.2(a)

   
  

Company Capital Stock

  |  

2.6(a)

   
  

Company Cure Period

  |  

8.1(d)

   
  

Company Disclosure Schedule

  |  

Article IV

   
  

 

 

  

 

 

 

  

 

12  

  

 

 

 

  

  

 

 

    

Term

  |  

Section

   
---|--- 
  

Company Financial Statements

  |  

4.6(a)

   
  

Company Indemnified Parties

  |  

6.5(a)

   
  

Company Regulatory Filings

  |  

4.13(a)

   
  

Consent Agreement

  |  

Recitals

   
  

Continuing Employees

  |  

6.6(a)

   
  

Current Balance Sheet

  |  

4.6(a)

   
  

DOJ

  |  

6.4(b)

   
  

Effective Time

  |  

2.4

   
  

Equityholder Indemnified Parties

  |  

9.2(b)

   
  

Equityholders\' Representative

  |  

10.1(a)

   
  

Equityholders\' Representative Escrow Account

  |  

3.3

   
  

Escrow Termination Date

  |  

9.1

   
  

Estimated Closing Date Cash

  |  

2.7(a)

   
  

Estimated Closing Date Indebtedness

  |  

2.7(a)

   
  

Estimated Closing Statement

  |  

2.7(a)

   
  

Estimated Working Capital

  |  

2.7(a)

   
  

Excess Parachute Payments

  |  

6.10(a)(i)

   
  

Excess Parachute Waiver

  |  

6.10(a)(i)

   
  

Excess Payment

  |  

2.7(e)

   
  

Exchange Agent

  |  

3.1(a)(i)

   
  

Exchange Fund

  |  

3.1(a)(i)

   
  

FDA Permits

  |  

4.13(a)

   
  

Final Settlement Date

  |  

2.7(c)

   
  

Form S-1

  |  

4.6(b)

   
  

FTC

  |  

6.4(b)

   
  

Indemnified Party

  |  

9.6(a)

   
  

Indemnifying Party

  |  

9.6(a)

   
  

Information Statement

  |  

6.11

   
  

Iterative Process

  |  

2.9(a)

   
  

Leased Real Property

  |  

4.14(a)

   
  

Letter of Transmittal

  |  

3.1(b)

   
  

Material Contract

  |  

4.16(a)

   
  

Merger

  |  

Recitals

   
  

Merger Sub

  |  

Preamble

   
  

Notice of Disagreement

  |  

2.7(c)

   
  

Option Payment

  |  

2.6(d)

   
  

Option Holder Letter

  |  

2.6(d)

   
  

Outside Date

  |  

8.1(b)

   
  

Parent

  |  

Preamble

   
  

Parent Cure Period

  |  

8.1(e)

   
  

Parent Indemnified Parties

  |  

9.2(a)

   
  

Parent Subsidiaries

  |  

5.5

   
  

Parent Warranty Breaches

  |  

9.2(b)

   
  

Parties

  |  

Preamble

   
  

Pre-Closing Period

  |  

6.1(a)

   
  

Preferred Stock

  |  

2.6(a)

   
  

 

 

 

  

 

 

 

  

 

13  

  

 

 

 

  

  

 

 

    

Term

  |  

Section

   
---|--- 
  

Principal Stockholders

  |  

Recitals

   
  

Pro-Rata Bonus

  |  

2.8

   
  

Registered IP

  |  

4.15(g)

   
  

Required Company Stockholder Approval

  |  

4.1(b)

   
  

SEC

  |  

6.8(a)(v)

   
  

Sellers\' Counsel

  |  

10.16

   
  

Series A Preferred Stock

  |  

2.6(a)(ii)

   
  

Series B Preferred Stock

  |  

2.6(a)(iii)

   
  

Series B Warrant

  |  

2.6(e)(ii)

   
  

Series B Warrant Payment

  |  

2.6(e)(ii)

   
  

Series C Preferred Stock

  |  

2.6(a)(iv)

   
  

Series C Warrant

  |  

2.6(e)(iii)

   
  

Series C Warrant Payment

  |  

2.6(e)(iii)

   
  

Series C-1 Preferred Stock

  |  

2.6(a)(v)

   
  

Series C-1 Warrant

  |  

2.6(e)(iv)

   
  

Series C-1 Warrant Payment

  |  

2.6(e)(iv)

   
  

Shortfall Reduction

  |  

2.7(e)(i)(A)

   
  

Social Security Act

  |  

4.13(j)

   
  

Surviving Corporation

  |  

2.1

   
  

Terminating Company Breach

  |  

8.1(d)

   
  

Terminating Parent Breach

  |  

8.1(e)

   
  

Third Party Claim

  |  

9.6(a)

   
  

Threshold

  |  

9.2(a)

   
  

280G Shareholder Approval Requirements

  |  

6.10(a)(i)

   
  

Unaudited Company Financial Statements

  |  

4.6(a)

   
  

WARN

  |  

4.18(d)

   
  

Warrant Payments

  |  

2.6(e)

   
  

Warrants

  |  

2.6(e)

   
 

   
 

 

  

SECTION 1.3 Determination of Pro Rata Amounts Hereunder. For the purposes of
this Agreement and the Escrow Agreement, the pro rata portion of the General
Escrow Amount or the Equityholders' Representative Escrow Amount (or any
distribution from the General Escrow Account or the Equityholders'
Representative Escrow Account) attributed to any share of Common Stock or
Preferred Stock or any Company Option or Warrant shall be calculated based
upon the Iterative Process (and, if applicable, whether any additional Company
Options or Warrants would be "in-the-money") and (i) in the case of each share
of Common Stock and each share of Common Stock that is issuable upon the
exercise of a Company Option or a Common Warrant, the ratio (expressed as a
decimal) of (A) one, divided by (B) the number of shares of Fully-Diluted
Common Stock, (ii) in the case of each share of Preferred Stock, the ratio of
(A) the number of shares of Common Stock (which may be a fractional number)
into which such share of Preferred Stock is convertible, divided by (B) the
number of shares of Fully-Diluted Common Stock, and (iii) in the case of each
Warrant (other than a Common Warrant), the ratio of (A) the number of shares
of Common Stock (which may be a fractional number) into which the shares of
the applicable Preferred Stock (which may be a fractional number) issuable
upon exercise of such Warrants are convertible divided by (B) the number of
shares of Fully-Diluted Common Stock.

  


 

  

 

 

 

  

 

14  

  

 

 

 

  


 

  

  

ARTICLE II. 
 

  

THE MERGER

  


 

  

SECTION 2.1 The Merger. Upon the terms and subject to the conditions of this
Agreement, and in accordance with the DGCL, Merger Sub shall be merged with
and into the Company at the Effective Time. Following the Merger, the separate
corporate existence of Merger Sub shall cease, and the Company shall continue
as the surviving corporation (the "Surviving Corporation"). Without limiting
the generality of the foregoing, at the Effective Time, except as otherwise
provided herein, all the property, rights, privileges, powers and franchises
of the Company and Merger Sub shall vest in the Surviving Corporation, and all
debts, liabilities and duties of the Company and Merger Sub shall become the
debts, liabilities and duties of the Surviving Corporation.

  


 

  

SECTION 2.2 Effects of the Merger. At and after the Effective Time, the Merger
shall have the effects set forth in the DGCL.

  


 

  

SECTION 2.3 Closing. The closing of the transactions contemplated by this
Agreement (the "Closing") shall take place at the offices of Latham and Watkins
LLP, 885 Third Avenue, New York, New York at 10:00 a.m. New York City time on
a date to be mutually agreed to by the Parties hereto, which date shall be no
later than three (3) Business Days after the satisfaction or waiver of the
last of the conditions set forth in Article VII to be satisfied or waived in
accordance with the terms of this Agreement (other than those conditions
which, by their terms, are to be satisfied at the Closing), or at such other
location, time and date as the Parties hereto agree in writing (such date
hereinafter, the "Closing Date").

  


 

  

SECTION 2.4 Effective Time. Contemporaneously with or as promptly as
practicable after the Closing, Parent and the Company shall cause to be filed
with the Secretary of State of the State of Delaware a properly executed
certificate of merger conforming to the requirements of the DGCL, executed in
accordance with the relevant provisions of the DGCL (the "Certificate of
Merger"), and shall make all other filings or recordings required by the DGCL
in connection with the Merger. The Merger shall become effective when the
Certificate of Merger is accepted for recording by the Secretary of State of
the State of Delaware or at such later time as Parent and the Company shall
agree in writing and shall specify in the Certificate of Merger (the time at
which the Merger becomes effective, the "Effective Time").

  


 

  

SECTION 2.5 Certificate of Incorporation and Bylaws; Directors and Officers.

  


 

  

(a) At the Effective Time and without any further action on the part of the
Company or Merger Sub, the certificate of incorporation of the Surviving
Corporation shall be amended and restated in its entirety to read as the
certificate of incorporation of Merger Sub as in effect immediately prior to
the Effective Time, until thereafter changed or amended as provided therein or
by applicable Law; provided, that such certificate of incorporation shall
reflect as of the Effective Time "Advanced BioHealing, Inc." as the name of
the Surviving Corporation. The Bylaws of the Surviving Corporation shall be
amended and restated in its entirety to read as the Bylaws of Merger Sub as in
effect immediately prior to the Effective Time, until thereafter changed or
amended as provided therein or by the certificate of incorporation of the
Surviving Corporation and applicable Law.

  


 

  

(b) The directors of Merger Sub immediately prior to the Effective Time shall
be the directors of the Surviving Corporation as of the Effective Time, until
the earlier of their resignation or removal or otherwise ceasing to be a
director or until their respective successors are duly elected and qualified,
as the case may be.

  


 

  

 

 

 

  

 

15  

  

 

 

 

  

  

(c) The officers of the Company immediately prior to the Effective Time shall
be the officers of the Surviving Corporation as of the Effective Time, until
the earlier of their resignation or removal or otherwise ceasing to be an
officer or until their respective successors are duly elected and qualified,
as the case may be.

  


 

  

SECTION 2.6 Conversion of Securities; Treatment of Company Options and
Warrants. At the Effective Time, by virtue of the Merger and without any
action on the part of Merger Sub, Parent, the Company or the holder of any
shares of Company Capital Stock:

  


 

  

 

(a) Conversion of Company Capital Stock. Subject to Section 3.2 and Section
3.3, (i) each share of common stock, par value $0.001 per share, of the
Company ("Common Stock") issued and outstanding immediately prior to the
Effective Time (other than any shares of Common Stock to be canceled pursuant
to Section 2.6(b) and any shares of Common Stock which are held by Dissenting
Stockholders) shall be converted into the right to receive the Common Per-
Share Merger Consideration in cash, payable to the holder thereof, without
interest, (ii) each share of Series A Preferred Stock, par value $0.001 per
share, of the Company ("Series A Preferred Stock") issued and outstanding
immediately prior to the Effective Time (other than any shares of Series A
Preferred Stock to be canceled pursuant to Section 2.6(b) and any shares of
Series A Preferred Stock which are held by Dissenting Stockholders) shall be
converted into the right to receive the Series A Preferred Per-Share Merger
Consideration in cash, payable to the holder thereof, without interest, (iii)
each share of Series B Preferred Stock, par value $0.001 per share, of the
Company ("Series B Preferred Stock") issued and outstanding immediately prior
to the Effective Time (other than any shares of Series B Preferred Stock to be
canceled pursuant to Section 2.6(b) and any shares of Series B Preferred Stock
which are held by Dissenting Stockholders) shall be converted into the right
to receive the Series B Preferred Per-Share Merger Consideration in cash,
payable to the holder thereof, without interest, (iv) each share of Series C
Preferred Stock, par value $0.001 per share, of the Company ("Series C
Preferred Stock") issued and outstanding immediately prior to the Effective
Time (other than any shares of Series C Preferred Stock to be canceled
pursuant to Section 2.6(b) and any shares of Series C Preferred Stock which
are held by Dissenting Stockholders) shall be converted into the right to
receive the Series C Preferred Per-Share Merger Consideration, payable to the
holder thereof, without interest and (v) each share of Series C-1 Preferred
Stock, par value $0.001 per share, of the Company ("Series C-1 Preferred
Stock" and, together with the Series A Preferred Stock, the Series B Preferred
Stock and the Series C Preferred Stock, the "Preferred Stock") issued and
outstanding immediately prior to the Effective Time (other than any shares of
Series C-1 Preferred Stock to be canceled pursuant to Section 2.6(b) and any
shares of Series C-1 Preferred Stock which are held by Dissenting
Stockholders) shall be converted into the right to receive the Series C-1
Preferred Per-Share Merger Consideration in cash, payable to the holder
thereof, without interest. All such shares of Common Stock and Preferred Stock
(collectively, the "Company Capital Stock") shall no longer be outstanding and
shall automatically be canceled and retired and shall cease to exist, and each
Certificate which immediately prior to the Effective Time represented such
shares shall thereafter represent the right to receive the portion of the
Merger Consideration payable therefor. Certificates previously representing
shares of Company Capital Stock shall be exchanged for the portion of the
Merger Consideration payable in respect of such Certificates upon the
surrender of such Certificates in accordance with the provisions of Section
3.1.

   
 

  

(b) Cancellation of Certain Shares. Each share of Company Capital Stock held
by Parent, Merger Sub, any Subsidiary of Parent or Merger Sub, or in the
treasury of the Company immediately prior to the Effective Time shall be
canceled and extinguished without any conversion thereof and no payment shall
be made with respect thereto.

  


 

  

 

 

 

  

 

16  

  

 

 

 

  


 

  


 

  

(c) Merger Sub. Each issued and outstanding share of capital stock of Merger
Sub shall be converted into one share of common stock, par value $0.01, of the
Surviving Corporation, which shall constitute the only issued and outstanding
equity interests of the Surviving Corporation.

  


 

  

 

(d) Treatment of Company Options. Prior to the Effective Time, the Board of
Directors of the Company (or, if appropriate, any committee thereof) shall
adopt appropriate resolutions and take all other actions necessary and
appropriate to provide that, at the Effective Time, each unexpired and
unexercised Company Option shall become fully vested and exercisable and shall
be cancelled and, in exchange therefor, each former holder of any such
cancelled Company Option shall be entitled to receive, in consideration of
such cancellation, payments in cash (subject to any applicable withholding or
other Taxes required by applicable Law to be withheld) equal to the product of
(i) the total number of shares of Common Stock previously subject to such
Company Option multiplied by (ii) the amount by which the Option In-The-Money
Amount, calculated as of the Effective Time and recalculated, if applicable,
in connection with any recalculation of the Common Merger Consideration,
exceeds the exercise price of such Company Option (for the avoidance of doubt,
without duplication of any amounts previously paid to holders of such Company
Options in accordance herewith). Any such amount payable hereunder with
respect to any Company Option shall be referred to as an "Option Payment", and
the aggregate of all such amounts payable hereunder shall be referred to as
the "Option Payments". At or prior to the Effective Time, Parent will make
available to the Surviving Corporation the cash to be delivered in respect of
the Option Payments based on the calculation of the Common Merger
Consideration at the Effective Time (the "Closing Option Payments"). Option
Payments following the Effective Time shall be made on or about the same
dates, and subject to the same terms, as payments of the Merger Consideration
to the holders of Company Capital Stock. Any Company Options shall no longer
be exercisable by the former holder thereof, but shall only entitle such
holder to the payment of the applicable Option Payments in accordance with
this Section 2.6(d), which for the avoidance of doubt includes the right to
receive payments in connection with any Excess Payment or any release of funds
from the General Escrow Account or the Equityholders' Representative Escrow
Account. At the Effective Time, all Company Option Plans shall be terminated
and no further Company Options shall be granted thereunder. The Company will
use commercially reasonable efforts to cause each holder of Company Options to
enter into a written agreement effectuating the foregoing, and the payment of
the Option Payment to each holder of Company Options shall be subject to such
holder's execution and delivery of such agreement in the form attached hereto
as Exhibit D (such agreement, an "Option Holder Letter").

  

 

  

 

(e) Treatment of Warrants. Prior to the Effective Time, the Board of Directors
of the Company shall adopt appropriate resolutions and take all other actions
necessary and appropriate to provide that, at the Effective Time, (i) each
unexpired and unexercised warrant to purchase shares of Common Stock (the
"Common Warrants") pursuant to a contract or agreement to which the Company is
a party shall, immediately prior to its termination in accordance with its
terms at the Closing, be cancelled and, in exchange therefor, each former
holder of any such cancelled Common Warrant shall be converted into a right to
receive, in consideration of such cancellation, (a) a payment in cash (subject
to any applicable withholding or other Taxes required by applicable Law to be
withheld) in an amount equal to the product of (1) the total number of shares
of Common Stock subject to such Common Warrant multiplied by (2) the Common
Per-Share Merger Consideration less the exercise price per share of Common
Stock subject to such Common Warrant (any such amount payable hereunder with
respect to any such Common Warrant being referred to as a "Common Warrant
Payment", and the aggregate of all such amounts payable hereunder being
referred to as the "Common Warrant Payments"), and (b) the right to receive
payments from the General Escrow Account and the Equityholders' Representative
Escrow Account in accordance with the Escrow Agreement and Section 3.3, (ii)
each unexpired and unexercised warrant to purchase shares of Series B
Preferred Stock (the "Series B Warrants") pursuant to a contract or agreement
to which the Company is a party shall, immediately prior to its termination in
accordance with 
 

 

  

 

 

 

  

 

17  

  

 

 

 

  

  

its terms at the Closing, be cancelled and, in exchange therefor, each former
holder of any such cancelled Series B Warrant shall be converted into a right
to receive, in consideration of such cancellation, (a) a payment in cash
(subject to any applicable withholding or other Taxes required by applicable
Law to be withheld) in an amount equal to the product of (1) the total number
of shares of Series B Preferred Stock subject to such Series B Warrant
multiplied by (2) the Series B Preferred Per-Share Merger Consideration less
the exercise price per share of Series B Preferred Stock subject to such
Series B Warrant (any such amount payable hereunder with respect to any such
Series B Warrant being referred to as a "Series B Warrant Payment", and the
aggregate of all such amounts payable hereunder being referred to as the
"Series B Warrant Payments"), and (b) the right to receive payments from the
General Escrow Account and the Equityholders' Representative Escrow Account in
accordance with the Escrow Agreement and Section 3.3, (iii) each unexpired and
unexercised warrant to purchase shares of Series C Preferred Stock (the
"Series C Warrants") pursuant to a contract or agreement to which the Company
is a party shall, immediately prior to its termination in accordance with its
terms at the Closing, be cancelled and, in exchange therefor, each former
holder of any such cancelled Series C Warrant shall be converted into a right
to receive, in consideration of such cancellation, (a) a payment in cash
(subject to any applicable withholding or other Taxes required by applicable
Law to be withheld) in an amount equal to the product of (1) the total number
of shares of Series C Preferred Stock subject to such Series C Warrant
multiplied by (2) the Series C Preferred Per-Share Merger Consideration less
the exercise price per share of Series C Preferred Stock subject to such
Series C Warrant (any such amount payable hereunder with respect to any such
Series C Warrant being referred to as a "Series C Warrant Payment", and the
aggregate of all such amounts payable hereunder being referred to as the
"Series C Warrant Payments"), and (b) the right to receive payments from the
General Escrow Account and the Equityholders' Representative Escrow Account in
accordance with the Escrow Agreement and Section 3.3, and (iv) each unexpired
and unexercised warrant to purchase shares of Series C-1 Preferred Stock (the
"Series C-1 Warrants" and, together with the Common Warrants, the Series B
Warrants and the Series C Warrants, the "Warrants") pursuant to a contract or
agreement to which the Company is a party shall, immediately prior to its
termination in accordance with its terms at the Closing, be cancelled and, in
exchange therefor, each former holder of any such cancelled Series C-1 Warrant
shall be converted into a right to receive, in consideration of such
cancellation, (a) a payment in cash (subject to any applicable withholding or
other Taxes required by applicable Law to be withheld) in an amount equal to
the product of (1) the total number of shares of Series C-1 Preferred Stock
subject to such Series C-1 Warrant multiplied by (2) the Series C-1 Preferred
Per-Share Merger Consideration less the exercise price per share of Series C-1
Preferred Stock subject to such Series C-1 Warrant (any such amount payable
hereunder with respect to any such Series C-1 Warrant being referred to as a
"Series C-1 Warrant Payment", and the aggregate of all such amounts payable
hereunder being referred to as the "Series C-1 Warrant Payments" and, together
with the Common Warrant Payments, the Series B Warrant Payments and the Series
C Warrant Payments, the "Warrant Payments"), and (b) the right to receive
payments from the General Escrow Account and the Equityholders' Representative
Escrow Account in accordance with the Escrow Agreement and Section 3.3. All
such Warrants shall no longer be outstanding and shall automatically be
canceled and retired and shall cease to exist, and each Certificate which
immediately prior to the Effective Time represented such Warrants shall
thereafter represent the right to receive the Warrant Payment payable therefor
and the right to receive payments from the General Escrow Account and the
Equityholders' Representative Escrow Account in accordance with the Escrow
Agreement and Section 3.3. Certificates previously representing Warrants shall
be exchanged for the Warrant Payment payable in respect of such Certificates,
without interest, upon the surrender of such Certificates in accordance with
the provisions of Section 3.1. 
 

  

 

 

 

  

 

18  

  

 

 

 

  

 

  

 

SECTION 2.7 Total Cash Equity Price Adjustments

 

  

  

(a) Estimated Closing Statement. The Company shall deliver to Parent, no later
than three (3) Business Days prior to the Closing, a statement (the "Estimated
Closing Statement") setting forth good faith estimates of (i) the Working
Capital and Estimated Working Capital Adjustment, (ii) the Indebtedness of the
Company on the Closing Date but immediately prior to the Closing (the "Closing
Date Indebtedness"), (iii) the Cash Equivalents on hand at the Company on the
Closing Date but immediately prior to the Closing (the "Closing Date Cash"),
(iv) the Company Transaction Expenses, (v) the Estimated Balance Sheet and
(vi) the Estimated Total Cash Equity Price. For the avoidance of doubt, these
estimates (and the calculations resulting therefrom) shall take into account,
(x) in the case of and as a reduction to Closing Date Cash, the payment in
cash of the Company Transaction Expenses and the Management Retention Bonuses,
at or prior to Closing, as contemplated by Section 2.8 and (y) in the case of
the Working Capital, an accrual for the aggregate Pro-Rata Bonuses to be paid
by the Surviving Corporation after the Closing in accordance with Section 2.8.
The estimates of Working Capital, Closing Date Indebtedness and Closing Date
Cash provided in the Estimated Closing Statement are referred to herein as the
"Estimated Working Capital", the "Estimated Closing Date Indebtedness" and the
"Estimated Closing Date Cash", respectively. The Company shall also deliver to
Parent (1) its calculations of the following (each determined in accordance
with the definitions thereof as of the Closing and based on the Estimated
Total Cash Equity Price): Common Merger Consideration, Common Per-Share Merger
Consideration, Fully-Diluted Common Stock, Merger Consideration, Option In-the
Money Amount, Common Warrant In-the-Money Amount, Series B Warrant In-the-
Money Amount, Series C Warrant In-the-Money Amount, Series C-1 Warrant In-the-
Money Amount, Series A Preferred Per-Share Merger Consideration, Series B
Preferred Per-Share Merger Consideration, Series C Preferred Per-Share Merger
Consideration, Series C-1 Preferred Per-Share Merger Consideration, Total
Common Merger Consideration, Total Series A Preferred Merger Consideration,
Total Series A Preferred Merger Preference, Total Series B Preferred Merger
Consideration, Total Series B Preferred Merger Preference, Total Series C
Preferred Merger Consideration, Total Series C Preferred Merger Preference,
Total Series C-1 Preferred Merger Consideration and Total Series C-1 Preferred
Merger Preference and (2) a detailed schedule setting forth (A) the name of
each Equityholder, (B) the number of shares of Common Stock, Preferred Stock,
Options and Warrants held by each such Equityholder, and (C) based on the
calculations described above, the portion of the Merger Consideration, Option
Payments and Warrant Payments to be received by each such Equityholder.

  

 

  

(b) Closing Statements. Within sixty (60) days following the Closing Date,
Parent will prepare and deliver to the Equityholders' Representative an
unaudited balance sheet of the Company as of the Closing (the "Closing Balance
Sheet"), together with a statement (the "Closing Statement") setting forth the
Working Capital, the Closing Date Indebtedness, the Closing Date Cash and the
Adjustment Amount, in each case, as reflected on and derived from the Closing
Balance Sheet, and the Total Cash Equity Price. The Closing Balance Sheet and
Closing Statement shall be prepared in accordance with GAAP using the same
applicable accounting methods, accounting practices, assumptions, policies and
methodologies as were used in preparing the Company Financial Statements.
Section 2.7 of the Company Disclosure Schedule sets forth an example of the
calculation of the Working Capital, Closing Date Indebtedness and Closing Date
Cash as of June 30, 2011. The Working Capital, Closing Date Indebtedness,
Closing Date Cash and Adjustment Amount set forth on the Closing Working
Capital Statement shall be derived from the Closing Balance Sheet using the
same applicable accounting methods, accounting practices, assumptions,
policies and methodologies as were used in the calculation set forth on
Section 2. 7 of the Company Disclosure Schedule. In the event Parent does not
deliver the Closing Balance Sheet and Closing Statement to the Equityholders'
Representative within sixty (60) days following the Closing Date, the
Estimated Balance Sheet and Estimated Closing Statement shall be deemed to be
final and binding on the Parties and the Estimated Closing Statement shall be
deemed to be the Final Closing Statement for all purposes hereunder.

  


 

  

 

 

 

  

 

19  

  

 

 

 

  

  

 

 

 

 

(c) Notice of Disagreement. The Closing Statement shall become final and
binding upon the Parties on the date (the "Final Settlement Date") that is
forty-five (45) days following receipt thereof by the Equityholders'
Representative unless the Equityholders' Representative gives written notice
of its disagreement ("Notice of Disagreement") to Parent prior to such date.
Any Notice of Disagreement shall specify in reasonable detail the dollar
amount, nature and basis of any disagreement so asserted and any portion of
the Closing Statement not subject to any disagreement shall be deemed to be
final as set forth in the Closing Statement. If a Notice of Disagreement is
received by Parent in a timely manner, then the Closing Statement (as revised
in accordance with Section 2.7(d) below, if applicable) shall become final and
binding on the Parties on, and the Final Settlement Date shall be, the earlier
of (i) the date upon which the Equityholders' Representative and Parent agree
in writing with respect to all matters specified in the Notice of Disagreement
and (ii) the date upon which the Final Closing Statement is issued by the
Arbitrator.

  

  

(d) Final Closing Statement. During the first twenty (20) days following the
date upon which Parent receives a Notice of Disagreement, the Equityholders'
Representative and Parent shall attempt in good faith to resolve in writing
any differences that they may have with respect to all matters specified in
the Notice of Disagreement. If at the end of such twenty (20) day period (or
earlier by mutual agreement to arbitrate) Parent and the Equityholders'
Representative have not reached agreement on such matters, the matters that
remain in dispute may be submitted to Grant Thornton LLP (the "Arbitrator") by
either Party for review and resolution. If Grant Thornton LLP is unable to
serve as the "Arbitrator" hereunder, the Arbitrator shall be a internationally
recognized independent public accounting firm agreed upon by Parent and the
Equityholders' Representative in writing. As promptly as practicable (but in
no event more than thirty (30) days) after the retention of the Arbitrator,
Parent and the Equityholders' Representative shall each prepare and submit a
presentation to the Arbitrator. As soon as practicable (but in no event more
than thirty (30) days) thereafter, the Arbitrator shall determine the amount
of each item in dispute and prepare a Final Closing Statement and calculation
of Working Capital, Closing Date Indebtedness and Closing Date Cash in
accordance with the principles in this Section 2.7, which shall include an
explanation in writing of the Arbitrator's reasons for the determinations set
forth therein. The Arbitrator shall act as an arbitrator and shall address
only those items in dispute and for each item may not assign a value greater
than the greatest value for such item claimed by either Party or smaller than
the smallest value for such item claimed by either Party. The decision of the
Arbitrator shall be final and binding on the Parties. The costs, fees and
expenses of the Arbitrator in connection with the Arbitrator's review pursuant
to this Section 2.7(d) (including reasonable attorney's fees of the
Arbitrator) shall be borne fifty percent (50%) by Parent and fifty percent
(50%) by the Equityholders out of the Equityholders' Representative Escrow
Account. Each of Parent and the Equityholders' Representative shall pay its
own costs, fees and expenses (including attorney's fees) in connection with
the Arbitrator's review pursuant to this Section 2.7(d), without right of
reimbursement from such other Party; provided, that such costs, fees and
expenses of the Equityholders' Representative (up to a maximum of one million
dollars ($1,000,000)), including any amounts payable to the Arbitrator out of
the Equityholders' Representative Escrow Account pursuant to the previous
sentence) shall be paid out of the Equityholders' Representative Escrow
Account.

 

 

 

   
 

  

(e) Final Settlement and Adjustment to Total Cash Equity Price.

  


 

  

(i) (A) If the Adjustment Amount as derived from the Final Closing Statement
is a negative number, then the Total Cash Equity Price shall be decreased by
an amount, not to exceed the amount held in the General Escrow Account, equal
to such Adjustment Amount as derived from the Final Closing Statement
("Shortfall Reduction") and (B) if the Adjustment Amount as derived from the
Final Closing Statement is a positive number, then the Total Cash Equity Price
shall be increased by an amount equal to such Adjustment Amount ("Excess
Payment").

  


 

  

 

 

 

  

 

20  

  

 

 

 

  

  

 

(ii) Any Shortfall Reduction or Excess Payment described in clause (A) or (B)
in Section 2.7(e)(i) shall be paid not later than three (3) Business Days
after the Final Settlement Date (1) in the case of an Excess Payment, by
Parent by wire transfer of immediately available funds to the Exchange Agent
to be added to the Exchange Fund for the benefit of, and to be distributed to,
the Equityholders in accordance with Section 3.1, or (2) in the case of a
Shortfall Reduction, out of the General Escrow Account by the Equityholders'
Representative and Parent sending a joint written instruction to the Escrow
Agent to disburse funds in the amount of the Shortfall Reduction out of the
General Escrow Account to Parent; provided, that the amount of any such
payment shall not exceed the General Escrow Amount.

 

  


 

  

 

(f) Cooperation. For the purposes of complying with the terms set forth in
this Section 2.7, each Party shall cooperate with and make available to the
other Parties and their respective representatives all information, records,
data and working papers, and shall permit access to its facilities and
personnel, as may reasonably be required in connection with the preparation
and analysis of the Closing Balance Sheet and Closing Statement and the
resolution of any disputes related thereto.

 

  


 

  

(g) Adjustment to Total Cash Equity Price. Any Shortfall Reduction payable
pursuant to this Section 2.7 shall be deemed to be an adjustment to the Total
Cash Equity Price.

  


 

  

SECTION 2.8 Payment of Company Transaction Expenses; Pro-Rata Bonuses. At or
prior to the Closing, the Company shall pay (x) the Company Transaction
Expenses and (y) the Management Retention Bonuses to each Company Employee
eligible under the Management Retention Bonus Plan, as determined in
accordance with the Management Retention Bonus Plan by the Company. Within
five (5) Business Days after Closing, the Surviving Corporation shall pay to
each Company Employee eligible to receive an annual bonus pursuant to the
Annual Bonus Program a pro-rata annual bonus ("Pro-Rata Bonus") in an amount
equal to the product of (i) the Company Employee's target annual bonus under
the Annual Bonus Program with respect to the fiscal year in which the Closing
occurs and (ii) the ratio of (A) the number of days elapsed during the period
beginning on the first day of the Company's fiscal year in which the Closing
occurs and ending on the Closing Date to (B) 365.

  


 

  

SECTION 2.9 Calculations and Iterative Process.

  


 

  

(a) Section 2.9 of the Company Disclosure Schedule sets forth for illustrative
purposes a sample calculation of the allocation of the Merger Consideration,
Option Payments and Warrant Payments among the Equityholders that gives effect
to the provisions of this Agreement based on the assumptions set forth
therein. Such calculation shall use an iterative process (the "Iterative
Process") to determine which Company Options and Warrants are "in-the-money"
based on the applicable exercise price of the Company Options and Warrants in
conjunction with the calculation of the following amounts and definitions:
Common Merger Consideration, Common Per-Share Merger Consideration, Fully-
Diluted Common Stock, Merger Consideration, Option In-the-Money Amount, Common
Warrant In-the-Money Amount, Series B Warrant In-the-Money Amount, Series C
Warrant In-the-Money Amount, Series C-1 Warrant In-the-Money Amount, Series A
Preferred Per-Share Merger Consideration, Series B Preferred Per-Share Merger
Consideration, Series C Preferred Per-Share Merger Consideration, Series C-1
Preferred Per-Share Merger Consideration, Total Common Merger Consideration,
Total Series A Preferred Merger Consideration, Total Series A Preferred Merger
Preference, Total Series B Preferred Merger Consideration, Total Series B
Preferred Merger Preference, Total Series C Preferred Merger Consideration,
Total Series C Preferred Merger Preference, Total Series C-1 Preferred Merger
Consideration, and Total Series C-1 Preferred Merger Preference.

  


 

  

 

 

 

  

 

21  

  

 

 

 

  

  

(b) For the avoidance of doubt, the aggregate amounts payable by Parent or the
Surviving Corporation under this Agreement in respect of Company Capital
Stock, Company Options and Warrants shall equal (and not exceed) the Estimated
Total Cash Equity Price plus any Excess Payment plus funds released from time
to time from the General Escrow Account or the Equityholders' Representative
Escrow Account to the Equityholders.

  


 

  

ARTICLE III. 
 

  

EXCHANGE OF COMPANY CERTIFICATES

  


 

  

SECTION 3.1 Exchange of Company Certificates.

  


 

  

 

(a) Exchange Agent. At or prior to the Effective Time, and subject to Section
3.1(c), Parent shall deposit, or shall cause to be deposited, (i) with
JPMorgan Chase Bank, N.A., or another bank or trust company designated by
Parent and reasonably satisfactory to the Company (the "Exchange Agent"), for
the benefit of the holders of shares of Company Capital Stock and Warrants,
cash in U.S. dollars in an amount equal to the Estimated Total Cash Equity
Price less an amount equal to the Closing Option Payments (such cash, together
with any Excess Payment (and interest thereon) being hereinafter referred to
as the "Exchange Fund"), (ii) with the Escrow Agent, the General Escrow Amount
to the General Escrow Account and the Equityholders' Representative Escrow
Amount to the Equityholders' Representative Escrow Account, and (iii) with the
Surviving Corporation, the amount equal to the Closing Option Payments. The
Exchange Agent shall, pursuant to irrevocable instructions from the Company,
deliver the Merger Consideration and the Warrant Payments contemplated to be
paid pursuant to, and in accordance with the terms of, Section 2.6 and this
Article III out of the Exchange Fund. The Exchange Fund shall not be used for
any other purpose. Notwithstanding anything else in Article II or this Article
III to the contrary, payment of Merger Consideration and the Warrant Payments
may be made in installments as necessary to take into account any adjustments
to the Total Cash Equity Price pursuant to Section 2.7, and any Excess
Payment.

   
 

  

 

(b) Exchange Procedures. Subject to Section 3.1(c), promptly following the
Effective Time (but in no event later than two (2) Business Days following the
Effective Time), Parent shall instruct the Exchange Agent to mail to each
holder of record of a certificate or certificates which immediately prior to
the Effective Time represented outstanding shares of Company Capital Stock or
Warrants (the "Certificates") (A) a letter of transmittal substantially in the
form attached hereto as Exhibit C ("Letter of Transmittal"), which shall
specify that delivery shall be effected, and risk of loss and title to the
Certificates shall pass, only upon proper delivery of the Certificates to the
Exchange Agent and shall be in customary form reasonably satisfactory to
Parent and the Equityholders' Representative, and (B) instructions for use in
effecting the surrender of the Certificates in exchange for the portion of the
Merger Consideration or Warrant Payment (as applicable) receivable in respect
of such Certificates. Upon surrender of a Certificate for cancellation to the
Exchange Agent together with such Letter of Transmittal, properly completed
and duly executed, and such other documents as may be required pursuant to
such instructions, the holder of such Certificate shall be entitled to receive
in exchange therefor the portion of the Merger Consideration or Warrant
Payment (as applicable) which such holder has the right to receive in respect
of the shares of Company Capital Stock or Warrants formerly represented by
such Certificate (and the right to receive payments from the General Escrow
Account and the Equityholders' Representative Escrow Account in accordance
with the Escrow Agreement and Section 3.3), and the Certificate so surrendered
shall forthwith be canceled. Following any receipt of an Excess Payment, the
Exchange Agent will deliver to each holder of surrendered Certificates, such
holder's pro rata portion thereof; provided, that if the Exchange Agent
receives an Excess Payment prior to receipt of surrendered Certificates, then
payment of the portion thereof applicable to such unsurrendered Certificates
shall be made at the same time as payment of the balance of the applicable
Merger Consideration or Warrant 
 

 

  

 

 

 

  

 

22  

  

 

 

 

  


 

  

 

Payment (as applicable) upon surrender thereof. No interest will be paid or
accrued on any Merger Consideration or Warrant Payment (as applicable) payable
to holders of Certificates. In the event of a transfer of ownership of shares
of Company Capital Stock or Warrants that is not registered in the transfer
records of the Company, the portion of the Merger Consideration or Warrant
Payment (as applicable) payable in respect of such shares of Company Capital
Stock or Warrants may be issued to a transferee if the Certificate
representing such shares of Company Capital Stock or Warrants is presented to
the Exchange Agent, accompanied by any documents reasonably required to
evidence and effect such transfer and by evidence that any applicable stock
transfer Taxes have been paid. Until surrendered as contemplated by this
Section 3.1, each Certificate shall, subject to Section 3.2, be deemed at any
time after the Effective Time to represent only the right to receive upon such
surrender the portion of the Merger Consideration or Warrant Payment (as
applicable) payable in respect of such Certificate as set forth in Section
2.6.

   
 

  

 

(c) Exchange at Closing. Notwithstanding Section 3.1(b), each holder of a
Certificate, upon surrender thereof to the Exchange Agent at the Closing
together with a Letter of Transmittal (properly completed and duly executed)
and any other required documents of transfer, and provided such holder has
provided Parent and the Exchange Agent with at least five (5) Business Days'
written notice of its intention to so surrender its Certificates, shall be
entitled to receive at or immediately after the Closing in exchange therefor
the portion of the Merger Consideration or Warrant Payment (as applicable)
which such holder has the right to receive in respect of the shares of Company
Capital Stock or Warrants formerly represented by such Certificates (and shall
also be entitled to the right to receive payments from the General Escrow
Account and the Equityholders' Representative Escrow Account in accordance
with the Escrow Agreement and Section 3.3). Promptly following such surrender,
the Exchange Agent shall deliver the portion of the Merger Consideration or
Warrant Payment (as applicable) payable out of the Exchange Fund in respect of
such surrendered Certificates.

   
 

  

 

(d) Termination of Exchange Fund. Any portion of the Exchange Fund which
remains undistributed to the holders of Company Capital Stock and Warrants as
of the earlier to occur of (i) one (1) month after the Final Settlement Date
and (ii) one (1) year after the Effective Time shall be delivered to Parent
upon demand, and any holders of Company Capital Stock and Warrants who have
not theretofore complied with this Article III shall thereafter look only to
Parent for the Merger Consideration or Warrant Payments.

   
 

  

(e) No Liability. No Party shall be liable to any holder of shares of Company
Capital Stock or Warrants for any cash from the Exchange Fund or other amount
delivered to a public official pursuant to any abandoned property, escheat or
similar Law.

  


 

  

 

(f) Lost or Missing Certificates. If any Certificate shall have been lost,
stolen or destroyed or shall otherwise be missing, upon the making of an
affidavit of that fact by the Person claiming such Certificate to be lost,
stolen, destroyed or missing and, if required by Parent, the execution and
delivery by such Person of an indemnity agreement against any claim that may
be made against the Exchange Agent with respect to such Certificate in
customary form and substance reasonably satisfactory to Parent, the Exchange
Agent will deliver in exchange for such lost, stolen, destroyed or missing
Certificate, the portion of the Merger Consideration or Warrant Payment (as
applicable) payable in respect of such lost, stolen, destroyed or missing
Certificate (and such Person shall have the right to receive payments from the
General Escrow Account and the Equityholders' Representative Escrow Account in
accordance with the Escrow Agreement and Section 3.3).

   
 

  

(g) Withholding. Parent, the Surviving Corporation, the Exchange Agent and the
Escrow Agent shall be entitled to deduct and withhold from the consideration
otherwise payable pursuant

  


 

  

 

 

 

  

 

23  

  

 

 

 

  

  

to this Agreement or the Escrow Agreement to any holder of Company Capital
Stock, Company Options or Warrants such amounts as Parent, the Surviving
Corporation, the Exchange Agent and the Escrow Agent are required to deduct
and withhold under the Code, or any provision of state, local or foreign tax
Law, with respect to the making of such payment. To the extent that amounts
are so withheld by Parent, the Surviving Corporation, Exchange Agent or the
Escrow Agent and timely paid over to the applicable Government Authority, such
withheld amounts shall be treated for all purposes of this Agreement as having
been paid to the holder of Company Capital Stock, Company Options or Warrants
in respect of whom such deduction and withholding was made by Parent, the
Surviving Corporation, the Exchange Agent or the Escrow Agent.

  


 

  

SECTION 3.2 Appraisal Rights. Notwithstanding anything in this Agreement to
the contrary, if any Dissenting Stockholder shall demand to be paid the "fair
value" of such Dissenting Stockholder's shares of Company Capital Stock, as
provided in Section 262 of the DGCL, such shares of Company Capital Stock
shall not be converted into or exchangeable for the right to receive any
portion of the Merger Consideration (except as provided in this Section 3.2)
and shall entitle such Dissenting Stockholder only to payment of the fair
value of such shares of Company Capital Stock, in accordance with Section 262
of the DGCL, unless and until such Dissenting Stockholder withdraws (in
accordance with Section 262(k) of the DGCL) or effectively loses the right to
dissent. Neither the Company nor the Surviving Corporation shall, except with
the prior written consent of Parent, voluntarily make any payment with respect
to, or settle or offer to settle, any such demand for payment of fair value of
a Dissenting Stockholder's shares of Company Capital Stock and the Company
shall give Parent notice thereof and Parent shall have the right to
participate at its own expense in all negotiations and proceedings with
respect to any such demands. If any Dissenting Stockholder shall have
effectively withdrawn (in accordance with Section 262(k) of the DGCL) or lost
the right to dissent, then as of the later of the Effective Time or the
occurrence of such event, the shares of Company Capital Stock held by such
Dissenting Stockholder shall be converted into and represent the right to
receive the applicable portion of the Merger Consideration pursuant to Section
2.6.

  

  

SECTION 3.3 Escrow. The General Escrow Amount shall be delivered to the Escrow
Agent at or prior to the Effective Time to be held in escrow as security for
the payment of any Shortfall Reduction under Section 2.7(e) and
indemnification claims under Article IX pursuant to the provisions of the
Escrow Agreement. The Equityholders' Representative Escrow Amount delivered to
the Escrow Agent shall be deposited in a separate account (the "Equityholders'
Representative Escrow Account") to be held in escrow to fund the out-of-pocket
costs and expenses of the Equityholders' Representative pursuant to the
provisions of the Escrow Agreement. Within five (5) Business Days of the
Escrow Termination Date, except as otherwise provided in the Escrow Agreement
with respect to outstanding claims and the Investment Income Tax Amount (as
defined in the Escrow Agreement), each of Parent and the Equityholders'
Representative shall execute joint written instructions to the Escrow Agent
instructing the Escrow Agent to disburse to the holders of Company Capital
Stock and Warrants and to the Surviving Corporation (for distribution of
Option Payments to the holders of Company Options) their respective pro rata
portions of the balance of the Escrow Amount, together with any earnings
thereon pursuant to the Escrow Agreement, less any amounts owing to the
Equityholders' Representative.

  

  

SECTION 3.4 No Further Ownership Rights in Shares of Company Capital Stock;
Closing of Company Transfer Books. At and after the Effective Time, each
holder of Company Capital Stock shall cease to have any rights as a
stockholder of the Company, except for, in the case of a holder of Company
Capital Stock (other than shares to be cancelled pursuant to Section 2.6(b)),
the right to surrender his or her Certificate in exchange for payment of the
applicable Merger Consideration or, in the case of a Dissenting Stockholder,
to perfect his or her right to receive payment for his or her shares of
Company Capital Stock pursuant to the DGCL. At the Effective Time, the stock
transfer books

  

  

 

 

 

  

 

24  

  

 

 

 

  

  

of the Company shall be closed, and no transfer of shares of Company Capital
Stock shall thereafter be made. If, after the Effective Time, Certificates are
presented to the Surviving Corporation, they shall be cancelled and exchanged
as provided for in this Agreement.

  

  


 

  

ARTICLE IV. 
 

  

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

  


 

  

Contemporaneously with the execution and delivery of this Agreement by the
Parties hereto, the Company shall deliver to Parent and Merger Sub a
disclosure schedule with numbered sections corresponding to the relevant
sections in this Agreement (the "Company Disclosure Schedule"). Any exception
or qualification set forth in the Company Disclosure Schedule with respect to
a particular representation, warranty or covenant contained herein shall be
deemed to be an exception or qualification with respect to all other
applicable representations, warranties and covenants contained in this
Agreement if the applicability of such exception or qualification to any other
applicable representation, warranty or covenant would be reasonably apparent
to a Person reviewing the Company Disclosure Schedule regardless of whether an
explicit reference to such other representation, warranty or covenant is made.
Nothing in the Company Disclosure Schedule is intended to broaden the scope of
any representation, warranty or covenant of the Company contained in this
Agreement. Subject to the exceptions and qualifications set forth in the
Company Disclosure Schedule, the Company hereby represents and warrants to
Parent and Merger Sub, as of the date hereof and as of the Closing Date, as
follows:

  


 

  

SECTION 4.1 Authority.

  


 

  

(a) The Company has all requisite corporate power and authority to enter into
this Agreement, and subject to receipt of the Required Company Stockholder
Approval, to perform its obligations hereunder and to consummate the
transactions contemplated by this Agreement. The execution and delivery of
this Agreement by the Company, the performance by the Company of its
obligations hereunder, and the consummation by the Company of the transactions
contemplated by this Agreement have been duly authorized by the Board of
Directors of the Company, and no other corporate action on the part of the
Company is necessary to authorize the execution and delivery of this Agreement
by the Company, the performance by the Company of its obligations hereunder or
the consummation by the Company of the transactions contemplated by this
Agreement, other than the Required Company Stockholder Approval. This
Agreement has been duly executed and delivered by the Company and, assuming
due authorization, execution and delivery by the other Parties to this
Agreement, this Agreement constitutes a legally valid and binding obligation
of the Company, enforceable against the Company in accordance with its terms,
except as such enforceability may be limited by principles of public policy,
and subject to (i) the effect of any applicable Law of general application
relating to bankruptcy, reorganization, insolvency, or moratorium or similar
Laws affecting creditors' rights and relief of debtors generally and (ii) the
effect of rules of Law and general principles of equity, including rules of
Law and general principles of equity governing specific performance,
injunctive relief and other equitable remedies (regardless of whether such
enforceability is considered in a proceeding in equity or at Law).

  


 

  

(b) The affirmative vote or consent of (A) the holders of a majority of the
shares of the outstanding Company Capital Stock (excluding the Series C-1
Preferred Stock) voting or consenting, as the case may be, on an as-converted
to Common Stock basis and (B) the holders of sixty percent (60%) of the shares
of the outstanding Series C Preferred Stock voting or consenting, as the case
may be, together as a single class are the only votes of the holders of any
Company Capital Stock necessary under the DGCL and the Company Certificate of
Incorporation to adopt this Agreement (collectively, the "Required Company
Stockholder Approval").

  


 

  

 

 

 

  

 

25  

  

 

 

 

  

  

SECTION 4.2 Organization; Subsidiaries.

  


 

  

(a) The Company is a corporation duly organized, validly existing and in good
standing under the Laws of the State of Delaware, and has all requisite
corporate power and authority to carry on the Business in all material
respects. The Company is duly qualified to do business and is in good
standing, if applicable, in each jurisdiction where the conduct of the
Business requires such qualification, except where the failure to be so
qualified or in good standing would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect. True and complete
copies of the Company Certificate of Incorporation and Bylaws (the "Company
Bylaws") of the Company, each as amended to date, have been made available to
Parent or its advisors.

  


 

  

(b) The Company does not own or control, and has not owned or controlled,
directly or indirectly, any interest in any other Person. Except as listed in
Section 4.2(b) of the Company Disclosure Schedule, the Company is not a
participant in any joint venture, partnership, limited liability company or
similar arrangement.

  


 

  

SECTION 4.3 Capitalization.

  


 

  

 

(a) The authorized capital stock of the Company consists of 44,000,000 shares
of Common Stock, 500,561 shares of Series A Preferred Stock, 1,541,114 shares
of Series B Preferred Stock, 8,900,629 shares of Series C Preferred Stock and
1,335,643 shares of Series C-1 Preferred Stock. As of the date of this
Agreement, there are 734,992 shares of Common Stock, 500,561 shares of Series
A Preferred Stock, 1,501,117 shares of Series B Preferred Stock, 8,375,965
shares of Series C Preferred Stock and no shares of Series C-1 Preferred Stock
issued and outstanding. All such issued and outstanding shares of Company
Capital Stock have been duly authorized and validly issued, are fully paid and
nonassessable and were not issued in violation of any preemptive or similar
rights created by statute, the Company Certificate of Incorporation, the
Company Bylaws or any agreement to which the Company is a party or by which it
is bound, and have been issued in compliance with applicable federal and state
securities or "blue sky" Laws. As of the date of this Agreement, (i) the
applicable conversion price of the Series A Preferred Stock is $1.8370 per
share, (ii) the applicable conversion price of the Series B Preferred Stock is
$2.0411 per share, (iii) the applicable conversion price of the Series C
Preferred Stock is $1.3855 per share and (iv) the applicable conversion price
of the Series C-1 Preferred Stock is $1.3855 per share. Section 4.3(a) of the
Company Disclosure Schedule sets forth, as of the date of this Agreement, the
name of each holder of shares of Company Capital Stock and the number and
class of shares of Company Capital Stock held of record by each such
Equityholder. There are no accrued or unpaid dividends with respect to any
issued and outstanding shares of Company Capital Stock that will not be
satisfied by the payment of the Merger Consideration hereunder.

   
 

  

 

(b) (i) Common Warrants to purchase 454,698 shares of Common Stock, (ii)
Series B Warrants to purchase 39,404 shares of Series B Preferred Stock, (iii)
Series C Warrants to purchase 524,664 shares of Series C Preferred Stock and
(iv) Series C-1 Warrants to purchase 1,161,429 shares of Series C-1 Preferred
Stock are outstanding as of the date hereof. Section 4.3(b) of the Company
Disclosure Schedule sets forth, as of the date of this Agreement, the name of
each holder of Warrants and the number and class of shares of Company Capital
Stock that each Warrant has the right to purchase, and the exercise price of
each Warrant held of record by each such warrant holder.

   
 

  

(c) As of the date hereof, Company Options to purchase 8,987,303 shares of
Common Stock are issued and outstanding and 306,122 shares of Common Stock
remain available for issuance pursuant to the Company Stock Plan. Section
4.3(c) of the Company Disclosure Schedule sets forth, as of the date of this
Agreement, the name of each holder of Company Options, the number of

  

  

 

 

 

  

 

26  

  

 

 

 

  

  

Company Options held by such holder of Company Options, with vested and
unvested amounts separately reflected, whether the option is intended to be an
incentive stock option and the exercise price of each Company Option.

  


 

  

 

(d) As of the date of this Agreement, except as listed in Section 4.3(d) of
the Company Disclosure Schedule, there are no outstanding (i) options,
warrants, calls, rights of conversion or other rights, agreements,
arrangements or commitments of any kind or character, relating to the Company
Capital Stock to which the Company is a party, or by which it is bound,
obligating the Company to issue, deliver or sell, or cause to be issued,
delivered or sold, any shares of its capital stock or (ii) bonds debentures,
notes or other Indebtedness of the Company having the right to vote (or
convertible into, or exchangeable for, securities having the right to vote) on
any matters on which stockholders of the Company may vote.

   
 

  

 

(e) As of the date of this Agreement, except as listed in Section 4.3(e) of
the Company Disclosure Schedule, there are (i) no rights, agreements,
arrangements or commitments of any kind or character, whether written or oral,
relating to the Company Capital Stock to which the Company is a party, or by
which it is bound, obligating the Company to repurchase, redeem or otherwise
acquire any issued and outstanding shares of the Company Capital Stock; (ii)
no outstanding or authorized stock appreciation, phantom stock, profit
participation, or other similar rights with respect to the Company; and (iii)
no voting trusts, stockholder agreements, proxies or other agreements or
understandings in effect to which the Company is a party with respect to the
governance of the Company or the voting or transfer of any shares of capital
stock of the Company.

   
 

  

SECTION 4.4 Conflicts. Assuming the Required Company Stockholder Approval and
all consents, waivers, approvals, authorizations, orders, permits,
declarations, filings, registrations and notifications and other actions set
forth in Section 4.5 have been obtained or made, the execution and delivery of
this Agreement by the Company, the performance by the Company of its
obligations hereunder, and the consummation by the Company of the transactions
contemplated by this Agreement do not and will not (i) conflict with or result
in a violation or breach in any material respect of the Company Certificate of
Incorporation or Company Bylaws; (ii) conflict with or result in a violation
or breach of any material Governmental Order or material Law applicable to the
Company or its assets or properties; or (iii) result in a material violation
or breach of, or constitute a material default (or event which with the giving
of notice or lapse of time, or both, would become a material default) under,
or give rise to any rights of termination, amendment, modification,
acceleration or cancellation of or loss of any benefit under, or result in the
creation of any Encumbrance on any of the assets or properties of the Company
pursuant to, any material Contract, Permit or similar authorization to which
the Company is a party, or by which any of the assets or properties of the
Company is bound or affected.

  


 

  

SECTION 4.5 Consents, Approvals, Etc. Except as set forth in Section 4.5 of
the Company Disclosure Schedule, no material consent, waiver, approval,
authorization, order or permit of, or declaration, filing or registration
with, or notification to, any Governmental Authority is required to be made or
obtained by the Company in connection with the execution and delivery of this
Agreement by the Company, the performance by the Company of its obligations
hereunder, or the consummation by the Company of the transactions contemplated
by this Agreement, except: (i) the filing of the Certificate of Merger
pursuant to the DGCL; (ii) applicable requirements, if any, under the DGCL,
federal or state securities or "blue sky" Laws; and (iii) such filings as may
be required under the HSR Act.

  


 

  

 

 

 

  

 

27  

  

 

 

 

  

  

SECTION 4.6 Financial Statements; SEC Filings.

  


 

  

(a) The Company has prepared, or caused to be prepared, and made available to
Parent or its advisors the audited financial statements of the Company
(including the balance sheet and the related statements of income and cash
flows of the Company) as of and for the fiscal year ended January 1, 2011 (the
"Audited Company Financial Statements"), and the unaudited financial
statements of the Company (including the balance sheet and the related
statements of income and cash flows of the Company) as and for the three-
month period ended April 2, 2011 (the "Unaudited Company Financial
Statements", and together with the Audited Company Financial Statements, the
"Company Financial Statements"). Except as set forth therein and in Section
4.6(a) of the Company Disclosure Schedule, the Company Financial Statements
have been prepared in accordance with GAAP applied on a consistent basis
throughout the periods indicated therein and with each other (except that the
Unaudited Company Financial Statements may not contain all of the notes
required by GAAP and are subject to year-end audit adjustments), and present
fairly, in all material respects, the financial position, results of
operations and the cash flows of the Company as of the respective dates and
during the respective periods indicated therein. The audited balance sheet of
the Company as of January 1, 2011 shall be referred to in this Agreement as
the " Current Balance Sheet" and the date thereof shall be referred to in this
Agreement as the "Balance Sheet Date."

  


 

  

(b) The Company's Registration Statement on Form S-1 under the Securities Act
of 1933, as filed or amended on or prior to the date hereof ("Form S-1"), as
of the respective filing dates, (i) did not contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements in the Form S-1, in light of the
circumstances under which they were made, not misleading in any material
respect and (ii) complied as to form in all material respects with the
requirements of the Securities Act of 1933.

  


 

  

SECTION 4.7 Undisclosed Liabilities. The Company has no Liability that is of a
type required to be reflected on the face of a balance sheet of the Company,
or disclosed within the notes thereto, in accordance with GAAP, other than:
(i) as reflected in, reserved against or disclosed in the Company Financial
Statements or in the notes thereto; (ii) as has been incurred since the
Balance Sheet Date in the ordinary course of business consistent with past
practice; (iii) Liabilities arising from matters disclosed in the Company
Disclosure Schedule; (iv) Liabilities included in the calculation of the Final
Closing Statement; or (v) other undisclosed Liabilities which, individually or
in the aggregate, are not material to the Business.

  


 

  

SECTION 4.8 Certain Changes or Events. Since the Balance Sheet Date, except as
set forth in Section 4.8(a) of the Company Disclosure Schedule, the Company
has conducted the Business in the ordinary course consistent with past
practice, and there has not been any event or development that would
reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.

  


 

  

 

(b) Since the Balance Sheet Date until the date hereof, except as set forth in
Section 4.8(b) of the Company Disclosure Schedule, there has not been any
action taken by the Company that, if taken during the Pre-Closing Period
without Parent's consent, would constitute a breach of Section 6.1(b)(ii),
Section 6.1(b)(vii), Section 6.1(b)(ix), Section 6.1(b)(xi), Section
6.1(b)(xii) or Section 6.1(b)(xiii).

 

  

  

SECTION 4.9 Tax Matters.

  


 

  

(a) All material Tax Returns required to be filed by or with respect to the
Company have been timely filed (taking into account applicable extensions of
time to file) with the appropriate

  


 

  

 

 

 

  

 

28  

  

 

 

 

  


 

  

Governmental Authority, and all such Tax Returns are true and complete in all
material respects. All Taxes shown as due on such Tax Returns have been paid.

  


 

  

(b) (i) The charges, accruals and reserves for Taxes with respect to the
Company reflected on the Unaudited Company Financial Statements (excluding any
provision for deferred income taxes) are adequate to cover Tax liabilities
accruing through the date of the Unaudited Company Financial Statements; (ii)
since the end of the Unaudited Company Financial Statements, the Company has
not incurred any tax liabilities, other than in the ordinary course of
business.

  


 

  

(c) No deficiency for any material amount of Taxes has been proposed, asserted
or assessed in writing by any Governmental Authority against the Company,
which remains unpaid, except for any deficiencies that are being contested in
good faith by appropriate proceedings and for which an adequate reserve in
accordance with GAAP has been established on the Current Balance Sheet. All
income Tax Returns filed through the Tax year ended December 31, 2003 have
been examined and closed or are Tax Returns with respect to which the
applicable period for assessment under applicable Law, after giving effect to
extensions or waivers, has expired. To the Knowledge of the Company, there are
no audits, examinations or other administrative or judicial proceedings
currently ongoing, pending or threatened with respect to any material Taxes of
the Company. There are no waivers or extensions of any statute of limitations
currently in effect with respect to Taxes of the Company. No claim has been
made by any Governmental Authority in a jurisdiction where the Company does
not file Tax Returns that the Company is or may be subject to taxation by, or
required to file any Tax Return in, that jurisdiction.

  


 

  

(d) There are no material Encumbrances for Taxes (other than Permitted
Encumbrances) upon the assets of the Company.

  


 

  

(e) All material Taxes required to be withheld or collected by the Company
have been withheld and collected and, to the extent required by Law, timely
paid to the appropriate Governmental Authority.

  


 

  

(f) The Company has not participated in any "reportable transaction" as
defined in Treasury Regulation Section 1.6011-4.

  


 

  

(g) The Company has never been a member of an affiliated group filing a
consolidated federal income Tax Return or any similar group for federal,
state, local or foreign Tax purposes.

  


 

  


 

  

(h) The Company has not in the last three years been a party to any
transaction intended to qualify under Section 355 of the Code.

  


 

  

(i) The Company (i) is not a party to any Tax sharing, Tax allocation or Tax
indemnity agreement, other than pursuant to a customary commercial contract
not primarily related to Taxes and with respect to which, to the Knowledge of
the Company, the Company does not currently have any material liability
relating to Taxes and (ii) has not entered into any agreement or arrangement
with any Governmental Authority with regard to a material Tax liability of the
Company affecting any Tax period for which the applicable statute of
limitations, after giving effect to extensions or waivers, has not expired.

  


 

  

(j) (i) There are no requests for rulings or determinations in respect of any
Tax pending between the Company and any Governmental Authority; and (ii)
during the five-year period ending on the date hereof, the Company has not, to
the extent it may affect the Tax liability of the

  


 

  

 

 

 

  

 

29  

  

 

 

 

  

  

Company following the Closing Date, entered into any closing agreement with
the Internal Revenue Service or any other Tax authority.

  


 

  

(k) The Company will not be required to include any adjustment in taxable
income for any Tax period (or portion thereof) beginning after the Closing
Date under Section 481(c) of the Code (or any similar provision of the Tax
Laws of any jurisdiction) as a result of a change in a method of tax
accounting that is in effect prior to the Closing Date.

  


 

  

(l) The representations of the Company made in this Section 4.9 (other than
the representations set forth in Section 4.9(d), Section 4.9(j) and Section
4.9(k)) refer only to the past activities of the Company and are not intended
to serve as representations to, or a guarantee of, nor can they be relied upon
for with respect to, Taxes attributable to any Tax periods (or portions
thereof) beginning after, or Tax positions taken after, the Closing Date,
including any Taxes arising out of or resulting from any reduction in, loss
of, disallowance of, limitation on or other inability to utilize any net
operating loss, net capital loss, investment tax credit, foreign tax credit,
charitable tax deduction, or other tax credit or attribute.

  


 

  

SECTION 4.10 Litigation and Governmental Orders. (a) There is no Action
pending or, to the Knowledge of the Company, threatened against or affecting
the Company or any of its assets or properties that if determined or resolved
adversely in accordance with the plaintiff's demands would reasonably be
expected to be, individually or in the aggregate, material to the Company or
which in any manner challenges or seeks to prevent, enjoin, alter or
materially delay the transactions contemplated by this Agreement and (b)
neither the Company nor its assets and properties are subject to any material
Governmental Order relating to the Company or any of its assets or properties.
To the extent that any particular matter covered by this Section 4.10 is
covered by Section 4.13, Section 4.13 shall prevail with respect to such
matter.

  

  

SECTION 4.11 Compliance with Laws. The Company is conducting the Business in
compliance in all material respects with applicable Law. Since January 1,
2007, the Company has not violated or been in violation of, and to the
Knowledge of the Company, is not under investigation with respect to and has
not been threatened to be charged with or received any written notice from any
Governmental Authority (including, without limitation, the U.S. Department of
Health and Human Services, including its Office of Inspector General, the U.S.
Department of Justice and any State Attorney General) to the effect that the
Company is not in compliance in all material respects with any applicable Law.
To the extent that any particular matter covered by this Section 4.11 is
covered by Section 4.13, Section 4.13 shall prevail with respect to such
matter.

  

  

SECTION 4.12 Permits. The Company has all material Permits required to permit
the Company to conduct the Business. All of the material Permits held by or
issued to the Company are in full force and effect, the Company is in
compliance in all material respects with, and is not in default under (and no
event which with the giving of notice or lapse of time, or both, would become
a default under), each such Permit, and none of such Permits will be
terminated or impaired or become terminable, in whole or in part, as a result
of the transactions contemplated by this Agreement. This Section 4.12 does not
cover FDA Permits, which are covered solely by Section 4.13.

  

  

SECTION 4.13 Regulatory Matters.

  

  

(a) The Company has all Permits required by the FDA to conduct the Business
(the "FDA Permits"). All of the FDA Permits held by or issued to the Company
are in full force and effect, the Company is in compliance in all material
respects with, and is not in default in any material respect

  


 

  

 

 

 

  

 

30  

  

 

 

 

  


 

  

under (and to the Knowledge of the Company, no event which with the giving of
notice or lapse of time, or both, would become a default under), each such
Permit, and none of such Permits will be terminated or impaired or become
terminable, in whole or in part, as a result of the transaction contemplated
by this Agreement. The Company is the sole and exclusive owner of the FDA
Permits and the associated filings and applications with the FDA, including
any biologics license application, new drug application, 510(k) submission,
premarket approval, investigational new drug or investigational device
exemption application, comparable regulatory application or filing made or
held by or issued to the Company (collectively, the "Company Regulatory
Filings") and holds all right, title and interest in and to all Company
Regulatory Filings free and clear of any Encumbrance (other than Permitted
Encumbrances). The Company has not granted any third party any right or
license to use, access or reference any of the Company Regulatory Filings,
including, without limitation, any of the Know-How contained in any of the
Company Regulatory Filings or rights (including any regulatory exclusivities)
associated with each such Company Regulatory Filing.

  


 

  

(b) Except as set forth on Section 4.13(b) of the Company Disclosure Schedule,
since January 1, 2007, there has not been any voluntarily or involuntarily
initiated, conducted, or issued recall, market withdrawal, safety alert,
warning, "dear doctor" letter, market correction, or investigator notice
relating to an alleged material lack of safety or efficacy of any product of
the Company or product candidate of the Company.

  


 

  

(c) The Company is in compliance in all material respects with all applicable
Laws and any other letters, notices or guidances issued by the FDA or any
Governmental Authority which regulates the sale of pharmaceutical products or
biological, device or regenerative medicine products in any jurisdiction.
There are no pending or, to the Knowledge of the Company, threatened
regulatory Actions (other than non-material routine or periodic inspections or
reviews) against the Company, and to the Knowledge of the Company, there are
no pending or threatened regulatory Actions (other than non-material routine
or periodic inspections or reviews) pertaining to the products or product
candidates of the Company against any Person that manufactures any component,
ingredient, or material used in manufacturing the products or the product
candidates of the Company pursuant to a development, commercialization,
manufacturing, supply or other collaboration arrangement with the Company
("Collaborative Partners") by the FDA or any Governmental Authority which
regulates the sale of pharmaceutical products or biologic, device or
regenerative medicine products in any jurisdiction. Since January 1, 2007
there have been no written notices, reports, warning letters, or untitled
letters alleging or asserting noncompliance in any material respect with any
applicable Law relating to the Company or the products or product candidates
of the Company or any subpoenas or investigative demands or other written
inquiries that would reasonably be interpreted as raising a compliance concern
sent or delivered by any Governmental Authority with regard to any product of
the Company or any product candidate of the Company.

  


 

  

(d) The manufacture of the products of the Company is being conducted in
compliance in all material respects with current "good manufacturing
practices," as defined by the FDA, including, as applicable, the FDA's
"Quality System Regulation" set forth in 21 C.F.R. Part 820.

  


 

  

(e) The Company is and has been in compliance in all material respects with
all Laws requiring the maintenance or submission of reports or records under
requirements administered by the FDA or any other Governmental Authority,
including, for avoidance of doubt, records and reports relating to product
corrections and removals (including FDA requirements set forth in 21 C.F.R.
Part 806), MDRs (including FDA requirements set forth in 21 C.F.R. Part 803),
Adverse Experiences, Serious Adverse Events, Serious Injuries, incidents or
near-incidents and product malfunctions.

  


 

  

 

 

 

  

 

31  

  

 

 

 

  

  

(f) None of the Company or, to the Knowledge of the Company, any of its
Collaborative Partners, agents or subcontractors has been convicted of any
crime or engaged in any conduct which has resulted or could result in
debarment or disqualification by the FDA or any other Governmental Authority,
and there are no proceedings pending or, to the Knowledge of the Company,
threatened that reasonably might be expected to result in criminal or civil
liability or debarment or disqualification by the FDA or any other
Governmental Authority. None of the Company or, to the Knowledge of the
Company, any of its Collaborative Partners has committed any act, made any
statement or failed to make any statement that would reasonably be expected to
provide a basis for the FDA to invoke its policy with respect to "Fraud,
Untrue Statements of Material Facts, Bribery, and Illegal Gratuities" or for
any other Governmental Authority to invoke any similar policy.

  


 

  

(g) There have been no Serious Adverse Events, Serious Injuries or MDR
Reportable Events associated with the use (including in clinical trials) of
the products of the Company or product candidates of the Company that have not
been reported to the FDA in accordance with applicable Law.

  


 

  

(h) To the Knowledge of the Company, all studies, tests, and preclinical and
clinical research being conducted by the Company, and to the Knowledge of the
Company, on behalf of the Company by any of its Collaborative Partners, are
being, and at all times have been, conducted in compliance in all material
respects with all applicable Laws, including, as applicable, good laboratory
practice regulations set forth in 21 C.F.R. Part 58, good clinical practices,
as defined or recognized by the FDA, including the ICH Tripartite Guideline
for Good Clinical Practice, other applicable provisions of the Federal Food,
Drug and Cosmetic Act and its applicable implementing regulations at 21 C.F.R.
Parts 50, 54, 56, 58, 312 and 812, and comparable Laws of any other
Governmental Authority. No clinical trial conducted by the Company or, to the
Knowledge of the Company, on behalf of the Company has been terminated or
suspended prior to completion for safety or non- compliance reasons, and
neither the FDA nor any other Governmental Authority, clinical investigator or
institutional review board that has or had jurisdiction over or participated
in any such clinical trial has initiated, or, to the Knowledge of the Company,
threatened to initiate, any action to place a clinical hold order on, or
otherwise terminate, materially delay or suspend, any such ongoing clinical
trial, or to disqualify, restrict or debar any clinical investigator or other
person or entity involved in any such clinical trial.

  


 

  

(i) Neither the Company nor any officer, director, managing employee (as those
terms are defined in 42 C.F.R.  1001.1001) of the Company, nor, to the
Knowledge of the Company, any agent (as such term is defined in 42 C.F.R. 
1001.1001(a)(1)(ii)) of the Company is a party to, or bound by, any order,
individual integrity agreement, corporate integrity agreement or other formal
or informal agreement with any Governmental Authority concerning compliance
with Federal Health Care Program Laws. 
 

  


 

  

 

(j) Neither the Company nor any officer, director, managing employee (as those
terms are defined in 42 C.F.R.  1001.1001) of the Company, nor, to the
Knowledge of the Company, any agent (as such term is defined in 42 C.F.R. 
1001.1001(a)(1)(ii)) of the Company: (i) has been debarred, excluded or
suspended from participation in any Federal Health Care Program; (ii) has had
a civil monetary penalty assessed against it, him or her under Section 1128A
of the Social Security Act of 1935, codified at Title 42, Chapter 7, of the
United States Code (the "Social Security Act"); (iii) is currently listed on
the General Services Administration published list of parties excluded from
federal procurement programs and non-procurement programs; (iv) to the
Knowledge of the Company, is the target or subject of any current
investigation by a Governmental Authority relating to any Federal Health Care
Program-related offense; or (v) is currently charged with or convicted of any
criminal offense relating to the delivery of an item or service under any
Federal Health Care Program

   
 

  

 

 

 

  

 

32  

  

 

 

 

  


 

  

(k) The Company reasonably believes that it has the requisite know-how and
processes to, subject to any required regulatory approvals, manufacture and
market Dermagraft based on a new cell line in the event that the current cell
line is no longer viable.

  


 

  

(l) To the Knowledge of the Company, there are no pending or threatened
filings against the Company of an action relating to the Company under any
federal or state whistleblower statute, including under the False Claims Act
of 1863 (31 U.S.C.  3729 et seq.).

  


 

  

(m) To the Knowledge of the Company, the Company is not under investigation by
any Governmental Authority for a violation of the Health Insurance Portability
and Accountability Act of 1995, as amended by the Health Information
Technology for Economic and Clinical Health Act ("HIPAA"), or the regulations
contained in 45 C.F.R. Parts 160 and 164, including receiving any notices from
the United States Department of Health and Human Services Office of Civil
Rights relating to any such violations, or any comparable state or local Laws.
The Company is not a "covered entity" as that term is defined in HIPAA. The
Company has been in compliance in all material respects with federal and state
data breach Laws.

  


 

  

(n) To the extent the Company provides reimbursement coding or billing advice
regarding products offered for sale by the Company and procedures related
thereto, such advice is and has been true and complete in all material
respects and in compliance in all material respects with the payment
requirements of Medicare and other Federal Health Care Program Laws.

  


 

  

SECTION 4.14 Tangible Property.

  


 

  

(a) The Company does not own, and has not owned, any real property. Section
4.14(a) of the Company Disclosure Schedule contains a true, correct and
complete list of each parcel of real property that, as of the date of this
Agreement, is leased or licensed from or to a third party by the Company
("Leased Real Property"), the name of the third party lessor(s) or lessee(s)
thereof, as the case may be, the date of the lease or license relating thereto
and all amendments thereof. The Company has a valid and subsisting leasehold
interest in all material Leased Real Property leased by it or license in all
material Leased Real Property licensed by it, in each case free and clear of
all Encumbrances, other than Permitted Encumbrances.

  


 

  

(b) Except as would not reasonably be expected to be, individually or in the
aggregate, material to the Company or the Business, the Company has valid and
subsisting ownership or leasehold interests in all of the tangible personal
assets and properties used or leased for use by the Company in connection with
the conduct of the Business, free and clear of all Encumbrances, other than
Permitted Encumbrances.

  


 

  

(c) The plants, buildings, structures and equipment owned or leased by the
Company have no material defects, are in good operating condition and repair
in all material respects and have been reasonably maintained consistent with
standards generally followed in the industry (giving due account to the age
and length of use of same, ordinary wear and tear excepted), are, to the
Knowledge of the Company, adequate and suitable in all material respects for
their present uses and, in the case of plants, buildings and other structures
(including the roofs thereof), structurally sound in all material respects.

  


 

  

SECTION 4.15 Intellectual Property.

  


 

  

(a) Section 4.15(a) of the Company Disclosure Schedule sets forth a true and
complete list of all (1) material Patents, (2) material registered Trademarks
and applications therefor, (3)

  


 

  

 

 

 

  

 

33  

  

 

 

 

  

  

material registered Copyrights and applications therefor, (4) domain name
registrations and websites and (5) material unregistered Intellectual
Property, in each case, owned or controlled by the Company in the conduct of
the Business specifying as to each such item, as applicable (i) the owner of
the item, (ii) the jurisdictions in which the item is issued or registered or
in which any application for issuance or registration has been filed, (iii)
the respective issuance, registration, or application number of the item, and
(iv) the date of application and issuance or registration of the item.

  

  

(b) Section 4.15(b) of the Company Disclosure Schedule sets forth a true and
complete list of all licenses, sublicenses and other agreements under which
the Company obtains a license, right to use, or a covenant not to be sued
under, Intellectual Property owned or controlled by a third party, excluding
off-the-shelf, shrink-wrap, or click-wrap licenses for commercially available
software under fifty thousand dollars ($50,000).

  


 

  

(c) Section 4.15(c) of the Company Disclosure Schedule sets forth a true and
complete list of all licenses, sublicenses and other agreements under which
the Company grants a license, right to use, or a covenant not to be sued
under, any Intellectual Property.

  


 

  

(d) The Company owns, has a license to or otherwise has the valid and
enforceable right to use, all Intellectual Property necessary to, or used or
held for use in, the operation of the Business as it is currently conducted
and proposed to be conducted as set forth in the Form S-1. The consummation of
the transactions contemplated by this Agreement will not alter, encumber,
impair or extinguish any Owned Intellectual Property or material Licensed
Intellectual Property, impair the right, whether exercised by or on behalf of
the Company, to use, sell, license or dispose of, or bring any Action for the
infringement of, any Owned Intellectual Property or any material Licensed
Intellectual Property, or, through operation of any agreements to which the
Company is a party or is otherwise bound, encumber any of the Intellectual
Property licensed or owned by Parent.

  


 

  

(e) The Company is not a party to or otherwise bound by any agreement that
imposes material restrictions on the use, license or transfer of the Owned
Intellectual Property.

  


 

  

(f) The Company has not infringed, induced or contributed to the infringement
of, misappropriated or otherwise violated, any Intellectual Property of any
third party in any material respect. The Company has not made any pending, or
otherwise threatened in writing to make any, claims that a third party has
infringed, misappropriated or otherwise violated any Owned Intellectual
Property and, to the Knowledge of the Company, no third party has infringed,
misappropriated or otherwise violated in any material respect any Owned
Intellectual Property. There is no Action pending against, or, to the
Knowledge of the Company, threatened against, the Company or to the Company's
Knowledge affecting the Owned Intellectual Property or Licensed Intellectual
Property (i) based upon, or challenging or seeking to deny or restrict, the
rights of the Company in any of the Owned Intellectual Property and the
Licensed Intellectual Property, (ii) alleging that the use of the Owned
Intellectual Property or the Licensed Intellectual Property or any services
provided, processes used or products manufactured, used, imported, offered for
sale or sold by the Company do or may conflict with, misappropriate, infringe
or otherwise violate any Intellectual Property owned or controlled, or
purported to be owned or controlled, by any third party or (iii) otherwise
alleging that the Company has infringed, misappropriated or otherwise violated
any Intellectual Property owned or controlled, or purported to be owned or
controlled, by any third party.

  


 

  

(g) The Company has not received written notice of any claim that any Owned
Intellectual Property or Licensed Intellectual Property is invalid or
unenforceable and, to the Knowledge of the Company, no such claim has
otherwise been threatened against the Company. None of the Owned

  


 

  

 

 

 

  

 

34  

  

 

 

 

  

  

Intellectual Property or, to the Company's Knowledge, Licensed Intellectual
Property has been adjudged invalid or unenforceable in whole or part. All
issued Patents, registered Trademarks and registered Copyrights included in
the Owned Intellectual Property ("Registered IP") are, to the Knowledge of the
Company, valid, enforceable, in full force and effect and subsisting in all
material respects. All registration, maintenance and renewal fees applicable
to the Registered IP that are currently due have been paid and all documents
and certificates related to such items have been filed with the relevant
Governmental Authority or other authorities in the applicable jurisdictions
for the purposes of maintaining such items. Effective written assignments
constituting an unbroken, complete chain-of-title from the original owner(s)
to the Company have been obtained with respect to all of the Owned
Intellectual Property and, as to the Registered IP, have been duly recorded
with the appropriate Governmental Authorities. To the Knowledge of the
Company, there is no relevant prior art revealed, disclosed or discovered
after the issuance of a Patent within the Owned Intellectual Property which
was not cited during prosecution of such Patent.

  


 

  

(h) The Company is the sole and exclusive owner of all Owned Intellectual
Property and holds all right, title and interest in and to all Owned
Intellectual Property and Licensed Intellectual Property free and clear of any
Encumbrance (other than Permitted Encumbrances).

  


 

  

(i) The Company has taken reasonable steps in accordance with normal industry
practice to maintain the confidentiality of all Owned Intellectual Property
and Licensed Intellectual Property that is material to the Business and the
value of which to the Company is contingent upon maintaining the
confidentiality thereof and no such Intellectual Property has been disclosed,
other than to employees, representatives, independent contractors,
collaborators, licensors, licensees, agents and advisors of the Company all of
whom are bound by written confidentiality agreements, or to the Company's
legal, business or financial advisors all of whom are bound to keep such
Intellectual Property confidential, whether by written agreement or otherwise.

  


 

  

(j) The Company has appropriate procedures in place designed to provide that
all Intellectual Property conceived or developed by employees performing their
duties for the Company and by third parties performing research and
development for the Company have been assigned to the Company. To the extent
that any Intellectual Property has been developed or created by a third party
(including any current or former employee of the Company) for the Company, the
Company has a written agreement with such third party with respect thereto,
and the Company thereby either (i) has obtained ownership of and is the sole
and exclusive owner of, or (ii) has obtained a valid and unrestricted right to
exploit, sufficient for the conduct of its Business as currently conducted or
proposed to be conducted in the Form S-1, such Intellectual Property.

  


 

  

(k) The IT Assets operate and perform in a manner that permits the Company to
conduct the Business as currently conducted in all material respects. The
Company takes commercially reasonable actions, consistent with current
industry standards, to protect the confidentiality, integrity and security of
the IT Assets (and all information and transactions stored or contained
therein or transmitted thereby) against any unauthorized use, access,
interruption, modification or corruption, including but not limited to the
implementation of commercially reasonable (i) data backup, (ii) disaster
avoidance and recovery procedures and (iii) business continuity procedures, in
each case consistent with industry practices. 
 

  


 

  

(l) The Company is in compliance in all material respects with all applicable
Laws relating to privacy, data protection and the collection and use of
personal information and user information gathered or accessed in the course
of the operations of the Company. The Company is in compliance in all material
respects with all rules, policies and procedures established by the Company

  


 

  

 

 

 

  

 

35  

  

 

 

 

  

  

from time to time with respect to the foregoing. No claims have been asserted
or threatened against the Company (and to the Knowledge of the Company, no
such claims are likely to be asserted or threatened against the Company) by
any Person alleging a violation of such Person's privacy, personal or
confidentiality rights under any such Laws, rules, policies or procedures. The
consummation of the transaction contemplated by this Agreement will not breach
or otherwise cause any violation of any such Laws, rules, policies or
procedures.

  


 

  

(m) With respect to all personal and user information referred to in Section
4.15(l) above, the Company has at all times taken all steps reasonably
necessary consistent with current industry standards to ensure that such
information is protected against loss and against unauthorized access, use,
modification, disclosure or other misuse. To the Knowledge of the Company,
there has been no unauthorized access to or other misuse of such information.

  


 

  

SECTION 4.16 Certain Contracts.

  


 

  

(a) Section 4.16 of the Company Disclosure Schedule sets forth, as of the date
of this Agreement, a true and complete list of all of the following Contracts
to which the Company is a party (each, a "Material Contract"):

  


 

  

(i) any Contract relating to Indebtedness in excess of five hundred thousand
dollars ($500,000) and whether incurred, assumed, guaranteed or secured by any
asset;

  


 

  

(ii) any joint venture Contract, partnership agreement, limited liability
company agreement, collaboration arrangement or similar arrangement;

  


 

  

(iii) any Contract that contemplates or involves (A) the payment or delivery
of cash or other consideration in an amount or having a value in excess of
five hundred thousand dollars ($500,000) in the aggregate after the date of
this Agreement or (B) the performance of services having a value in excess of
five hundred thousand dollars ($500,000) in the aggregate after the date of
this Agreement;

  


 

  

 

(iv) any Contract with a Governmental Authority;

 

  


 

  

 

(v) any Contract between the Company, on the one hand, and any stockholder,
director, officer or Affiliate of the Company, on the other hand (other than
Contracts set forth on Section 4.17 of the Company Disclosure Schedule);

 

  


 

  

(vi) Contracts containing covenants limiting, in any material respect, the
freedom of the Company to compete with any Person in any line of business or
in any area or territory;

  


 

  

 

(vii) any lease involving Leased Real Property;

 

  


 

  

 

(viii) any Contract listed on Section 4.15(b) or Section 4.15(c) of the
Company Disclosure Schedule;

 

  


 

  

(ix) any Contract that provides for the acquisition, directly or indirectly
(by merger or otherwise), of material assets (whether tangible or intangible)
of any business or the capital stock of another Person;

  


 

  

(x) any agency, dealer, sales representative, marketing or other similar
agreement;

  


 

  

 

 

 

  

 

36  

  

 

 

 

  

  

(xi) any stockholders, investors rights, registration rights or similar
Contracts; and

  


 

  

(xii) to the Knowledge of the Company, any other Contract that is material to
the Business.

  


 

  

(b) The Company has made available to Parent or its advisors true and complete
copies of all Material Contracts.

  


 

  

(c) Each of the Material Contracts is a valid and binding obligation of the
Company and, to the Knowledge of the Company, the other parties thereto,
enforceable against the Company and, to the Knowledge of the Company, the
other parties thereto in accordance with its terms, subject to (i) the effect
of any applicable Law of general application relating to bankruptcy,
reorganization, insolvency, or moratorium or similar Laws affecting creditors'
rights and relief of debtors generally and (ii) the effect of rules of Law and
general principles of equity, including rules of Law and general principles of
equity governing specific performance, injunctive relief and other equitable
remedies (regardless of whether such enforceability is considered in a
proceeding in equity or at Law).

  


 

  

(d) The Company is not, nor to the Knowledge of the Company is any other
party, in breach, default or violation (and no event has occurred or not
occurred through the Company's action or inaction or, to the Knowledge of the
Company, through the action or inaction of any third party, that with notice
or the lapse of time or both would constitute a breach, default or violation)
of any term, condition or provision of any Material Contract, except for
breaches, defaults or violations that would not reasonably be expected to be,
individually or in the aggregate, material to the Company.

  


 

  

SECTION 4.17 Employee Benefit Matters.

  


 

  

 

(a) Section 4.17(a) of the Company Disclosure Schedule contains a true and
complete list, as of the date of this Agreement, of all material, "employee
benefit plans," within the meaning of Section 3(3) of ERISA, each material,
employment, severance, retention change in control or similar agreement, plan,
arrangement or policy and all other material, plans, arrangements or policies
providing for compensation, bonuses, severance, pension, retirement, post-
employment, profit-sharing, equity-based rights or other forms of incentive or
deferred compensation, vacation, insurance (including self insured
arrangements), health, disability and fringe benefits, sponsored or maintained
by the Company in which current or former employees, directors, officers or
independent contractors of the Company were eligible to participate as of the
date of this Agreement or pursuant to which the Company has any outstanding
obligations or Liability (each, a "Company Benefit Plan" and, collectively,
the "Company Benefit Plans"). With respect to each Company Benefit Plan, the
Company has made available to Parent (if applicable to such Company Benefit
Plan): (i) all documents embodying or governing any Company Benefit Plan, any
funding mechanism for the Company Benefit Plan (including, without limitation,
trust agreements); (ii) the most recent IRS determination letter with respect
to such Company Benefit Plan, as applicable; (iii) the most recently filed IRS
Forms 5500 (where required to be filed with the IRS); (iv) the summary plan
description for such Company Benefit Plan (or other descriptions of such
Company Benefit Plan provided to employees); and (v) any insurance policy
related to such Company Benefit Plan.

   
 

  

(b) Except as would not reasonably be expected to subject the Company to any
material Liability, each Company Benefit Plan has been operated in compliance
with its terms and the applicable requirements of ERISA, the Code and other
applicable Laws. There are no audits, inquiries or proceedings pending or, to
the Knowledge of the Company, threatened by the IRS or any other

  


 

  

 

 

 

  

 

37  

  

 

 

 

  

  

Governmental Authority with respect to any Company Benefit Plan that would
reasonably be expected to subject the Company to any material Liability. No
litigation or other formal proceeding (other than routine claims for benefits)
is pending or, to the Knowledge of the Company, asserted in writing, in each
case against the Company Benefit Plans that would reasonably be expected to
subject the Company to any material Liability.

  


 

  

(c) Each Company Benefit Plan that is intended to be qualified under Section
401(a) of the Code has received a favorable determination letter from the IRS
(or can rely on an opinion letter obtained by a prototype or volume submitter
plan sponsor). No events have occurred with respect to any Company Benefit
Plan that could result in (i) the loss of tax-qualified status or (ii) any
excise taxes under Sections 4975 or 4980B of the Code.

  


 

  

 

(d) Neither the Company nor any or member of its Controlled Group contributes
or has in the past been required to contribute to (i) a pension plan (as
defined in Section 3(2) of ERISA) subject to Title IV of ERISA or Section 412
of the Code or (ii) a "multiemployer plan," as defined in Section 3(37) of
ERISA. No Company Benefit Plan provides for post-employment life or health
insurance benefits for any former or current employees of the Company (or any
beneficiary or dependant of any current or former employee), except as may be
required by part 6 of Subtitle B of Title 1 of ERISA or similar state
continuation Laws. Neither the Company nor any member of the Controlled Group
has engaged in any transaction described in Section 4069 of ERISA.

   
 

  

(e) With respect to each Company Benefit Plan, all contributions have been
made in full or, with respect to payments not due, proper accruals for such
contributions have been made and are reflected in the accounting records of
the Company, other than any failure that could not reasonably be expected to
subject the Company to any material Liability.

  


 

  

 

(f) Except as set forth on Section 4.17(f) of the Company Disclosure Schedule,
the execution, delivery and performance of, and consummation of the
transactions contemplated by this Agreement will not, either alone or in
conjunction with any other event (i) entitle any Person to any payment or
additional benefits, including but not limited to severance pay, termination
benefits or any other payment, or (ii) accelerate the time of payment or
vesting of any benefits under any Company Benefit Plan or increase the amount
of compensation due to any person.

   
 

  

SECTION 4.18 Labor Matters.

  


 

  

(a) Section 4.18(a) of the Company Disclosure Schedule lists each Company
Employee as of the date of this Agreement and such list correctly reflects
each Company Employee's hire date, department, function, location, title, base
salary or base wage rate, target bonus or incentive compensation, exempt or
nonexempt status (where applicable), and whether such employee is full- time
or part-time. None of the Company Employees has indicated to the Company in
writing that he or she intends to terminate his or her employment.

  


 

  

(b) The Company has complied in all material respects with all applicable Law
relating to labor and employment, including those relating to wages, hours,
collective bargaining, unemployment, compensation, worker's compensation,
equal employment opportunity, age and disability discrimination, immigration
control, employee classification, information privacy and security, payment
and withholding of taxes and continuation coverage with respect to group
health plans.

  


 

  

(c) The Company is not a party to any agreement with respect to Company
Employees with any labor organization, union, group or association, nor have
there been any attempts to

  


 

  

 

 

 

  

 

38  

  

 

 

 

  

  

organize the Company Employees. There is no labor strike, labor disturbance or
work stoppage pending against the Company. The Company is not a party to or
subject to any Actions before any court or Governmental Authority regarding
any Company Employee nor are any such proceedings threatened.

  


 

  

(d) There has been no "mass layoff" or "plant closing" within the meaning of
the Worker Adjustment and Retraining Notification Act of 1988, as amended ("
WARN"), or layoffs, reductions in force, facility closings or comparable
events subject to any similar state, local or foreign Law with respect to the
Company within the twelve (12) months prior to Closing.

  


 

  

SECTION 4.19 Environmental Matters.

  


 

  

(a) No Hazardous Material is present in violation of any applicable
Environmental Law at, or has otherwise been discharged, disposed of, dumped,
spilled, leaked, emitted or released on, under, to, from or at, any of the
Leased Real Property or any other property currently or formerly owned, leased
or operated by the Company or any of its predecessors, in an amount which
would reasonably be expected to result in a material Liability to the Company.

  


 

  

(b) The Company has not engaged in any Hazardous Materials Activity in
violation, in any material respect, of any applicable Environmental Law.

  


 

  

(c) No material Action is pending or, to the Knowledge of the Company, has
been threatened against the Company concerning any Environmental Law or any of
the Hazardous Materials Activities of the Company or Hazardous Materials
Activity on any of the Leased Real Property.

  


 

  

(d) The Company has not received any written notice of alleged, actual or
potential responsibility for, or any written inquiry or written notice of an
investigation regarding, any Hazardous Materials Activities at the Leased Real
Property or alleged violation of, non-compliance with or Liability under any
Environmental Law, nor to the Knowledge of the Company is there any
information which might form the basis of any such notice or inquiry, in each
case, that would reasonably be expected to result in a material Liability to
the Company.

  


 

  

(e) No material penalty has been assessed against the Company that remains
outstanding or unresolved, with respect to any alleged violation of, or
Liability under, any applicable Environmental Law.

  


 

  

SECTION 4.20 Foreign Corrupt Payments. The Company has not made any offer,
payment, promise to pay or authorization for the payment of money or an offer,
gift, promise to give, or authorization for the giving of anything of value to
any person in violation of the Foreign Corrupt Practices Act of 1977, as
amended and the rules and regulations promulgated thereunder and any
predecessors thereto, or any similar Laws that are applicable to the Company
and the Business.

  


 

  

SECTION 4.21 Insurance Coverage. Section 4.21 of the Company Disclosure
Schedule sets forth a true and complete list of all material insurance
policies and fidelity bonds held by or on behalf of the Company. Except as set
forth on Section 4.21 of the Company Disclosure Schedule, (i) the Company has
not received any notice from the insurer under any material insurance policy
applicable to the Company disclaiming, questioning, denying or disputing
coverage, reserving rights with respect to a particular claim or such policy
in general or canceling or materially amending any such policy and (ii) there
is no material claim, suit or other matter currently pending in respect of
which the Company has received such a notice. All premiums payable under all
such material insurance policies have been paid or accrued, when due or within
applicable grace periods. Such policies of insurance and bonds (or other

  


 

  

 

 

 

  

 

39  

  

 

 

 

  

  

policies and bonds providing substantially similar insurance coverage) are in
full force and effect. Such policies and bonds are of the type and in amounts
customarily carried by Persons conducting businesses similar to the Business.

  


 

  

SECTION 4.22 Brokers. Except for Bank of America Merrill Lynch, which is
entitled to certain advisory fees in connection with this Agreement, the
Company has not entered into any contract or other arrangement or
understanding (written or oral, express or implied) with any Person which
would result in the obligation of the Company to pay any fees or commissions
to any investment banker, broker or finder in connection with the execution
and delivery of this Agreement or the consummation of the transactions
contemplated by this Agreement.

  


 

  

SECTION 4.23 Affiliate Transactions. No officer or director of the Company (or
members of any of their "immediate family" as such terms are respectively
defined in Rule 12b-2 and Rule 16a-1 of the Securities Exchange Act of 1934,
as amended) or, to the Knowledge of the Company, any stockholder of the
Company (i) is, or has in the past two (2) years been, involved, directly or
indirectly, in any material business arrangement or other material
relationship with the Company (whether written or oral) (other than
arrangements or relationships related solely to such Person's capacity as an
officer, director or stockholder), (ii) directly or indirectly owns, or
otherwise has any material right, title or interest in, to or under, any
material asset, property or right, tangible or intangible, that is used by the
Company or (iii) is, or has in the past two (2) years been, engaged, directly
or indirectly, in business with the Company (other than in such Person's
capacity as an officer, director or stockholder).

  


 

  

SECTION 4.24 Information Statement. The Information Statement and any
amendments or supplements thereto will, when first mailed to Equityholders,
comply as to form in all material respects with the applicable requirements of
the DGCL, and will not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not
misleading. The representations and warranties contained in this Section 4.24
will not apply to statements or omissions included in the Information
Statement based upon information furnished to the Company in writing by Parent
specifically for use therein.

  


 

  

SECTION 4.25 Takeover Laws. No "fair price," "affiliated transactions,"
"moratorium," "control share acquisitions," "business combination" or other
similar anti-takeover statute, provision or regulation (including Section 203
of the DGCL) enacted under state or federal Law of the United States
applicable to the Company is applicable to the Merger or the other
transactions contemplated by this Agreement.

  


 

  

SECTION 4.26 No Other Representations or Warranties. Except for the
representations and warranties contained in this Article IV (as modified by
the Company Disclosure Schedule), neither the Company nor any other Person
makes any other express or implied representation or warranty with respect to
the Company or the transactions contemplated by this Agreement, and the
Company disclaims any other representations or warranties, whether made by the
Company or any other Person (including its Affiliates, officers, directors,
employees, agents or representatives). Except for the representations and
warranties contained in Article IV hereof (as modified by the Company
Disclosure Schedule), the Company hereby disclaims all liability and
responsibility for any representation, warranty, statement, or information
made, communicated, or furnished (orally or in writing) to Parent or its
Affiliates or advisors (including any opinion, information, projection, or
advice (including any information provided during due diligence or management
presentations, including but not limited to information in the data room, and
any oral, written or electronic response to any information request provided
to Parent or its advisors) that may have been or may be provided to Parent or
its advisors by any director, officer, employee, agent,

  


 

  

 

 

 

  

 

40  

  

 

 

 

  

  

consultant, or representative of the Company or any of its Affiliates). The
Company makes no representations or warranties to Parent regarding any
projection or forecast regarding future results or activities or the probable
success or profitability of the Company.

  


 

  

ARTICLE V. 
 

  

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

  


 

  

Parent and Merger Sub hereby jointly and severally represent and warrant to
the Company, as of the date hereof and as of the Closing Date, as follows:

  


 

  

SECTION 5.1 Authority. Each of Parent and Merger Sub has all requisite
corporate power and authority to enter into this Agreement, to perform its
obligations hereunder and to consummate the transactions contemplated by this
Agreement. The execution and delivery of this Agreement by each of Parent and
Merger Sub, the performance by each of Parent and Merger Sub of its respective
obligations hereunder, and the consummation by each of Parent and Merger Sub
of the transactions contemplated by this Agreement have been duly authorized
by the board of directors of each of Parent and Merger Sub, and by Parent as
holder of all outstanding shares of capital stock of Merger Sub, and no other
corporate or other action on the part of either Parent or Merger Sub is
necessary to authorize the execution and delivery of this Agreement by each of
Parent and Merger Sub, the performance by each of Parent and Merger Sub of its
respective obligations hereunder or the consummation by each of Parent and
Merger Sub of the transactions contemplated by this Agreement. This Agreement
has been duly executed and delivered by each of Parent and Merger Sub and,
assuming due authorization, execution and delivery by the Company, this
Agreement constitutes a legally valid and binding obligation of each of Parent
and Merger Sub, enforceable against each of Parent and Merger Sub in
accordance with its terms, except as such enforceability may be limited by
principles of public policy, and subject to (i) the effect of any applicable
Law of general application relating to bankruptcy, reorganization, insolvency,
or moratorium or similar Laws affecting creditors' rights and relief of
debtors generally and (ii) the effect of rules of Law and general principles
of equity, including rules of Law and general principles of equity governing
specific performance, injunctive relief and other equitable remedies
(regardless of whether such enforceability is considered in a proceeding in
equity or at Law).

  


 

  

SECTION 5.2 Organization. Each of Parent and Merger Sub is a corporation duly
organized, validly existing and in good standing under the Laws of the
jurisdiction of its organization, and has all requisite corporate power and
authority to own, operate or lease the properties and assets now owned,
operated or leased by it, and to carry on its business in all material
respects as currently conducted. Each of Parent and Merger Sub is duly
qualified to do business as a foreign corporation, and is in good standing, if
applicable, in each jurisdiction where the conduct of its business requires
such qualification, except in those jurisdictions where the failure to be so
qualified or in good standing would not reasonably be expected to have,
individually or in the aggregate, a material adverse effect on the ability of
Parent and Merger Sub to perform their obligations under this Agreement or
consummate the transactions contemplated by this Agreement.

  


 

  

SECTION 5.3 Conflicts. Assuming all consents, approvals, authorizations,
filings and notifications and other actions set forth in Section 5.4 have been
obtained or made, the execution and delivery of this Agreement by each of
Parent and Merger Sub, the performance by each of Parent and Merger Sub of its
obligations hereunder, and the consummation by each of Parent and Merger Sub
of the transactions contemplated by this Agreement do not and will not (i)
conflict with or result in a violation or breach of the organizational
documents of Parent or Merger Sub; (ii) conflict with or result in a violation
or breach of any Governmental Order or Law applicable to Parent or Merger Sub
or their respective assets or properties; or (iii) result in a violation or
breach of, or constitute a material default (or

  


 

  

 

 

 

  

 

41  

  

 

 

 

  


 

  

event which with the giving of notice or lapse of time, or both, would become
a material default) under, or give rise to any rights of termination,
amendment, modification, acceleration or cancellation of or loss of any
benefit under, or result in the creation of any Encumbrance on any of the
assets or properties of Parent or Merger Sub pursuant to, any Contract, Permit
or similar authorization to which Parent or Merger Sub is a party, or by which
any of the assets or properties of Parent or Merger Sub is bound or affected,
except, in the case of clauses (ii) and (iii) of this Section 5,3, as would
not reasonably be expected to have, individually or in the aggregate, a
material adverse effect on the ability of Parent or Merger Sub to perform its
respective obligations under this Agreement or consummate the transactions
contemplated by this Agreement.

  


 

  

SECTION 5.4 Consents, Approvals, Etc. No consent, waiver, approval,
authorization, order or permit of, or declaration, filing or registration
with, or notification to, any Governmental Authority is required to be made or
obtained by Parent or Merger Sub in connection with the execution and delivery
of this Agreement by each of Parent and Merger Sub, the performance by each of
Parent and Merger Sub of its respective obligations hereunder, or the
consummation by each of Parent and Merger Sub of the transactions contemplated
by this Agreement, except (i) the filing of the Certificate of Merger pursuant
to the DGCL; (ii) applicable requirements, if any, under the DGCL, federal or
state securities or "blue sky" Laws; (iii) such filings as may be required
under the HSR Act; and (iv) where the failure to obtain such consent,
approval, authorization or action, or to make such filing or notification
would not reasonably be expected to have, individually or in the aggregate, a
material adverse effect on the ability of Parent or Merger Sub to perform its
respective obligations under this Agreement or consummate the transactions
contemplated by this Agreement.

  


 

  

SECTION 5.5 Litigation and Governmental Orders. (i) There is no Action (or any
basis therefor) pending against Parent, Merger Sub or any other Subsidiaries
of Parent ("Parent Subsidiaries") that could reasonably be expected to have a
material adverse effect on the ability of Parent or Merger Sub to perform its
respective obligations under this Agreement or consummate the transactions
contemplated by this Agreement and (ii) Parent, Merger Sub and the Parent
Subsidiaries and their respective assets and properties are not subject to any
material Governmental Order that would prevent either Parent or Merger Sub
from performing its respective obligations under this Agreement or
consummating the transactions contemplated by this Agreement.

  


 

  

SECTION 5.6 Due Diligence Investigation. Parent and Merger Sub have had an
opportunity to discuss the business, management, operations and finances of
the Company with the Company's officers, directors, employees, agents,
representatives and Affiliates, and have had an opportunity to inspect the
facilities of the Company. Parent and Merger Sub have conducted their own
independent investigation of the Company. In making their decision to execute
and deliver this Agreement and to consummate the transactions contemplated by
this Agreement, Parent and Merger Sub have relied solely upon the
representations and warranties of the Company set forth in Article IV (and
acknowledge that such representations and warranties are the only
representations and warranties made by the Company) and have not relied upon
any other information provided by, for or on behalf of the Company or its
Affiliates, officers, directors, employees, agents or representatives to
Parent or its advisors in connection with the transactions contemplated by
this Agreement. Parent and Merger Sub have entered into the transactions
contemplated by this Agreement with the understanding, acknowledgement and
agreement that no representations or warranties, express or implied, are made
with respect to any projection or forecast regarding future results or
activities or the probable success or profitability of the Company. Parent and
Merger Sub acknowledge that no current or former stockholder, director,
officer, employee, Affiliate or advisor of the Company has made or is making
any representations, warranties or commitments whatsoever regarding the
subject matter of this Agreement,

  


 

  

 

 

 

  

 

42  

  

 

 

 

  

  

express or implied, except as may be set forth in the Consent Agreement, the
Escrow Agreement, the Letter of Transmittal or the Option Holder Letter.

  


 

  

SECTION 5.7 Brokers. No broker, finder or investment banker is entitled to any
brokerage, finder's or other fee or commission from the Company or any of its
Affiliates or the Equityholders in connection with the transactions
contemplated by this Agreement based upon any arrangements made by or on
behalf of Parent, Merger Sub or any of their respective Affiliates.

  


 

  

SECTION 5.8 No Prior Activities. Merger Sub has not incurred nor will it incur
any liabilities or obligations, except those incurred in connection with its
organization and with the negotiation of this Agreement and the performance of
its obligations hereunder and the consummation of the transactions
contemplated by this Agreement, including the Merger. All of the issued and
outstanding capital stock of Merger Sub is owned beneficially and of record by
Parent.

  


 

  

SECTION 5.9 Sufficient Funds. Parent has sufficient funds available to it,
without requiring the prior consent, approval or other discretionary action of
any third party, to make the payments required under Article II and Article
III, to pay all fees and expenses to be paid by Parent and Merger Sub in
connection with the transactions contemplated by this Agreement, and to
satisfy any other payment obligations that may arise in connection with, or
may be required in order to consummate, the transactions contemplated by this
Agreement. Parent and Merger Sub expressly acknowledge that Parent's and
Merger Sub's ability to obtain financing is not a condition to the obligations
of Parent and Merger Sub hereunder.

  


 

  

SECTION 5.10 No Other Representations or Warranties. Except for the
representations and warranties contained in this Article V, none of Parent,
Merger Sub nor any other Person makes any other express or implied
representation or warranty with respect to Parent or Merger Sub or the
transactions contemplated by this Agreement, and Parent and Merger Sub
disclaim any other representations or warranties, whether made by Parent,
Merger Sub or any other Person (including their respective Affiliates,
officers, directors, employees, agents or representatives).

  


 

  

ARTICLE VI. 
 

  

ADDITIONAL AGREEMENTS

  


 

  

SECTION 6.1 Conduct of the Company Prior to the Effective Time.

  


 

  

 

(a) Unless Parent otherwise consents in writing (which consent shall not be
unreasonably withheld, conditioned or delayed) and except as otherwise
contemplated by this Agreement or set forth in Section 6.1 of the Company
Disclosure Schedule, during the period commencing with the execution and
delivery of this Agreement and terminating upon the earlier to occur of the
Effective Time and the termination of this Agreement pursuant to and in
accordance with Section 8.1 (the "Pre-Closing Period"), the Company shall (i)
conduct the Business in the ordinary course; (ii) use commercially reasonable
efforts, subject to the limitations set forth in this Agreement, to keep
available the services of the officers and key employees of the Company; and
(iii) use commercially reasonable efforts to maintain the material assets and
material properties of the Company in their current condition, normal wear and
tear excepted.

   
 

  

(b) Except as otherwise contemplated by this Agreement or set forth in Section
6.1 of the Company Disclosure Schedule, during the Pre-Closing Period, the
Company shall not do or cause to be done any of the following without the
prior written consent of Parent (which consent shall not be unreasonably
withheld, conditioned or delayed):

  


 

  

 

 

 

  

 

43  

  

 

 

 

  

  

(i) issue or sell, or authorize the issuance or sale of, (A) any capital stock
of the Company, except upon the exercise of Company Options or Warrants issued
and outstanding as of the date of this Agreement or upon the conversion of
Preferred Stock into Common Stock, or (B) any options, warrants, rights of
conversion or other rights, agreements, arrangements or commitments obligating
the Company to issue, deliver or sell any capital stock of the Company;

  


 

  

(ii) create, incur, assume or otherwise become liable for an amount in excess
of five hundred thousand dollars ($500,000) of Indebtedness in the aggregate
or create any Encumbrance on any material assets or properties (whether
tangible or intangible) of the Company, other than (y) Permitted Encumbrances;
and (z) Encumbrances on assets or properties having an aggregate value not in
excess of five hundred thousand dollars ($500,000);

  


 

  

(iii) sell, assign, transfer, lease, license or otherwise dispose of, or agree
to sell, assign, transfer, lease, license or otherwise dispose of (x) any
material Owned Intellectual Property or Licensed Intellectual Property or (y)
any other material assets of the Company, in the case of clause (y) having a
value, in any individual case, in excess of one million dollars ($1,000,000)
or, in the aggregate, in excess of five million dollars ($5,000,000);

  


 

  

(iv) acquire (by merger, consolidation or combination, or acquisition of stock
or assets) any Person or division thereof;

  


 

  

(v) (A) enter into any Contract for Leased Real Property, (B) enter into any
Contract that if entered into prior to the date hereof would be deemed a
Material Contract or (C) modify, amend, extend, or supplement in any material
respect, transfer or terminate any Material Contract or waive, release or
assign any rights or claims thereto or thereunder;

  


 

  

 

(vi) (A) enter into or amend any employment, consultancy, retirement, deferred
compensation, severance or similar agreement; (B) hire any employee with an
annual rate of compensation in excess of one hundred and fifty thousand
dollars ($150,000); (C) increase the number of employees engaged as sales
representatives or engaged to provide reimbursement assistance to consumers or
health care providers; (D) terminate the employment of any officer other than
for Cause or take any actions that would provide a basis for any officer to
terminate employment for Good Reason (as Cause and Good Reason are defined in
any applicable employment, change of control, severance, retention or similar
agreement); (E) establish, adopt or amend any Company Benefit Plan; (F)
increase the compensation of any Company Employee or director or officer of
the Company; (G) grant any severance or termination pay to any Company
Employee or director or officer of the Company; or (H) increase the benefits
of any Company Employee or director or officer of Company, other than as
required by the terms of any Company Benefit Plan, in connection with the
payment of Pro-Rata Bonuses, or as required by applicable Law;

   
 

  

(vii) materially change any method of financial accounting or financial or
accounting practice used by the Company, other than such changes required by
GAAP, as applicable;

  


 

  

(viii) split, combine or reclassify any shares of capital stock of the Company
or declare, set aside or pay any dividend or other distribution (whether in
cash, stock or property or any combination thereof), or redeem, repurchase or
otherwise acquire or offer to redeem, repurchase or acquire any capital stock
of the Company;

  


 

  

(ix) amend any term of any Company Capital Stock, Company Option or warrant;

  


 

  

 

 

 

  

 

44  

  

 

 

 

  

  

(x) except for capital expenditures made to repair or replace assets or
properties that are damaged or destroyed, incur any capital expenditures or
any Liabilities in respect thereof in excess of one million and five hundred
thousand dollars ($1,500,000) in the aggregate;

  


 

  

(xi) enter into any Contract containing covenants limiting the freedom of the
Company to compete with any Person in any line of business or in any area or
territory or would so limit Parent or any of its Affiliates after the Closing
Date;

  


 

  

(xii) make any loans, advances or capital contributions to, or investments in,
any other Person, other than travel and similar advances to its employees in
the ordinary course of business consistent with past practice;

  


 

  

 

(xiii) settle, or offer or propose to settle, any material Action;

 

  


 

  

 

(xiv) adopt or propose any change in the Company Certificate of Incorporation
or Company Bylaws; or

 

  


 

  

(xv) enter into any agreement or otherwise commit to take, or cause to be
taken, any of the actions set forth in this Section 6.1(b).

  


 

  

SECTION 6.2 Access to Information. Subject to the terms of the Confidentiality
Agreement, during the Pre-Closing Period, upon reasonable advance notice and
during normal business hours, the Company shall, and shall cause each of its
officers, employees, agents and representatives to, (i) afford the officers,
employees and authorized agents and representatives of Parent reasonable
access to the offices, properties, books and records of the Company and (ii)
furnish to the officers, employees and authorized agents and representatives
of Parent such additional financial and operating data and other information
regarding the assets, properties and business of the Company as Parent may
from time to time reasonably request in order to assist Parent in fulfilling
its obligations under this Agreement and to facilitate the consummation of the
transactions contemplated by this Agreement; provided, however, that Parent
shall not interfere unreasonably with any of the operations or business
activities of the Company. Notwithstanding the foregoing, the Company shall
not be required to provide access to or disclose information where such access
or disclosure would waive the attorney-client privilege of any party or
contravene any Law. Parent agrees to indemnify and hold harmless the Company,
its Affiliates and their respective officers, directors, employees, agents and
representatives for any and all claims or Liabilities to the extent arising
out of the access rights under this Section 6.2, including any claims by any
of Parent's officers, directors, employees, agents and representatives for any
injuries or property damage while present at the Company's facilities.

  


 

  

SECTION 6.3 Confidentiality. Parent and Merger Sub hereby agree to be bound by
and comply with the terms of the Confidentiality Agreement, which are hereby
incorporated into this Agreement by reference and shall continue in full force
and effect until the Effective Time, such that the information obtained by
Parent and Merger Sub, or their respective officers, employees, agents or
representatives, during any investigation conducted pursuant to Section 6.2,
or in connection with the negotiation and execution of this Agreement or the
consummation of the transactions contemplated by this Agreement, or otherwise,
shall be governed by the terms of the Confidentiality Agreement.

  


 

  

SECTION 6.4 Efforts to Consummate; Notification.

  


 

  

(a) Subject to the terms and conditions of this Agreement, each of Parent and
the Company will use its commercially reasonable efforts to take, or cause to
be taken, all actions and to do,

  


 

  

 

 

 

  

 

45  

  

 

 

 

  

  

 

or cause to be done, all things necessary, proper or advisable under
applicable Law to consummate the Merger and the other transactions
contemplated by this Agreement, including using commercially reasonable
efforts to accomplish the following: (i) the taking of all reasonable acts
necessary to cause the conditions precedent set forth in Article VII to be
satisfied; (ii) the obtaining of all necessary actions or non-actions,
waivers, consents, approvals, orders and authorizations from Governmental
Authorities and the making of all necessary registrations, declarations and
filings (including registrations, declarations and filings with Governmental
Authorities, if any) and the taking of all reasonable steps as may be
necessary to avoid any Action by any Governmental Authority; (iii) the
obtaining of all necessary consents, approvals or waivers from third parties;
(iv) the defending of any Actions, whether judicial or administrative,
challenging this Agreement or the consummation of the Merger and the other
transactions contemplated hereby, including seeking to have any stay or
temporary restraining order, decree, injunction or other agreement entered by
any court or other Governmental Authority vacated or reversed; and (v) the
execution or delivery of additional certificates, instruments or other
documents necessary to consummate the Merger and the other transactions
contemplated hereby, and to fully carry out the purposes of, this Agreement;
provided, that the Parties hereto understand and agree that the commercially
reasonable efforts of any party hereto shall not be deemed to include (A)
entering into any settlement, undertaking, consent decree, stipulation or
agreement with any Governmental Authority in connection with the transactions
contemplated hereby or (B) divesting or otherwise holding separate (including
by establishing a trust or otherwise), or taking any other action (or
otherwise agreeing to do any of the foregoing) with respect to any of its or
their respective Affiliates' businesses, assets or properties.

   
 

  

 

(b) In furtherance and not in limitation of the foregoing, Parent and the
Company shall make or cause to be made the registrations, declarations and
filings required of such Party under the HSR Act and any other Antitrust Laws
with respect to the transactions contemplated by this Agreement as promptly as
reasonably practicable and advisable after the date of this Agreement (and, in
the case of any filings required under the HSR Act, use best efforts to make
such filings within ten (10) days and in no event later than fifteen (15) days
from the execution of this Agreement); (i) furnish to the other Party as
promptly as reasonably practicable all information required for any
application or other filing to be made by the other Party pursuant to any
applicable Law in connection with the transactions contemplated by this
Agreement; (ii) respond as promptly as reasonably practicable to any inquiries
received from, and supply as promptly as reasonably practicable any additional
information or documentation that may be requested by, the Antitrust Division
of the U.S. Department of Justice (the "DOJ"), the U.S. Federal Trade
Commission ("FTC") or by any other Governmental Authority in respect of such
registrations, declarations and filings; (iii) promptly notify the other Party
of any material communication between that Party and the FTC, the DOJ or any
other Governmental Authority and of any material communication received or
given in connection with any Action by a private party, in each case regarding
any of the transactions contemplated hereby (including, without limitation,
any communication relating to the antitrust merits, any potential remedies,
commitments or undertakings, the timing of any waivers, consents, approvals,
permits, orders, decrees, injunctions or other agreements or authorizations
(including the expiration or termination of any waiting periods), or any
agreement regarding the timing of consummation of the Merger and the other
transactions contemplated by this Agreement), (iv) subject to applicable Law,
discuss with and permit the other Party (and its counsel) to review in
advance, and accept all reasonable additions, deletions or changes suggested
by the other Party in connection with, any proposed filing or communication to
the FTC, the DOJ or any other Governmental Authority or, in connection with
any Action by a private party or any other Person, relating to any Antitrust
Law or any Action pursuant to any Antitrust Law in connection with the Merger
and the other transactions contemplated by this Agreement; (v) not participate
or agree to participate in any substantive meeting, telephone call or
discussion (including, without limitation, any substantive meeting, telephone
call or discussion relating to the expiration or termination of any waiting
periods or any agreement regarding the timing of consummation of the Merger
and the other transactions contemplated by this Agreement) with 
 

 

  

 

 

 

  

 

46  

  

 

 

 

  


 

  

 

the FTC, the DOJ or any other Governmental Authority in respect of any
filings, investigation or inquiry relating to any Antitrust Law or any Action
pursuant to any Antitrust Law in connection with this Agreement or the Merger
or the other transactions contemplated hereby unless it consults with the
other Party in advance and, to the extent permitted by such Governmental
Authority, gives the other Party the opportunity to attend and participate in
such meeting, telephone call or discussion; (vi) furnish the other Party
promptly with copies of all correspondence, filings and communications
relating to any Antitrust Law or any Action pursuant to any Antitrust Law
between them and their Affiliates and their respective representatives, on the
one hand, and the FTC, the DOJ or any other Governmental Authority or members
of their respective staffs, on the other hand, with respect to this Agreement
and the Merger and the other transactions contemplated hereby; and (vii) act
in good faith and reasonably cooperate with the other Party in connection with
any such registrations, declarations and filings and in connection with
resolving any investigation or other inquiry of any such agency or other
Governmental Authority under the HSR Act or any other Antitrust Law with
respect to any such registration, declaration and filing. Parent and Company
may, as each deems advisable and necessary, reasonably designate any
competitively sensitive material provided to the other under this Section
6.4(b) as "Antitrust Counsel Only Material." Such materials and the
information contained therein shall be given only to the outside antitrust
counsel of the recipient and will not be disclosed by such outside counsel to
employees, officers or directors of the recipient unless express permission is
obtained in advance from the source of the materials (Parent or the Company,
as the case may be) or its legal counsel.

   
 

  

SECTION 6.5 Indemnification; Directors' and Officers' Insurance.

  


 

  

 

(a) From and after the Effective Time, Parent shall, or shall cause the
Surviving Corporation to, (i) indemnify and hold harmless each present and
former director, officer and employee of the Company (collectively, the
"Company Indemnified Parties") against any and all Damages incurred or
suffered by any of the Company Indemnified Parties in connection with any
Liabilities or any Action, whether civil, criminal, administrative or
investigative, arising out of or pertaining to matters existing or occurring
at or prior to the Effective Time, whether asserted or claimed prior to, at or
after the Effective Time, to the fullest extent that the Company would have
been permitted under applicable Law and under the Company Certificate of
Incorporation and the Company Bylaws as in effect on the date of this
Agreement, to indemnify such Company Indemnified Parties and (ii) advance
reasonable expenses of counsel (reasonably satisfactory to the Surviving
Corporation) as incurred by any Company Indemnified Party in connection with
any matters for which such Company Indemnified Party is entitled to
indemnification from Parent pursuant to this Section 6.5(a) to the fullest
extent permitted under applicable Law and under the Company Certificate of
Incorporation and the Company Bylaws as in effect on the date of this
Agreement; provided, however, that the Company Indemnified Party to whom
expenses are advanced provides an undertaking to repay such advances if it is
ultimately and finally determined by a court of competent jurisdiction and all
rights of appeal have lapsed that such Company Indemnified Party is not
entitled to indemnification under applicable Law, the Company Certificate of
Incorporation and the Company Bylaws, and pursuant to this Section 6.5(a); and
provided further that Parent and the Surviving Corporation shall not be
obligated to pay expenses of more than one counsel for all Company Indemnified
Parties in any single Action unless a conflict of interest precludes the
effective representation of more than one Company Indemnified Party with
respect to such Action.

   
 

  

(b) For a period of six (6) years following the Effective Time, Parent shall
maintain, or shall cause the Surviving Corporation for itself to maintain, in
effect a directors' and officers' liability insurance policy covering those
persons who are currently covered by the Company's directors' and officers'
liability insurance policy (copies of which have been heretofore made
available to Parent or its advisors) with coverage in amount and scope at
least as favorable as the Company's existing coverage; provided, however, that
this Section 6.5(b) shall be deemed to have been satisfied if a prepaid policy
or

  


 

  

 

 

 

  

 

47  

  

 

 

 

  


 

  

policies (i.e., "tail coverage") have been obtained by the Company which
policy or policies provide such directors and officers with the coverage
described in this Section 6.5(b) for an aggregate period of not less than six
(6) years with respect to claims arising from facts or events that occurred on
or before the Closing Date, including with respect to the transactions
contemplated by this Agreement.

  


 

  

(c) The terms and provisions of this Section 6.5 are intended to be in
addition to the rights otherwise available to the Company Indemnified Parties
by applicable Law, charter, bylaw or agreement, and shall operate for the
benefit of, and shall be enforceable by, the Company Indemnified Parties and
their respective heirs and representatives, each of whom is an intended third
party beneficiary of this Section 6.5.

  


 

  

SECTION 6.6 Employee Benefit Matters.

  


 

  

 

(a) Not more than ten (10) and not less than five (5) days prior to the
Closing Date, the Company shall provide Parent with an updated version of
Section 4.18(a) of the Company Disclosure Schedule, which shall reflect any
terminations of employment, new employee hires or changes to the employee
information otherwise contained therein. All Company Employees who are
employed by the Company immediately preceding the Closing, including those on
vacation and authorized leave of absence (including, without limitation,
family medical leave, military leave, sick leave, and short-term disability
leave), will remain employed immediately following the Closing (such
employees, the "Continuing Employees"). Notwithstanding the foregoing, nothing
in this Agreement shall be construed as an obligation of Parent or the
Surviving Corporation to continue the employment of a Company Employee for any
period following the Closing Date.

  

  

(b) Subject to Section 6.6(e), from and after the Effective Time, Parent
shall, and shall cause the Surviving Corporation to, assume, honor, pay,
perform and satisfy any and all Liabilities, obligations and responsibilities
to or in respect of all Company Employees arising under the terms of each
Company Benefit Plan, as in effect immediately prior to the Effective Time,
for as long as such Company Benefit Plan is in effect.

  

  

(c) For a period of not less than one (1) year following the Effective Time
(the "Benefits Continuation Period"), Parent shall, and shall cause the
Surviving Corporation to, provide each Continuing Employee with (i) base
salary (or base wages) no less favorable than the base salary (or base wages)
provided to such Continuing Employee immediately prior to the Effective Time,
(ii) bonus or incentive opportunities (other than equity-based compensation)
that are no less favorable than the bonus or incentive opportunities (other
than equity-based compensation) provided to such Continuing Employee
immediately prior to the Effective Time, and (iii) benefits that are
substantially comparable in the aggregate to the employee benefits provided to
such Continuing Employee immediately prior to the Effective Time.

  

  

(d) From and after the Effective Time, for the purposes of determining
eligibility to participate, vesting and entitlement to benefits where length
of service is relevant under any benefit plan or arrangement of Parent, the
Surviving Corporation or any of their respective Affiliates, Parent shall, and
shall cause the Surviving Corporation to, cause each Continuing Employee to
receive service credit for service with the Company to the same extent such
service credit was granted under the Company Benefit Plans (other than for the
purposes of benefit accrual under a defined benefit plan) immediately prior to
the Effective Time. Parent shall, and shall cause the Surviving Corporation to
(i) waive all limitations as to preexisting conditions exclusions and waiting
periods with respect to participation and coverage requirements applicable to
the Company Employees (and any dependents or beneficiaries thereof) under any
welfare benefit plans that such employees may be eligible to participate in
after the Effective Time, 
 

 

  

 

 

 

  

 

48  

  

 

 

 

  


 

  

 

  other than limitations or waiting periods that are already in effect with
respect to such employees and that have not been satisfied as of the Effective
Time under any welfare benefit plan maintained for the Company Employees
immediately prior to the Effective Time and (ii) use commercially reasonable
efforts to provide each Company Employee with credit for any co-payments and
deductibles paid prior to the Effective Time in satisfying any applicable
deductible or out-of-pocket requirements under any welfare plans that such
employees are eligible to participate in after the Effective Time. Parent
shall, and shall cause the Surviving Corporation to, honor all vacation,
personal and sick days accrued by Company Employees under the plans, policies,
programs and arrangements of the Company immediately prior to the Effective
Time.  

  

(e) Notwithstanding anything herein to the contrary, Parent, Merger Sub, the
Company and the Equityholders' Representative acknowledge and agree that all
provisions contained in this Section 6.6 are included for the sole benefit of
Parent, Merger Sub and the Company, and that nothing in this Agreement,
whether express or implied, (i) shall be treated as an amendment or other
modification of any Company Benefit Plan or other employee benefit plan,
agreement or other arrangement, (ii) shall limit the right of Parent or the
Surviving Corporation or their respective Affiliates to amend, terminate or
otherwise modify any Company Benefit Plan or other employee benefit plan,
agreement or other arrangement following the Effective Time, or (iii) shall
confer upon the Equityholders' Representative, or upon any other Person who is
not a party to this Agreement (including, without limitation, any
Equityholder, any current or former director, officer, employee or independent
contractor of the Company, or any participant in any Company Benefit Plan or
other employee benefit plan, agreement or other arrangement (or any dependent
or beneficiary thereof)), any right to continued or resumed employment or
recall, any right to compensation or benefits, or any third party beneficiary
or other right of any kind or nature whatsoever. 
 

 

  

SECTION 6.7 Tax Matters.

  


 

  

(a) From the date hereof until the Effective Time, the Company shall not make
or change any material Tax election, change any annual tax accounting period,
adopt or change any method of Tax accounting, file any material amended Tax
Returns or claims for material Tax refunds, enter into any material closing
agreement, surrender any material Tax claim, audit or assessment, surrender
any right to claim any material Tax refund, offset or other reduction in Tax
liability or consent to any extension or waiver of the limitations period
applicable to any Tax claim or assessment without Parent's written consent,
such consent not to be unreasonably withheld or delayed.

  


 

  

(b) All transfer, documentary, sales, use, stamp, registration, value added
and other such taxes and fees (including any penalties and interest) incurred
in connection with the Merger (including any real property transfer tax and
any similar tax) shall be shared equally by Parent and the Company when due,
and Parent and the Company shall, sharing expenses equally, file all necessary
Tax Returns and other documentation with respect to all such taxes and fees,
and, if required by applicable Law, the Company shall join in the execution of
any such Tax Returns and other documentation.

  


 

  

(c) From the Effective Time until the Escrow Termination Date, Buyer shall
not, and shall cause the Company not to, amend any Tax Return of the Company
or file any claim for refund of Taxes paid by the Company for any Tax period
that ends on or before, or that includes, the Closing Date, other than any
amended Tax Return or claim for a refund, in each case, arising as a result of
a carryback of losses, credits or other similar tax items, without the prior
written consent of the Equityholders' Representative, such consent not to be
unreasonably withheld or delayed; provided, that, if Parent agrees to waive
any claim for indemnification under Section 9.2 that may result from the
filing of an amended Tax Return or claim for refund, such consent shall not be
required.

  


 

  

 

 

 

  

 

49  

  

 

 

 

  


 

  

SECTION 6.8 No Solicitation.

  


 

  

 

(a) The Company agrees that, from the date hereof through the earlier of the
Closing or the termination of this Agreement, it shall not, and it shall
direct its representatives not to, directly or indirectly, (i) initiate,
solicit, knowingly encourage or knowingly facilitate any inquiries, proposals
or offers with respect to, or the making or completion of, an Alternative
Proposal or any inquiry, proposal or offer that is reasonably likely to lead
to an Alternative Proposal, (ii) engage, continue or participate in any
negotiations concerning, or provide or cause to be provided any non-public
information or data relating to the Company in connection with, or have any
discussions (other than to state that they are not permitted to have
discussions and to refer to this Agreement) with any Person relating to, or
that is reasonably likely to lead to, an Alternative Proposal, (iii) approve,
endorse or recommend, or propose publicly to approve, endorse or recommend,
any Alternative Proposal, (iv) execute or enter into, any letter of intent,
agreement in principle, merger agreement, acquisition agreement, option
agreement or other similar agreement relating to any Alternative Proposal, or
(v) resolve to propose or agree to do any of the foregoing. The Company
further agrees that, (A) at the Closing, it shall submit a request to the
Securities and Exchange Commission (the "SEC") requesting that the SEC consent
to the immediate withdrawal of the Form S-1 together with all exhibits and
amendments thereto and (B) from the date hereof, it shall not take any action
(including without limitation any preparation in connection therewith and any
filing in furtherance thereof) to register itself or any of its securities
under the Securities Act of 1933 or the Securities Exchange Act of 1934.

  

  

(b) "Alternative Proposal" means any bona fide proposal or offer made by any
Person for (i) a merger, reorganization, share exchange, consolidation,
business combination, joint venture, recapitalization, dissolution,
liquidation, collaboration arrangement or similar transaction involving the
Company; (ii) the acquisition by any Person of a significant amount of assets
of the Company outside the ordinary course of business; or (iii) the
acquisition by any Person of ten percent (10%) or more of the Company Capital
Stock, except for the acquisition of Company Capital Stock as a result of the
exercise of Company Options or Warrants or the conversion of Preferred Stock.

   
 

  

SECTION 6.9 FIRPTA Certificate. At or prior to the Effective Time, the Company
shall deliver to Parent a certificate prepared in accordance with Treasury
Regulations Section 1.1445-2(c)(3) certifying that interests in the Company
are not U.S. real property interests.

  


 

  

SECTION 6.10 Section 280G Waiver Agreement and Shareholder Approval.

  


 

  

(a) To the extent that (i) any current or former officer, employee or service
provider of the Company would be entitled to any payment or benefit as a
result of the transactions contemplated by this Agreement and (ii) such
payment or benefit would or could potentially constitute a "parachute payment"
under Section 280G of the Code, prior to the Closing:

  


 

  

(i) the Company shall use its commercially reasonable efforts to obtain a
binding written waiver by such officer, employee or service provider (each, an
"Excess Parachute Waiver") of any portion of such parachute payment as exceeds
2.99 times such individual's "base amount" within the meaning of Section
280G(b)(3) of the Code (collectively, the "Excess Parachute Payments") to the
extent such excess is not subsequently approved pursuant to a stockholder vote
in accordance with the requirements of Section 280G(b)(5)(B) of the Code (the
"280G Shareholder Approval Requirements"); and

  


 

  

 

 

 

  

 

50  

  

 

 

 

  


 

  

(ii) the Company shall use its commercially reasonable efforts to obtain a
stockholder approval that satisfies the 280G Shareholder Approval Requirements
in respect of the Excess Parachute Payments payable to all such officers,
employees and service providers.

  


 

  

(b) Within twenty (20) days of the date hereof, the Company shall provide to
Parent all information reasonably necessary to enable Parent to determine
whether any Person would be entitled to any payment or benefit in connection
with the transactions contemplated by this Agreement that would potentially
constitute a "parachute payment" under Section 280G of the Code.

  


 

  

SECTION 6.11 Information Statement. Promptly after the execution of this
Agreement, the Company, in consultation with Parent, shall prepare an
Information Statement (the "Information Statement") which (i) describes the
principal terms of this Agreement, (ii) notifies the holders of Company
Capital Stock of the approval of the Merger by the Board of Directors of the
Company and the approval by written consent of holders of the requisite amount
of Company Capital Stock in accordance with Section 228(e) of the DGCL, (iii)
provides copies of Section 262 of Delaware Law and a description of the
appraisal procedure to be followed and (iv) contains such other information as
is required by applicable Law. Parent and its counsel shall be given a
reasonable opportunity to review and comment on the Information Statement
before it is mailed to the holders of Company Capital Stock (other than the
Principal Stockholders), and the Company shall not permit the Information
Statement to be distributed without Parent's prior written approval (such
approval not to be unreasonably withheld or delayed); provided, that Parent
shall in no way be responsible for any of the content of the Information
Statement except for information supplied in writing by Parent expressly for
inclusion therein. The Company shall mail or cause to be mailed the
Information Statement to the Stockholders (other than the Principal
Stockholders) promptly upon completion thereof and receipt of Parent's
approval as set forth in the previous sentence.

  

  

SECTION 6.12 Notices and Consents. Upon Parent's request, the Company shall
use its commercially reasonable efforts to cooperate in good faith with Parent
in connection with the giving of notices of the Merger and the transactions
contemplated by this Agreement to any third parties, including via the
Information Statement and pursuant to any Contracts to which the Company is a
party. Parent and the Company shall use their respective commercially
reasonable efforts and work together to obtain any third party consents,
waivers or novations required pursuant to the terms of any Contracts that are
necessary or appropriate, in Parent's reasonable discretion, to operate the
Surviving Corporation after the Effective Time; provided, that the Company
shall not distribute any correspondence relating to such consents, waivers or
novations to any such third parties without Parent's prior written approval
(such approval not to be unreasonably withheld or delayed). Except as set
forth in Section 6.12 of the Company Disclosure Schedule, Parent shall be
responsible for the legal and other administrative fees and expenses of the
counterparties to such contracts, if any, that are required to be paid in
connection with the granting of such consents.

  


 

  

ARTICLE VII. 
 

  

CONDITIONS TO CLOSING

  


 

  

SECTION 7.1 Conditions to Obligations of the Company . The obligations of the
Company to consummate the Merger and the other transactions contemplated by
this Agreement shall be subject to the satisfaction, fulfillment or written
waiver by the Company, at or prior to the Closing, of each of the following
conditions:

  


 

  

(a) Representations and Warranties; Covenants. (i) The representations and
warranties of Parent and Merger Sub set forth in Article V (disregarding all
qualifications set forth therein

  


 

  

 

 

 

  

 

51  

  

 

 

 

  

  

 

 

relating to materiality or material adverse effect) shall be true and correct
in all respects at and as of the date of this Agreement and as of the Closing
Date as though then made (except that those representations and warranties
that are made as of a specific date need only be true and correct in all
respects as of such date), except where the failure of such representations
and warranties to be true and correct would not reasonably be expected to
have, individually or in the aggregate, a material adverse effect on the
ability of Parent to consummate the transactions contemplated hereby; (ii) the
covenants and agreements set forth in this Agreement to be performed or
complied with by Parent and Merger Sub at or prior to the Effective Time shall
have been performed or complied with in all material respects; and (iii) the
Company shall have received an officer's certificate of each of Parent and
Merger Sub, dated as of the Closing Date, certifying as to the matters set
forth in clauses (i) and (ii) of this Section 7.1(a).

  

 

 

  

(b) No Governmental Order. No Governmental Authority shall have enacted,
issued, promulgated, enforced or entered any Governmental Order which is in
effect and has the effect of making the Merger or any other transactions
contemplated by this Agreement illegal or otherwise restraining or prohibiting
the consummation of the Merger or any of the other material transactions
contemplated by this Agreement.

  


 

  

(c) HSR Act. The waiting period under the HSR Act, if applicable, shall have
expired or been terminated.

  


 

  

(d) Stockholder Approval. The Company shall have obtained the Required Company
Stockholder Approval.

  


 

  

(e) Escrow Agreement. Parent and the Escrow Agent shall have executed and
delivered the Escrow Agreement.

  


 

  

SECTION 7.2 Conditions to Obligations of Parent and Merger Sub. The
obligations of Parent and Merger Sub to consummate the Merger and the other
transactions contemplated by this Agreement shall be subject to the
satisfaction, fulfillment or written waiver by Parent, at or prior to the
Closing, of each of the following conditions:

  


 

  

 

(a) Representations and Warranties; Covenants. (i) The representations and
warranties of the Company set forth in Article IV (disregarding all
qualifications set forth therein relating to materiality or Material Adverse
Effect) shall be true and correct in all respects at and as of the date of
this Agreement and as of the Closing Date (except that those representations
and warranties that are made as of a specific date need only be true and
correct in all respects as of such date), except where the failure of such
representations and warranties to be true and correct would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect;
provided, that, notwithstanding the foregoing, each of the Fundamental
Representations shall be true and correct in all material respects at and as
of the date of this Agreement and as of the Closing Date (except for any such
representations and warranties that are made as of a specific date need only
be true and correct in all respects as of such date); (ii) the covenants and
agreements set forth in this Agreement to be performed or complied with by the
Company at or prior to the Closing shall have been performed or complied with
in all material respects; and (iii) Parent shall have received an officer's
certificate of the Company, dated as of the Closing Date, certifying as to the
matters set forth in clauses (i) and (ii) of this Section 7.2(a).

   
 

  

(b) Material Adverse Effect. Since the date hereof, there shall not have been
any change, effect, event, occurrence, state of facts or development that,
individually or together with one or more changes, effects, events,
occurrences, state of facts or developments that has had or would reasonably
be expected to have, individually or in the aggregate, a Material Adverse
Effect.

  


 

  

 

 

 

  

 

52  

  

 

 

 

  

  

(c) No Governmental Order. No Governmental Authority shall have enacted,
issued, promulgated, enforced or entered any Governmental Order which is in
effect and has the effect of making the Merger or any of the other material
transactions contemplated by this Agreement illegal or otherwise restraining
or prohibiting the consummation of the Merger or any of the other transactions
contemplated by this Agreement.

  


 

  

(d) HSR Act. The waiting period under the HSR Act, if applicable, shall have
expired or been terminated.

  


 

  

(e) Stockholder Approval. The Company shall have obtained the Required Company
Stockholder Approval.

  


 

  

(f) Escrow Agreement. The Equityholders' Representative and the Escrow Agent
shall have executed and delivered the Escrow Agreement.

  


 

  

(g) Additional Closing Deliverables. Parent shall have received (i) a true and
correct copy of the resolutions of the board of directors of the Company
authorizing the execution, delivery and performance of this Agreement, the
Merger and all other transactions contemplated thereby and (ii) a long-form
good standing certificate for the Company dated a date reasonably prior to the
Closing from the Secretary of State of the State of Delaware.

  


 

  

(h) La Jolla Manufacturing Facility. There shall not have occurred and be
continuing any damage to or destruction of, or disruption of production at,
the La Jolla Manufacturing Facility that has had, or would reasonably be
expected have, a material adverse effect on the business, assets, Liabilities,
operations, financial condition or results of operations of the Company.

  


 

  

ARTICLE VIII. 
 

  

TERMINATION, AMENDMENT AND WAIVER

  


 

  

SECTION 8.1 Termination. This Agreement may be terminated and the transactions
contemplated hereby abandoned:

  


 

  

(a)By mutual written consent of the Company and Parent at any time prior to
the Closing.

  


 

  

 

(b) By either the Company or Parent, by written notice to the other Party if
the Closing has not occurred on or before November 17, 2011 (the "Outside
Date"), other than as a result of a breach of a representation, warranty,
covenant or agreement of the terminating Party; provided, that the right to
terminate pursuant to this Section 8.1(b) shall not be available to any Party
whose failure to fulfill any obligation under this Agreement has been the
cause of, or resulted in, the failure of the Closing to occur on or before
such date.

  

  

(c) By either the Company or Parent, by written notice to the other Party if
any Governmental Authority shall have issued a final Governmental Order or
taken any other final Action restraining, enjoining or otherwise prohibiting
the consummation of the transactions contemplated by this Agreement and such
Governmental Order or other Action is or shall have become final and
nonappealable; provided, however, that the Party seeking to terminate this
Agreement pursuant to this Section 8.1(c) shall have used its commercially
reasonable efforts to prevent the entry of and to remove such Governmental
Order or final Action.

   
 

  

 

 

 

  

 

53  

  

 

 

 

  


 

  

 

(d) Prior to the Closing, by written notice to the Company from Parent if
there is any material breach of any representation, warranty, covenant or
agreement on the part of the Company set forth in this Agreement, or if a
representation or warranty of the Company shall be untrue in any material
respect, in either case, such that the condition specified in Section 7.2(a)
hereof would not be satisfied at the Closing (a "Terminating Company Breach"),
except that, if such Terminating Company Breach is curable by the Company
through the exercise of its commercially reasonable efforts, then, for a
period of thirty (30) days after receipt of notice of such breach, but only as
long as the Company continues to use its commercially reasonable efforts to
cure such Terminating Company Breach (the "Company Cure Period"), such
termination shall not be effective, and such termination shall become
effective only if the Terminating Company Breach is not cured within the
Company Cure Period.

  

  

(e) Prior to the Closing, by written notice to Parent from the Company if
there is any material breach of any representation, warranty, covenant or
agreement on the part of Parent or Merger Sub set forth in this Agreement, or
if a representation or warranty of Parent or Merger Sub shall be untrue in any
material respect, in either case, such that the condition specified in Section
7.1(a) hereof would not be satisfied at the Closing (a "Terminating Parent
Breach"), except that, if such Terminating Parent Breach is curable by Parent
through the exercise of its commercially reasonable efforts, then, for a
period of thirty (30) days after receipt of notice of such breach, but only as
long as Parent continues to exercise such commercially reasonable efforts to
cure such Terminating Parent Breach (the "Parent Cure Period"), such
termination shall not be effective, and such termination shall become
effective only if the Terminating Parent Breach is not cured within the Parent
Cure Period.

   
 

  

SECTION 8.2 Effect of Termination. In the event of termination and abandonment
of this Agreement pursuant to Section 8.1, this Agreement shall forthwith
become null and void and have no effect, without any Liability on the part of
any Party hereto or its respective Affiliates, officers, directors or
equityholders, other than Liability of the Company, Parent or Merger Sub, as
the case may be, for any intentional and willful breach of this Agreement
occurring prior to such termination. Notwithstanding the foregoing, the
Confidentiality Agreement and the provisions of Sections 6.3 and this Section
8.2 hereof shall survive any termination of this Agreement.

  


 

  

ARTICLE IX. 
 

  

SURVIVAL; INDEMNIFICATION

  


 

  

SECTION 9.1 Survival. The representations, warranties, pre-Closing covenants
and pre-Closing agreements of the Parties hereto contained in this Agreement
or in any certificate or other writing delivered by any of the Parties
pursuant hereto or in connection herewith shall survive the Closing until
March 31, 2012 (the "Escrow Termination Date"). The post- Closing covenants
and post-Closing agreements of the Parties hereto contained in this Agreement
or in any certificate or other writing delivered by any of the Parties
pursuant hereto or in connection herewith shall survive the Closing until the
date specified in such covenants or agreements, or if no such date is so
specified, until they are performed. Notwithstanding the preceding sentences,
any breach of representation, warranty, covenant or agreement in respect of
which indemnity may be sought under this Agreement shall survive the time at
which it would otherwise terminate pursuant to the preceding sentences, if
notice of the inaccuracy or breach thereof giving rise to such right of
indemnity shall have been given to Parent (if indemnity is being sought
against Parent) or the Equityholders' Representative (if indemnity is being
sought against the Equityholders), as applicable, prior to such time.

  


 

  

SECTION 9.2 Indemnification.

  


 

  

 

 

 

  

 

54  

  

 

 

 

  

  

 

(a) Effective at and after the Effective Time, the Equityholders, severally
and not jointly, hereby indemnify Parent, its Affiliates and their respective
successors and assignees and, effective as of the Effective Time, without
duplication, the Company and its successors and assignees (collectively, the
"Parent Indemnified Parties") against and agree to hold each of them harmless
from any and all Damages incurred or suffered by Parent or any other Parent
Indemnified Party arising out of (i) any misrepresentation or breach of
warranty (determined, except with respect to Section 4.6, Section 4.7, Section
4.8(a) and Section 4.9(a), without regard to any qualification or exception
contained therein relating to materiality or Material Adverse Effect or any
similar qualification or standard) of the Company (each such misrepresentation
and breach of warranty a "Warranty Breach"), (ii) any breach of covenant or
agreement made or to be performed by the Company or the Equityholders'
Representative pursuant to this Agreement, (iii) any claim by any current or
former holder of any security of the Company, in its capacity as such,
challenging this Agreement, the Merger or the other transactions contemplated
hereby, including, any claims made by Dissenting Stockholders during the
twenty (20) day period within which Dissenting Stockholders seeking to assert
appraisal rights must make a written demand for appraisal pursuant to Section
262(d) of the DGCL, (iv) any Company Transaction Expenses to the extent not
paid by the Company at or prior to the Closing and not included in the
calculation of Closing Date Cash, Closing Date Indebtedness or Working
Capital, (v) any Pro-Rata Bonuses in excess of the amount included in the
calculation of Working Capital and (vi) any Management Retention Bonuses to
the extent not paid by the Company at or prior to the Closing and not included
in the calculation of Closing Date Cash, Closing Date Indebtedness or Working
Capital; provided, that (A) with respect to indemnification for Warranty
Breaches, the Equityholders shall not be liable unless (x) the amount of
Damages with respect to such Warranty Breach arising from a single claim (or
series of related claims) exceeds twenty-five thousand dollars ($25,000) and
(y) the aggregate amount of Damages with respect to such Warranty Breaches
exceeds five million six hundred and twenty five thousand dollars ($5,625,000)
(the "Threshold") and then for the full amount of such Damages and (B) the
Equityholders' aggregate maximum liability pursuant to this Section 9.2(a)
shall not exceed the then-remaining General Escrow Amount.

   
 

  

 

(b) Effective at and after the Effective Time, Parent hereby indemnifies the
Equityholders, their Affiliates and their respective successors and assignees
(collectively, the "Equityholder Indemnified Parties") against and agrees to
hold each of them harmless from any and all Damages incurred or suffered by
the Equityholder Indemnified Party arising out of (i) any misrepresentation or
breach of warranty (determined without regard to any qualification or
exception contained therein relating to materiality or material adverse effect
or any similar qualification or standard) of Parent or Merger Sub (each such
misrepresentation and breach of warranty a "Parent Warranty Breach") or (ii)
any breach of covenant or agreement made or to be performed by Parent or
Merger Sub pursuant to this Agreement; provided, that (A) with respect to
indemnification for Parent Warranty Breaches pursuant to this Section 9.2(b),
Parent shall not be liable unless the aggregate amount of Damages with respect
to such Parent Warranty Breaches exceeds the Threshold and then for the full
amount of such Damages and (B) Parent's maximum liability shall not exceed
thirty-seven million and five hundred thousand dollars ($37,500,000); and
provided further, that the Equityholder Indemnified Parties can only execute
any claim pursuant to this Section 9.2(b) against Parent through the
Equityholders' Representative.

   
 

  

SECTION 9.3 Limitations.

  


 

  

(a) The indemnification obligations under Section 9.2 shall be subject to each
of the following limitations:

  

  

(i) there shall be no obligation on the part of the Equityholders to indemnify
the Parent Indemnified Parties under Section 9 .2(a) to the extent that any
claim for indemnification relates

  

  

 

 

 

  

 

55  

  

 

 

 

  

  

to an amount otherwise taken into account in determining the Working Capital,
Closing Date Cash and Closing Date Indebtedness;

  


 

  

(ii) the Damages suffered by any Indemnified Party shall be calculated after
giving effect to any amounts recovered from third parties, including insurance
proceeds, in each case net of the reasonable third party out-of- pocket costs
and expenses associated with such recoveries, and taking into account any tax
benefit and/or tax detriment actually realized or incurred by the Indemnified
Party and its Affiliates that is associated with such Damages or the receipt
of an indemnification payment in respect thereof (it being understood and
agreed that the Indemnified Parties shall use their commercially reasonable
efforts to seek insurance recoveries in respect of Damages to be indemnified
hereunder). If any insurance proceeds or other recoveries from third parties
are actually realized (in each case calculated net of the reasonable third
party out-of-pocket costs and expenses associated with such recoveries) by an
Indemnified Party subsequent to the receipt by such Indemnified Party of an
indemnification payment hereunder in respect of the claims to which such
insurance proceedings or third party recoveries relate, the Indemnified Party
shall hold such amounts in trust and appropriate refunds shall be made
promptly to the Indemnifying Party regarding the amount of such
indemnification payment;

  


 

  

(iii) there shall be no obligation to indemnify for any Damages which would
not have arisen but for any alteration or repeal or enactment of any Law after
the Closing Date; and

  


 

  

(iv) all indemnification payments under Section 9.2(a) shall be made
exclusively by payments from the General Escrow Account and, upon the
depletion of the General Escrow Account, there shall be no further recoveries
by the Parent Indemnified Parties whatsoever.

  


 

  

(b) Any liability for indemnification hereunder shall be determined without
duplication of recovery by reason of the same set of facts giving rise to such
liability constituting a breach of more than one representation, warranty,
covenant or agreement.

  


 

  

(c) PARENT AND THE EQUITYHOLDERS ON BEHALF OF EACH OF THEIR RESPECTIVE
INDEMNIFIED PARTIES WAIVE ANY RIGHT TO RECOVER INCIDENTAL, INDIRECT, SPECIAL,
EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOST REVENUES OR
PROFITS, UNLESS (X) SUCH INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL
DAMAGES, INCLUDING LOST REVENUES OR PROFITS, ARE REASONABLY FORESEEABLE OR THE
PROXIMATE RESULT OF THE EVENT THAT GAVE RISE THERETO OR THE MATTER FOR WHICH
INDEMNIFICATION IS SOUGHT HEREUNDER OR (Y) SUCH INCIDENTAL, INDIRECT, SPECIAL,
EXEMPLARY, PUNITIVE, CONSEQUENTIAL OR OTHER KIND OF SPECIAL DAMAGES ARE
AWARDED TO A PERSON IN AN INDEMNIFIABLE THIRD PARTY CLAIM.

  


 

  

SECTION 9.4 Limitation on Set-off. Neither Parent nor Merger Sub shall have
any right to set-off any unresolved indemnification claim pursuant to this
Article IX against any payment due pursuant to Article II or III.

  


 

  

SECTION 9.5 Mitigation. The Indemnified Parties and the Indemnifying Parties
shall use their respective commercially reasonable efforts to mitigate any
Damages.

  


 

  

SECTION 9.6 Third Party Claim Procedures.

  

  

(a) The Party seeking indemnification under Section 9.2 (the "Indemnified
Party") agrees to give prompt notice in writing to the Party against whom
indemnity is to be sought (or the

  

  

 

 

 

  

 

56  

  

 

 

 

  

  

Equityholders' Representative (with a copy to the Escrow Agent) in the case of
an indemnification claim pursuant to Section 9.2(a) against the Equityholders)
(the "Indemnifying Party") of the assertion of any claim or the commencement
of any Action by any third party (a "Third Party Claim") in respect of which
indemnity may be sought under such section. Such notice shall set forth in
reasonable detail such Third Party Claim and the basis for indemnification
(taking into account the information then available to the Indemnified Party).
The failure to so notify the Indemnifying Party shall not relieve the
Indemnifying Party of its obligations hereunder, except to the extent such
failure shall have materially and adversely prejudiced the Indemnifying Party.

  


 

  

 

(b) The Indemnifying Party shall be entitled to participate in the defense of
any Third Party Claim and, subject to the limitations set forth in this
Section 9.6, shall be entitled to control and appoint lead counsel for such
defense, in each case at its own expense; provided, that prior to assuming
control of such defense, the Indemnifying Party must (i) acknowledge that, if
the facts as alleged by the claimant in the Third Party Claim are true, it
would have an indemnity obligation for the Damages resulting from such Third
Party Claim as provided under this Article IX and (ii) must furnish the
Indemnified Party with reasonable evidence that the Indemnifying Party has
adequate resources to defend the Third Party Claim and fulfill its indemnity
obligations hereunder.

  

  

(c) The Indemnifying Party shall not be entitled to assume or maintain control
of the defense of any Third Party Claim and shall pay the fees and expenses of
one counsel retained by the Indemnified Party if (i) the Indemnifying Party
does not deliver the acknowledgment referred to in Section 9.6(b)(i) within
thirty (30) days of receipt of notice of the Third Party Claim pursuant to
Section 9.3(a), (ii) the Third Party Claim relates to or arises in connection
with any criminal proceeding, Action, indictment or allegation, (iii) the
Indemnified Party reasonably believes an adverse determination with respect to
the Third Party Claim would be detrimental to the reputation or future
business prospects of the Indemnified Party or any of its Affiliates, (iv) the
Third Party Claim seeks an injunction or equitable relief against the
Indemnified Party or any of its Affiliates, (v) the Indemnifying Party (or the
Equityholders' Representative on behalf of the Equityholders) has failed or is
failing to prosecute or defend vigorously the Third Party Claim or (vi) in the
case of a Parent Indemnified Party as the Indemnified Party, if the amount of
the Third Party Claim, if determined in favor of the claimant, would
reasonably result in Damages, together with all other claims for
indemnification hereunder, that would exceed the remaining amount of the
General Escrow Amount. The Indemnified Party shall obtain the prior written
consent of the Indemnifying Party before entering into any settlement of a
Third Party Claim.

  

  

(d) If the Indemnifying Party shall assume the control of the defense of any
Third Party Claim in accordance with the provisions of this Section 9.6, the
Indemnifying Party shall obtain the prior written consent of the Indemnified
Party (which shall not be unreasonably withheld, delayed or conditioned)
before entering into any settlement of such Third Party Claim, if the
settlement does not expressly unconditionally release the Indemnified Party
and its Affiliates from all Liabilities with respect to such Third Party Claim
or the settlement imposes injunctive or other equitable relief against the
Indemnified Party or any of its Affiliates.

  

  

(e) In circumstances where the Indemnifying Party is controlling the defense
of a Third Party Claim in accordance with paragraphs (b) and (c) above, the
Indemnified Party shall be entitled to participate in the defense of any Third
Party Claim and to employ separate counsel of its choice for such purpose, in
which case the fees and expenses of such separate counsel shall be borne by
the Indemnified Party; provided, that in such event the Indemnifying Party
shall pay the fees and expenses of one such separate counsel (i) incurred by
the Indemnified Party prior to the date the Indemnifying Party assumes control
of the defense of the Third Party Claim or (ii) if representation of both the
Indemnifying 
 

 

  

 

 

 

  

 

57  

  

 

 

 

  

Party and the Indemnified Party by the same counsel would, in the good faith
judgment of the Indemnified Party, create a conflict of interest.

  


 

  

(f) Each Party shall cooperate, and cause their respective Affiliates to
cooperate, in the defense or prosecution of any Third Party Claim and shall
furnish or cause to be furnished such records, information and testimony, and
attend such conferences, discovery proceedings, hearings, trials or appeals,
as may be reasonably requested in connection therewith.

  


 

  

SECTION 9.7 Direct Claim Procedures. In the event an Indemnified Party has a
claim for indemnity under Section 9.2 against an Indemnifying Party that does
not involve a Third Party Claim, the Indemnified Party agrees to give prompt
notice in writing of such claim to the Indemnifying Party. Such notice shall
set forth in reasonable detail such claim and the basis for indemnification
(taking into account the information then available to the Indemnified Party).
The failure to so notify the Indemnifying Party shall not relieve the
Indemnifying Party of its obligations hereunder, except to the extent such
failure shall have materially and adversely prejudiced the Indemnifying Party.
If the Indemnifying Party disputes its indemnity obligation for any Damages
with respect to such claim, the Parties shall proceed in good faith to
negotiate a resolution of such dispute and, if not resolved through
negotiations, such dispute shall be resolved by litigation in an appropriate
court of jurisdiction determined pursuant to Section 10.11. 
 

  


 

  

SECTION 9.8 Treatment of Indemnification Payments. The Parties agree that any
indemnity payments pursuant to this Article IX shall be deemed to be an
adjustment to the Total Cash Equity Price to the extent permitted by
applicable Law.

  


 

  

SECTION 9.9 Exclusive Remedy. From and after the Effective Time, except for
the Consent Agreement, the Letter of Transmittal and the Escrow Agreement and
in the case of fraud, Section 2.7 , Section 3.2 and this Article IX shall
constitute the sole and exclusive remedy of the Parties and the other
Indemnified Parties in connection with all matters in connection with this
Agreement, the Merger and the other transactions contemplated hereby (whether
based on contract, tort, strict liability, other Laws or otherwise).

  


 

  

ARTICLE X. 
 

  

GENERAL PROVISIONS

  


 

  

SECTION 10.1 Equityholders' Representative.

  


 

  

(a) Appointment. By virtue of the adoption of this Agreement by the Company's
stockholders, and without further action of any Equityholder, each
Equityholder shall be deemed to have irrevocably constituted and appointed
Canaan VII L.P. (and by execution of this Agreement it hereby accepts such
appointment) as agent and attorney-in-fact ("Equityholders' Representative")
for and on behalf of the Equityholders (in their capacity as such), with full
power of substitution, to act in the name, place and stead of each
Equityholder with respect to Section 2.7, Article III, Article IX, Article X,
and the Escrow Agreement and the taking by the Equityholders' Representative
of any and all actions, including litigating, defending or enforcing any
actions, delivering or signing any certificates, notice, consent or instrument
required or permitted to be made or delivered under this Agreement or for the
enforcement of any rights the Equityholders have against Parent or the
Surviving Corporation, hiring or retaining, at the sole expense of the
Equityholders, such counsel, investment bankers, accountants, representatives
and other professional advisors as it determines in its sole and absolute
discretion to be necessary, advisable or appropriate in order to carry out and
perform its rights and obligations hereunder and the making of any decisions
required or permitted to be taken by the Equityholders' Representative under
this

  


 

  

 

 

 

  

 

58  

  

 

 

 

  

  

Agreement and the Escrow Agreement (it being understood that the
Equityholders' Representative shall have no right to pursue any claim on
behalf of any Company Indemnified Party in respect of the rights granted to
Company Indemnified Parties under Section 6.5). The power of attorney granted
in this Section 10.1 is coupled with an interest and is irrevocable, may be
delegated by the Equityholders' Representative and shall survive the death or
incapacity of each Equityholder. Such agency may be changed by, (x) prior to
the Effective Time, the affirmative vote or consent of the holders of a
majority of the shares of the outstanding Company Capital Stock (excluding the
Series C -1 Preferred Stock) voting or consenting, as the case may be, on an
as-converted to Common Stock basis and (y) after the Effective Time, the
holders of a majority in interest of the General Escrow Account from time to
time until all obligations under this Agreement have been discharged
(including within twenty (20) Business Days in the event of the death,
disability or other incapacity of an Equityholders' Representative that is an
individual), and any such successor shall succeed the Equityholders'
Representative as Equityholders' Representative hereunder. No bond shall be
required of the Equityholders' Representative, and the Equityholders'
Representative shall receive no compensation for its services.

  


 

  

 

(b) Limitation on Liability. The Equityholders' Representative shall not be
liable to any Person for any act of the Equityholders' Representative taken in
good faith and in the exercise of its reasonable judgment and arising out of
or in connection with the acceptance or administration of its duties under
this Agreement and the Escrow Agreement (it being understood that any act done
or omitted pursuant to the advice of legal counsel shall be conclusive
evidence of such good faith and reasonable judgment), except to the extent any
Liability or Damage is actually incurred by such Person as a proximate result
of the gross negligence or bad faith of the Equityholders' Representative. The
Equityholders' Representative shall not be liable for, and may seek
indemnification from the Equityholders for, any Liability or Damage incurred
by the Equityholders' Representative while acting in good faith and in the
exercise of its reasonable judgment and arising out of or in connection with
the acceptance or administration of its duties under this Agreement and the
Escrow Agreement, except to the extent that any such Liability or Damage is
the proximate result of the gross negligence or bad faith of the
Equityholders' Representative. The Equityholders' Representative Escrow
Account shall be available to indemnify and hold the Equityholders'
Representative harmless against any Liability or Damage incurred by the
Equityholders' Representative arising out of or in connection with the
acceptance or administration of its duties under this Agreement and the Escrow
Agreement, except to the extent that any such Liability or Damage is the
proximate result of the gross negligence or bad faith of the Equityholders'
Representative. The Equityholders' Representative shall be entitled to recover
any out-of-pocket costs and expenses reasonably incurred by the Equityholders'
Representative in connection with actions taken by the Equityholders'
Representative pursuant to the terms of Section 2.7, Article III, Article IX,
Article X or the Escrow Agreement (including the hiring of legal counsel and
the incurring of legal fees and costs) from the Equityholders' Representative
Escrow Account.

   
 

  

(c) Access. From and after the Effective Time, Parent shall cause the
Surviving Corporation to provide the Equityholders' Representative with
reasonable access to information about the Surviving Corporation and the
reasonable assistance of the officers and employees of Parent and the
Surviving Corporation for the purposes of performing its duties and exercising
its rights under this Agreement; provided, that the Equityholders'
Representative shall treat confidentially any nonpublic information about the
Surviving Corporation (except in connection with the performance by the
Equityholders' Representative of its duties or the exercise of its rights
under this Agreement).

  


 

  

(d) Actions of the Equityholders' Representative. From and after the Effective
Time, a decision, act, consent or instruction of the Equityholders'
Representative shall constitute a decision of all Equityholders and shall be
final, binding and conclusive upon each Equityholder, and the Escrow Agent and
Parent may rely upon any decision, act, consent or instruction of the
Equityholders'

  


 

  

 

 

 

  

 

59  

  

 

 

 

  

  

Representative as being the decision, act, consent or instruction of each
Equityholder. Parent is hereby relieved from any Liability to any Person for
any acts done by Parent in accordance with any such decision, act, consent or
instruction of the Equityholders' Representative.

  


 

  

(e) Representations and Warranties. The Equityholders' Representative, solely
in its capacity as the representative of the Equityholders, represents and
warrants to Parent and Merger Sub, as of the date hereof and as of the Closing
Date, as follows:

  


 

  

(i) the Equityholders' Representative is a Delaware limited partnership duly
organized, validly existing and in good standing under the Laws of the State
of Delaware, and has all requisite limited partnership power and authority and
all material Permits required to carry on its business in all material
respects as currently conducted;

  


 

  

(ii) the execution and delivery of this Agreement by the Equityholders'
Representative, and the performance by the Equityholders' Representative of
its obligations hereunder, have been duly authorized by all necessary limited
partnership action on the part of the Equityholders' Representative;

  


 

  

(iii) this Agreement has been duly executed and delivered by the
Equityholders' Representative and, assuming due authorization, execution and
delivery by the other Parties to this Agreement, this Agreement constitutes a
legally valid and binding obligation of the Equityholders' Representative,
enforceable against the Equityholders' Representative in accordance with its
terms, except as enforceability may be limited by principles of public policy,
and subject to (A) the effect of any applicable Law of general application
relating to bankruptcy, reorganization, insolvency, or moratorium or similar
Laws affecting creditors' rights and relief of debtors generally and (B) the
effect of rules of Law and general principles of equity, including rules of
Law and general principles of equity governing specific performance,
injunctive relieve and other equitable remedies (regardless of whether such
enforceability is considered in a proceeding in equity or at Law); and

  


 

  

(iv) the execution and delivery of this Agreement by the Equityholders'
Representative, and the performance by the Equityholders' Representative of
its obligations hereunder and under the Escrow Agreement do not and will not
(A) conflict with or result in a violation of the organizational documents of
the Equityholders' Representative, (B) violate any Law applicable to the
Equityholders' Representative or (C) require any consent or approval that has
not been given or other action that has not been taken by any Person under any
Contract binding upon the Equityholders' Representative.

  


 

  

SECTION 10.2 Expenses. Except as otherwise expressly provided in this
Agreement, all costs and expenses (including all fees and disbursements of
counsel, financial advisors and accountants) incurred in connection with the
negotiation and preparation of this Agreement, the performance of the terms of
this Agreement and the consummation of the transactions contemplated by this
Agreement shall be paid by the respective Party incurring such costs and
expenses, whether or not the Closing shall have occurred.

  


 

  

SECTION 10.3 Notices. All notices, requests, demands and other communications
under this Agreement shall be in writing and shall be deemed to have been duly
given or made as follows: (i) if sent by registered or certified mail in the
United States return receipt requested, upon receipt; (ii) if sent by
nationally recognized overnight air courier, one (1) Business Day after
mailing; (iii) if sent by facsimile transmission, with a copy mailed on the
same day in the manner provided in clauses (i) or (ii) of this Section 10.3,
when transmitted and receipt is confirmed by telephone and (iv) if otherwise
actually

  


 

  

 

 

 

  

 

60  

  

 

 

 

  

  

personally delivered, when delivered; provided, that such notices, requests,
demands and other communications are delivered to the address set forth below,
or to such other address as any Party shall provide by like notice to the
other Parties to this Agreement:

  


 

  

 

     |  

(a)

  |  

if to the Company (prior to the Closing), to:

  

  

Advanced BioHealing, Inc.

   
---|---|--- 
 

 

  

36 Church Lane

  

Westport, Connecticut 06880

  

Facsimile: (203) 557-0739

  

Attention: Luke Albrecht

  


 

  

with a copy (which shall not constitute notice) to:

  


 

  

Latham and Watkins LLP

  

885 Third Avenue

  

New York, NY

  

     |  

Facsimile:

  |  

(212) 751-4864

   
---|---|--- 
 

  

     |  

Attention:

  |  

Charles Ruck   

David Kurzweil

 

   
---|---|--- 
 

  


 

  


 

  

     |  

(b)

  |  

if to Parent, Merger Sub, Buyer Parent or, if after the Closing, to the
Surviving Corporation, to:

   
---|---|--- 
 

  


 

  

Shire Pharmaceuticals Inc.

  

725 Chesterbrook Blvd.

  

Wayne, PA 19087

  

Facsimile: (484) 595-8674

  

Attention: Ellen Rosenberg

  


 

  

with a copy (which shall not constitute notice) to:

  


 

  

Davis Polk and Wardwell LLP

  

450 Lexington Avenue

  

New York, NY 10017

  

Facsimile: (212) 701-5800

  

Attention: John K. Knight

  


 

  

 

     |  

(c)

  |  

if to the Equityholders' Representative, to:

  

  

Canaan VII L.P.

   
---|---|--- 
 

 

  

285 Riverside Avenue

  

Suite 250

  

Westport, CT 06880

  

Facsimile: (203) 854-9117

  

Attention: Stephen Bloch, MD

  


 

  

 

 

 

  

 

61  

  

 

 

 

  

  

with a copy (which shall not constitute notice) to:

  


 

  

Latham and Watkins LLP

  

885 Third Avenue

  

New York, NY

  

Facsimile: (212) 751-4864

  

Attention: Charles Ruck

  

David Kurzweil

  


 

  

SECTION 10.4 Public Announcements. Unless otherwise required by applicable
Law, any listing agreement with any U.S. or U.K. securities exchange or share
market, or any listing authority including the U.K. Listing Authority, no
Party to this Agreement shall make any public announcement in respect of this
Agreement or the transactions contemplated by this Agreement, or otherwise
communicate with any news media regarding this Agreement or the transactions
contemplated by this Agreement, without the prior written consent of the other
Parties to this Agreement; provided, that if any such announcement or
communication is so required, the Parties shall consult with each other, to
the extent reasonably practicable, in advance as to the contents and timing
thereof.

  


 

  

SECTION 10.5 Interpretation. The Article and Section headings in this
Agreement are for convenience of reference only and shall not be deemed to
alter or affect the meaning or interpretation of any provision of this
Agreement. References to Articles, Sections, Schedules or Exhibits in this
Agreement, unless otherwise indicated, are references to Articles, Sections,
Schedules and Exhibits of or to this Agreement. The Parties to this Agreement
have participated jointly in the negotiation and drafting of this Agreement.
In the event an ambiguity or question of intent or interpretation arises with
respect to any term or provision of this Agreement, this Agreement shall be
construed as if drafted jointly by the Parties to this Agreement, and no
presumption or burden of proof shall arise favoring or disfavoring any Party
to this Agreement by virtue of the authorship of any of the terms or
provisions of this Agreement. Any reference to any Law shall be deemed also to
refer to all rules and regulations promulgated thereunder, unless the context
requires otherwise. For all purposes of and under this Agreement, (i) the word
"including" shall be deemed to be immediately followed by the words "without
limitation;" (ii) words (including defined terms) in the singular shall be
deemed to include the plural and vice versa; (iii) words of one gender shall
be deemed to include the other gender as the context requires; (iv) the terms
"hereof," "herein," "hereto," "herewith" and any other words of similar import
shall, unless otherwise stated, be construed to refer to this Agreement as a
whole (including all of the Exhibits to this Agreement) and not to any
particular term or provision of this Agreement, unless otherwise specified;
and (v) unless otherwise defined in this Agreement, accounting terms shall
have the respective meanings assigned to them in accordance with GAAP.

  


 

  

SECTION 10.6 Severability. In the event that any one or more of the terms or
provisions contained in this Agreement or in any other certificate, instrument
or other document referred to in this Agreement, shall, for any reason, be
held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect any other term or provision of
this Agreement or any other such certificate, instrument or other document
referred to in this Agreement. Any term or provision of this Agreement held
invalid or unenforceable only in part, degree or within certain jurisdictions
shall remain in full force and effect to the extent not held invalid or
unenforceable to the extent consistent with the intent of the Parties as
reflected by this Agreement. To the extent permitted by applicable Law, each
Party waives any term or provision of Law which renders any term or provision
of this Agreement to be invalid, illegal or unenforceable in any respect.

  


 

  

 

 

 

  

 

62  

  

 

 

 

  

  

SECTION 10.7 Entire Agreement. This Agreement (including the Exhibits to this
Agreement), the Company Disclosure Schedule and the Confidentiality Agreement
constitute the entire agreement of the Parties to this Agreement with respect
to the subject matter of this Agreement, the Company Disclosure Schedule and
the Confidentiality Agreement, and supersede all prior agreements and
undertakings, both written and oral, among the Parties to this Agreement with
respect to the subject matter of this Agreement, the Company Disclosure
Schedule and the Confidentiality Agreement, except as otherwise expressly
provided in this Agreement.

  


 

  

SECTION 10.8 Assignment. Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by any of the Parties to
this Agreement (whether by operation of Law or otherwise) without the prior
written consent of the other Parties to this Agreement, and any purported
assignment or other transfer without such consent shall be void and
unenforceable, except that Parent or Merger Sub may transfer or assign its
rights and obligations under this Agreement, in whole or from time to time in
part, to (i) one or more of their Affiliates at any time and (ii) after the
Effective Time, to any Person; provided, that such transfer or assignment
shall not relieve Parent or Merger Sub of its obligations hereunder or
enlarge, alter or change any obligation of any other party hereto or due to
Parent or Merger Sub. Subject to the preceding sentence, this Agreement shall
be binding upon, inure to the benefit of and be enforceable by the Parties to
this Agreement and their respective successors and assigns.

  

  

SECTION 10.9 No Third-Party Beneficiaries. Except for Article II, Article III
and Section 6.5, this Agreement is for the sole benefit of the Parties to this
Agreement and nothing in this Agreement, express or implied, is intended to or
shall confer upon any other Person any legal or equitable right, benefit or
remedy of any nature whatsoever under or by reason of this Agreement.

  

  

SECTION 10.10 Waivers and Amendments. This Agreement may be amended or
modified only by a written instrument executed by all of the Parties to this
Agreement. Any failure of the Parties to this Agreement to comply with any
obligation, covenant, agreement or condition in this Agreement may be waived
by the Party entitled to the benefits thereof only by a written instrument
signed by the Party granting such waiver. No delay on the part of any Party to
this Agreement in exercising any right, power or privilege hereunder shall
operate as a waiver thereof, nor shall any waiver on the part of any Party to
this Agreement of any right, power or privilege hereunder operate as a waiver
of any other right, power or privilege hereunder, nor shall any single or
partial exercise of any right, power or privilege hereunder preclude any other
or further exercise thereof or the exercise of any other right, power or
privilege hereunder. Unless otherwise provided, the rights and remedies
provided for in this Agreement are cumulative and are not exclusive of any
rights or remedies which the Parties to this Agreement may otherwise have at
Law or in equity. Whenever this Agreement requires or permits consent by or on
behalf of a Party, such consent shall be given in writing in a manner
consistent with the requirements for a waiver of compliance as set forth in
this Section 10.10.

  


 

  

SECTION 10.11 Governing Law; Consent to Jurisdiction.

  


 

  

(a) This Agreement and the transactions contemplated hereby, and all disputes
between the Parties under or related to the Agreement or the facts and
circumstances leading to its execution, whether in contract, tort or
otherwise, shall be governed by, and construed in accordance with, the Laws of
the State of Delaware applicable to contracts executed in and to be performed
entirely within such State, without regard to conflict of law principles that
would result in the application of any Laws other than the Laws of the State
of Delaware. Each of the Parties to this Agreement hereby irrevocably and
unconditionally submits, for itself and its assets and properties, to the
exclusive jurisdiction of any Delaware State court, or Federal court of the
United States of America, sitting within the State of Delaware, and any
appellate court from any thereof, in any Action arising out of or relating to
this

  


 

  

 

 

 

  

 

63  

  

 

 

 

  

  

 

Agreement, the agreements delivered in connection with this Agreement, or the
transactions contemplated hereby or thereby, or for recognition or enforcement
of any judgment relating thereto, and each of the Parties to this Agreement
hereby irrevocably and unconditionally (i) agrees not to commence any such
Action except in such courts; (ii) agrees that any claim in respect of any
such Action may be heard and determined in such Delaware State court or, to
the extent permitted by Law, in such Federal court; (iii) waives, to the
fullest extent it may legally and effectively do so, any objection which it
may now or hereafter have to the laying of venue of any such Action in any
such Delaware State or Federal court; and (iv) waives, to the fullest extent
permitted by Law, the defense of an inconvenient forum to the maintenance of
such Action in any such Delaware State or Federal court. Each of the Parties
to this Agreement hereby agrees that a final judgment in any such Action shall
be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by Law. Each of the Parties to this
Agreement hereby irrevocably consents to service of process in the manner
provided for notices in Section 10.3. Nothing in this Agreement shall affect
the right of any Party to this Agreement to serve process in any other manner
permitted by applicable Law.

   
 

  

(b) Buyer Parent hereby irrevocably designates, appoints, authorizes and
empowers as agent for service of process, Parent, to accept, for and on behalf
of Buyer Parent, service of any and all process, notices or other documents
that may be served in any Action relating hereto in any Delaware State or
Federal court sitting in the State of Delaware.

  


 

  

SECTION 10.12 Waiver of Jury Trial. EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES
AND AGREES THAT ANY CLAIM OR CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT
IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE, IT
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION
WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH
PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE,
AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE
EITHER OF SUCH WAIVERS, (II) IT UNDERSTANDS AND HAS CONSIDERED THE
IMPLICATIONS OF SUCH WAIVERS, (III) IT MAKES SUCH WAIVERS VOLUNTARILY AND (IV)
IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE
MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.12.

  


 

  

SECTION 10.13 Equitable Remedies. Each of the Parties to this Agreement
acknowledges and agrees that the other Parties to this Agreement would be
irreparably damaged in the event that any of the terms or provisions of this
Agreement are not performed in accordance with their specific terms or
otherwise are breached. Therefore, notwithstanding anything to the contrary
set forth in this Agreement, each of the Parties to this Agreement hereby
agrees that the other Parties to this Agreement shall be entitled to an
injunction or injunctions to prevent breaches of any of the terms or
provisions of this Agreement, and to enforce specifically the performance by
any other Party under this Agreement, and each Party to this Agreement hereby
agrees to waive the defense (and not to interpose as a defense or in
opposition) in any such suit that the other Parties to this Agreement have an
adequate remedy at Law, and hereby agrees to waive any requirement to post any
bond in connection with obtaining such relief. The equitable remedies
described in this Section 10.13 shall be in addition to, and not in lieu of,
any other remedies at Law or in equity that the Parties to this Agreement may
elect to pursue.

  


 

  

 

 

 

  

 

64  

  

 

 

 

  

  

SECTION 10.14 Counterparts. This Agreement may be executed in one or more
counterparts, each of which when executed shall be deemed to be an original,
but all of which taken together shall constitute one and the same agreement.
In the event that any signature is delivered by facsimile transmission, or by
e-mail delivery of a ".pdf" format data file, such signature shall create a
valid and binding obligation of the Party executing (or on whose behalf such
signature is executed) with the same force and effect as if such facsimile or
".pdf" format data file signature page were an original thereof.

  


 

  

SECTION 10.15 Time is of the Essence. Time is of the essence with respect to
the performance of this Agreement. Whenever this Agreement refers to a number
of days, such number shall refer to calendar days unless Business Days are
specified. Whenever any action must be taken hereunder on or by a day that is
not a Business Day, then such action may be validly taken on or by the next
day that is a Business Day.

  


 

  

SECTION 10.16 Legal Representation. It is acknowledged by each of the parties
hereto that the Company, the Equityholders' Representative and the Principal
Stockholders (and their respective Affiliates) have retained Latham and Watkins
LLP ("Sellers' Counsel") to act as their counsel in connection with the
transactions contemplated hereby and that Sellers' Counsel has not acted as
counsel for any other Person in connection with the transactions contemplated
hereby and that no other party or Person has the status of a client of the
Sellers' Counsel for conflict of interest or any other purposes as a result
thereof. Parent, Merger Sub and the Surviving Corporation hereby agree that,
in the event that a dispute arises between Parent, Merger Sub, the Company or
any of their respective Affiliates and the Equityholders' Representative, the
Principal Stockholders or any of their respective Affiliates, Sellers' Counsel
may represent the Equityholders' Representative, the Principal Stockholders or
any of their respective Affiliates in such dispute even though the interests
of the Equityholders' Representative, the Principal Stockholders or any of
their respective Affiliates may be directly adverse to Parent, Merger Sub, the
Company, the Surviving Corporation or any of their respective Affiliates and
even though Sellers' Counsel may have represented the Company in a matter
substantially related to such dispute, and Parent, Merger Sub, the Company,
the Surviving Corporation and their respective Affiliates hereby waive, on
behalf of themselves and each of their Affiliates, any conflict of interest in
connection with such representation by Sellers' Counsel. Each of Parent,
Merger Sub and the Company further agrees that, as to all pre-Closing
communications among Sellers' Counsel, the Company and any stockholder of the
Company that relate in any way to the transactions contemplated by this
Agreement, the attorney-client privilege, the expectation of client confidence
and all other rights to any evidentiary privilege belong to the Equityholders'
Representative, the Principal Stockholders and their respective Affiliates, as
applicable, and may be controlled by the Equityholders' Representative, the
Principal Stockholders and their respective Affiliates and shall not pass to
or be claimed by Parent, Merger Sub, the Company, the Surviving Corporation or
any of their respective Affiliates; provided, however, that the foregoing
sentence will not be applicable with respect to disputes or claims arising
under Article IX of the Merger Agreement. Parent, Merger Sub and the Company
agree to take, and to cause their respective Affiliates to take, all steps
necessary to implement the intent of this Section 10.16.

  


 

  

SECTION 10.17 Buyer Parent Guarantee. In consideration of, and as an
inducement to the Company and the Equityholders' Representative entering into
this Agreement and performing their obligations hereunder, Buyer Parent hereby
irrevocably, absolutely and unconditionally guarantees to the Company and the
Equityholders' Representative the full performance and payment by Parent and
Merger Sub of the covenants, obligations, monetary or otherwise, and
undertakings of Parent and Merger Sub pursuant to or otherwise in connection
with this Agreement (the "Buyer Guaranteed Obligations"). Upon breach of, or
other failure to perform, any representation, warranty, covenant, obligation,
agreement or undertaking of Parent or Merger Sub, the Company or the
Equityholders'

  


 

  

 

 

 

  

 

65  

  

 

 

 

  


 

  

 

Representative shall give written notice of such breach or failure to Buyer
Parent, which notice shall specify in reasonable detail the nature and basis
of such breach or failure, and Buyer Parent shall have three (3) Business Days
from the date such notice is given to Buyer Parent to cause Parent or Merger
Sub to perform its obligations with respect to such breach or failure;
provided, that if such obligations are not satisfied within such three (3)
Business Day period, the Company and the Equityholders' Representative shall
have the right, exercisable in their sole discretion, to pursue any and all
available remedies they may have under this Agreement arising out of any such
breach or nonperformance directly against any or all of Parent, Merger Sub and
Buyer Parent in the first instance. In this respect, for the avoidance of
doubt, Buyer Parent confirms that it is bound by the provisions of Section
10.3, Section 10.5, Section 10.6, Section 10.7, Section 10.8, Section 10.9,
Section 10.10, Section 10.11, Section 10.12, Section 10.13 and Section 10.14
as if it were a "Party" therein. This guarantee is a guarantee of performance
and not exclusively of collection. Without limiting any rights or defenses
that would be available to Buyer Parent if it were a direct obligor hereunder
or any rights or defenses that Buyer Parent, Parent or Merger Sub has
hereunder, (x) to the fullest extent permitted by Law, Buyer Parent hereby
expressly waives any and all rights or defenses arising by reason of any Law
that would otherwise require any election of remedies by the Company or the
Equityholders' Representative and (y) except for the second sentence of this
Section 10.17, Buyer Parent waives promptness, diligence, notice of the
acceptance of this guaranty and of the Buyer Guaranteed Obligations,
presentment, demand for payment, notice of non-performance, default, dishonor
and protest, notice of any Buyer Guaranteed Obligations incurred and all other
notices of any kind, all defenses which may be available by virtue of any
valuation, stay, moratorium law or other similar law now or hereafter in
effect, any right to require the marshalling of assets of Buyer Parent, and
all suretyship defenses generally. Buyer Parent's obligations under this
Section 10.17 shall terminate upon the satisfaction by Parent and Merger Sub
of their obligations hereunder. Buyer Parent acknowledges that it will receive
substantial direct and indirect benefits in connection with this Agreement and
that the waivers set forth in this Section 10.17 are knowingly made in
contemplation of such benefits.

   
 

  


 

  


 

  

(Remainder of Page Intentionally Left Blank)

  


 

  

 

 

 

  

 

66  

  

 

 

 

  

IN WITNESS WHEREOF, Parent, Merger Sub, the Company, solely for the purposes
of Section 2.7 and Articles III, IX and X, the Equityholders' Representative
and, solely for the purposes of Section 10.17, Buyer Parent have caused this
Agreement to be executed by their respective officers thereunto duly
authorized, as of the date first above written.

  

  

     |  

SHIRE PHARMACEUTICALS INC.,

  

a Delaware corporation

  |   
---|---|--- 
   |  |  |   
   |  | /s/ Michael Cola |   
   |  

Name:

  | Michael Cola |   
   |  

Title:

  | President |   
   |  |  |   
 

  

  

 

  

     |  

 

ABH MERGER SUB INC.,

  

a Delaware corporation

 

  |   
---|---|--- 
   |  |  |   
   |  | /s/ Michael Cola |   
   |  

Name:

  | Michael Cola |   
   |  

Title:

  | Vice President |   
   |  |  |   
 

  

 

  

     |  

 

ADVANCED BIOHEALING, INC.,

  

a Delaware corporation

 

  |   
---|---|--- 
   |  |  |   
   |  | /s/ Luke J. Albrecht |   
   |  

Name:

  | Luke J. Albrecht |   
   |  

Title:

  | Corporate Secretary |   
   |  |  |   
 

  

 

 

  

  

 

Canaan VII L.P., as Equityholders' Representative

  

(solely for the purposes of Section 2.7, and Articles III, IX and X),

 

  

 

 

  

     |  |  |   
---|---|---|--- 
   |  

Canaan VII L.P.

  |  |   
  

 

Name:

 

  |  

By: Canaan Partners VII LLC

  |  |   
  

 

 

Title:

 

 

  |  

By: /s/ Guy M. Russo

  

Member/Manager

  |  |   
   |  |  |   
 

  

 

 

  

 

SHIRE PLC as Buyer Parent 
 

  

(solely for the purposes of Section 10.17),

 

  

  

     |  |  |   
---|---|---|--- 
   | /s/ Angus Russell |  |   
  

Name:

  | Angus Russell |  |   
  

Title:

  | Chief Executive Officer |  |   
   |  |  |   
 

  

 

 

 

 

  

  


 

  

Signature Page to Agreement and Plan of Merger

  

    

  

     '

